0001164888 false Q2 --03-31 2022 0001164888 2021-04-01 2021-09-30 0001164888 2021-11-15 0001164888 2021-09-30 0001164888 2021-03-31 0001164888 us-gaap:SeriesAPreferredStockMember 2021-09-30 0001164888 us-gaap:SeriesAPreferredStockMember 2021-03-31 0001164888 us-gaap:SeriesBPreferredStockMember 2021-09-30 0001164888 us-gaap:SeriesBPreferredStockMember 2021-03-31 0001164888 2021-07-01 2021-09-30 0001164888 2020-07-01 2020-09-30 0001164888 2020-04-01 2020-09-30 0001164888 us-gaap:PreferredStockMember 2021-06-30 0001164888 KBPH:PreferredStockBMember 2021-06-30 0001164888 us-gaap:CommonStockMember 2021-06-30 0001164888 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001164888 us-gaap:RetainedEarningsMember 2021-06-30 0001164888 2021-06-30 0001164888 us-gaap:PreferredStockMember 2021-07-01 2021-09-30 0001164888 KBPH:PreferredStockBMember 2021-07-01 2021-09-30 0001164888 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001164888 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001164888 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001164888 us-gaap:PreferredStockMember 2021-09-30 0001164888 KBPH:PreferredStockBMember 2021-09-30 0001164888 us-gaap:CommonStockMember 2021-09-30 0001164888 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001164888 us-gaap:RetainedEarningsMember 2021-09-30 0001164888 us-gaap:PreferredStockMember 2021-03-31 0001164888 KBPH:PreferredStockBMember 2021-03-31 0001164888 us-gaap:CommonStockMember 2021-03-31 0001164888 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001164888 us-gaap:RetainedEarningsMember 2021-03-31 0001164888 us-gaap:PreferredStockMember 2021-04-01 2021-09-30 0001164888 KBPH:PreferredStockBMember 2021-04-01 2021-09-30 0001164888 us-gaap:CommonStockMember 2021-04-01 2021-09-30 0001164888 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-09-30 0001164888 us-gaap:RetainedEarningsMember 2021-04-01 2021-09-30 0001164888 us-gaap:PreferredStockMember 2020-06-30 0001164888 KBPH:PreferredStockBMember 2020-06-30 0001164888 us-gaap:CommonStockMember 2020-06-30 0001164888 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001164888 us-gaap:RetainedEarningsMember 2020-06-30 0001164888 2020-06-30 0001164888 us-gaap:PreferredStockMember 2020-07-01 2020-09-30 0001164888 KBPH:PreferredStockBMember 2020-07-01 2020-09-30 0001164888 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001164888 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001164888 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001164888 us-gaap:SeriesBPreferredStockMember 2020-09-30 0001164888 us-gaap:PreferredStockMember 2020-09-30 0001164888 KBPH:PreferredStockBMember 2020-09-30 0001164888 us-gaap:CommonStockMember 2020-09-30 0001164888 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001164888 us-gaap:RetainedEarningsMember 2020-09-30 0001164888 2020-09-30 0001164888 us-gaap:PreferredStockMember 2020-03-31 0001164888 KBPH:PreferredStockBMember 2020-03-31 0001164888 us-gaap:CommonStockMember 2020-03-31 0001164888 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001164888 us-gaap:RetainedEarningsMember 2020-03-31 0001164888 2020-03-31 0001164888 us-gaap:PreferredStockMember 2020-04-01 2020-09-30 0001164888 KBPH:PreferredStockBMember 2020-04-01 2020-09-30 0001164888 us-gaap:CommonStockMember 2020-04-01 2020-09-30 0001164888 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-09-30 0001164888 us-gaap:RetainedEarningsMember 2020-04-01 2020-09-30 0001164888 KBPH:AbferoPharmaceuticalsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemeberTwoThousandTwentyTwoMember 2021-09-30 0001164888 KBPH:AbferoPharmaceuticalsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemeberTwoThousandTwentyTwoMember 2021-04-01 2021-09-30 0001164888 KBPH:AcheliosTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:AcheliosTherapeuticsIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneOneMember 2021-04-01 2021-09-30 0001164888 KBPH:AcheliosTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneOneMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:AcheliosTherapeuticsIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneTwoMember 2021-04-01 2021-09-30 0001164888 KBPH:AcheliosTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneTwoMember 2021-09-30 0001164888 KBPH:AcheliosTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSidecarTwentyFivePercentageDiscountNoInterestMember 2021-09-30 0001164888 KBPH:AOADXIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteFourPercentageDueMayTwoThousandTwentyFourMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:AOADXIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteFourPercentageDueMayTwoThousandTwentyFourMember 2021-04-01 2021-09-30 0001164888 KBPH:AvisiTechnologiesIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueJulyTwoThousandTwentyTwoMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:AvisiTechnologiesIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteEightPercentageDueJulyTwoThousandTwentyTwoMember 2021-04-01 2021-09-30 0001164888 KBPH:BasepawsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteOnePercentageDueAprilTwoThousandTwentyMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:BasepawsIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteOnePercentageDueAprilTwoThousandTwentyMember 2021-04-01 2021-09-30 0001164888 KBPH:BeamSemiConductorIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueAprilTwoThousandTwentyTwoMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:BeamSemiConductorIncMember KBPH:TechnologyMember KBPH:ConvertibleNoteEightPercentageDueAprilTwoThousandTwentyTwoMember 2021-04-01 2021-09-30 0001164888 KBPH:BeamSemiConductorIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueMarchTwoThousandTwentyOneMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:BeamSemiConductorIncMember KBPH:TechnologyMember KBPH:ConvertibleNoteEightPercentageDueMarchTwoThousandTwentyOneMember 2021-04-01 2021-09-30 0001164888 KBPH:BeamSemiConductorIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueMarchTwoThousandTwentyTwoMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:BeamSemiConductorIncMember KBPH:TechnologyMember KBPH:ConvertibleNoteEightPercentageDueMarchTwoThousandTwentyTwoMember 2021-04-01 2021-09-30 0001164888 KBPH:CoLabsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueFebruaryTwoThousandTwentyThreeMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:CoLabsIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteSixPercentageDueFebruaryTwoThousandTwentyThreeMember 2021-04-01 2021-09-30 0001164888 KBPH:CorinnovaIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyFourMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:CorinnovaIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyFourMember 2021-04-01 2021-09-30 0001164888 KBPH:CorinnovaIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyFourOneMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:CorinnovaIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyFourOneMember 2021-04-01 2021-09-30 0001164888 KBPH:CyberdonticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueSeptemberTwoThousandTwentyTwoMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:CyberdonticsIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteEightPercentageDueSeptemberTwoThousandTwentyTwoMember 2021-04-01 2021-09-30 0001164888 KBPH:CyberdonticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueFebruaryTwoThousandTwentyThreeMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:CyberdonticsIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteEightPercentageDueFebruaryTwoThousandTwentyThreeMember 2021-04-01 2021-09-30 0001164888 KBPH:CyberdonticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteZeroPercentageOnDueDateMember 2021-09-30 0001164888 KBPH:DeepBlueMedicalAdvancesIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueJuneTwoThousandTwentyTwoMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:DeepBlueMedicalAdvancesIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteSixPercentageDueJuneTwoThousandTwentyTwoMember 2021-04-01 2021-09-30 0001164888 KBPH:EveryKeyIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteFivePercentageDueDecemberTwoThousandTwentyThreeMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:EveryKeyIncMember KBPH:TechnologyMember KBPH:ConvertibleNoteFivePercentageDueDecemberTwoThousandTwentyThreeMember 2021-04-01 2021-09-30 0001164888 KBPH:IdenticalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteTwoPercentageDueMayTwoThousandTwentyTwoMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:IdenticalIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteTwoPercentageDueMayTwoThousandTwentyTwoMember 2021-04-01 2021-09-30 0001164888 KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteTwelvePercentageDueOctoberTwoThousandTwentyMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember KBPH:ConvertibleNoteTwelvePercentageDueOctoberTwoThousandTwentyMember 2021-04-01 2021-09-30 0001164888 KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteTwelvePercentageDueJulyTwoThousandTwentyOneMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember KBPH:ConvertibleNoteTwelvePercentageDueJulyTwoThousandTwentyOneMember 2021-04-01 2021-09-30 0001164888 KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteTwelvePercentageDueFebruaryTwoThousandTwentyTwoMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember KBPH:ConvertibleNoteTwelvePercentageDueFebruaryTwoThousandTwentyTwoMember 2021-04-01 2021-09-30 0001164888 KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteTwelvePercentageDueDecemberTwoThousandTwentyTwoMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember KBPH:ConvertibleNoteTwelvePercentageDueDecemberTwoThousandTwentyTwoMember 2021-04-01 2021-09-30 0001164888 KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteTwelvePercentageDueDecemberTwoThousandTwentyThreeMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember KBPH:ConvertibleNoteTwelvePercentageDueDecemberTwoThousandTwentyThreeMember 2021-04-01 2021-09-30 0001164888 KBPH:IrisRAndDGroupIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueMayTwoThousandTwentyThreeMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:IrisRAndDGroupIncMember KBPH:TechnologyMember KBPH:ConvertibleNoteEightPercentageDueMayTwoThousandTwentyThreeMember 2021-04-01 2021-09-30 0001164888 KBPH:KianaAnalyticsMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteThreePercentageDueDecemberTwoThousandTwentyTwoMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:KianaAnalyticsMember KBPH:TechnologyMember KBPH:ConvertibleNoteThreePercentageDueDecemberTwoThousandTwentyTwoMember 2021-04-01 2021-09-30 0001164888 KBPH:KiotechMedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:KiotechMedicalIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyMember 2021-04-01 2021-09-30 0001164888 KBPH:KiotechMedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueNovemberTwoThousandTwentyTwoMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:KiotechMedicalIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteSixPercentageDueNovemberTwoThousandTwentyTwoMember 2021-04-01 2021-09-30 0001164888 KBPH:LifewaveBiomedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:LifewaveBiomedicalIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyMember 2021-04-01 2021-09-30 0001164888 KBPH:LifewaveBiomedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyOnlyMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:LifewaveBiomedicalIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyOnlyMember 2021-04-01 2021-09-30 0001164888 KBPH:LifewaveBiomedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyOneMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:LifewaveBiomedicalIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyOneMember 2021-04-01 2021-09-30 0001164888 KBPH:LowellTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageNoDueDateMember 2021-09-30 0001164888 KBPH:MMTronIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteFourPercentageDueAprilTwoThousandTwentyThreeMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:MMTronIncMember KBPH:TechnologyMember KBPH:ConvertibleNoteFourPercentageDueAprilTwoThousandTwentyThreeMember 2021-04-01 2021-09-30 0001164888 KBPH:NavauxIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyThreeMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:NavauxIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyThreeMember 2021-04-01 2021-09-30 0001164888 KBPH:NeuroFoutyTwoIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueDecemberTwoThousandTwentyThreeMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:NeuroFoutyTwoIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteEightPercentageDueDecemberTwoThousandTwentyThreeMember 2021-04-01 2021-09-30 0001164888 KBPH:OctagonTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteFivePercentageDueJuneTwoThousandTwentyOneMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:OctagonTherapeuticsIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteFivePercentageDueJuneTwoThousandTwentyOneMember 2021-04-01 2021-09-30 0001164888 KBPH:OctagonTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteFivePercentageDueJuneTwoThousandTwentyOneOnlyMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:OctagonTherapeuticsIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteFivePercentageDueJuneTwoThousandTwentyOneOnlyMember 2021-04-01 2021-09-30 0001164888 KBPH:PerikineticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueMayTwoThousandTwentyTwoMember 2021-09-30 0001164888 KBPH:PerikineticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueMayTwoThousandTwentyTwoMember 2021-04-01 2021-09-30 0001164888 KBPH:PreviewMedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSevenPercentageDueJanuaryTwoThousandTwentyThreeMember 2021-09-30 0001164888 KBPH:PreviewMedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSevenPercentageDueJanuaryTwoThousandTwentyThreeMember 2021-04-01 2021-09-30 0001164888 KBPH:PromaxoIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteFivePercentageDueJulyTwoThousandTwentyTwoMember 2021-09-30 0001164888 KBPH:PromaxoIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteFivePercentageDueJulyTwoThousandTwentyTwoMember 2021-04-01 2021-09-30 0001164888 KBPH:RheosIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueAugustTwoThousandTwentySixMember 2021-09-30 0001164888 KBPH:RheosIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueAugustTwoThousandTwentySixMember 2021-04-01 2021-09-30 0001164888 KBPH:SaccharoIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSevenPercentageDueSeptemberTwoThousandTwentyTwoMember 2021-09-30 0001164888 KBPH:SaccharoIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSevenPercentageDueSeptemberTwoThousandTwentyTwoMember 2021-04-01 2021-09-30 0001164888 KBPH:SageMedicCorpMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueAprilTwoThousandTwentyOnePlusWarrantsMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:SageMedicCorpMember KBPH:LifeScienceMember KBPH:ConvertibleNoteEightPercentageDueAprilTwoThousandTwentyOnePlusWarrantsMember 2021-04-01 2021-09-30 0001164888 KBPH:SageMedicCorpMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueDecemberTwoThousandTwentyTwoPlusWarrantsMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:SageMedicCorpMember KBPH:LifeScienceMember KBPH:ConvertibleNoteEightPercentageDueDecemberTwoThousandTwentyTwoPlusWarrantsMember 2021-04-01 2021-09-30 0001164888 KBPH:SensingElectromagneticPlusCorpMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteFullyReservedMember 2021-09-30 0001164888 KBPH:SensingElectromagneticPlusCorpMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteFullyReservedOneMember 2021-09-30 0001164888 KBPH:SinglePassIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageAprilTwoThousandTwentyFourMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:SinglePassIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteSixPercentageAprilTwoThousandTwentyFourMember 2021-04-01 2021-09-30 0001164888 KBPH:ValfixMedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDecemberTwoThousandTwentyOneMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:ValfixMedicalIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteEightPercentageDecemberTwoThousandTwentyOneMember 2021-04-01 2021-09-30 0001164888 KBPH:XpanIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageMarchTwoThousandTwentyTwoMember 2021-09-30 0001164888 KBPH:XpanIncMember KBPH:LifeScienceMember us-gaap:CorporateNoteSecuritiesMember KBPH:ConvertibleNoteEightPercentageMarchTwoThousandTwentyTwoMember 2021-09-30 0001164888 us-gaap:CorporateNoteSecuritiesMember KBPH:XpanIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteEightPercentageMarchTwoThousandTwentyTwoMember 2021-04-01 2021-09-30 0001164888 KBPH:XpanIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageJuneTwoThousandTwentyTwoMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:XpanIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteEightPercentageJuneTwoThousandTwentyTwoMember 2021-04-01 2021-09-30 0001164888 KBPH:XpanIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageJuneTwoThousandTwentyTwoOnlyMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:XpanIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteEightPercentageJuneTwoThousandTwentyTwoOnlyMember 2021-04-01 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember country:US 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember country:CA 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:RestOfWorldMember 2021-09-30 0001164888 KBPH:AltisBiosystemsMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2021-09-30 0001164888 KBPH:AltisBiosystemsMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2021-04-01 2021-09-30 0001164888 KBPH:AstrocytePharmaceuticalsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-09-30 0001164888 KBPH:AstrocytePharmaceuticalsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-04-01 2021-09-30 0001164888 KBPH:CnoteGroupIncMember KBPH:FintechMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedTwoPreferredMember 2021-09-30 0001164888 KBPH:CnoteGroupIncMember KBPH:FintechMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedTwoPreferredMember 2021-04-01 2021-09-30 0001164888 KBPH:CnoteGroupIncMember KBPH:FintechMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedThreePreferredMember 2021-09-30 0001164888 KBPH:CnoteGroupIncMember KBPH:FintechMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedThreePreferredMember 2021-04-01 2021-09-30 0001164888 KBPH:CoLabsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredMember 2021-09-30 0001164888 KBPH:CoLabsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredMember 2021-04-01 2021-09-30 0001164888 KBPH:ConnectusServicesLtdMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2021-09-30 0001164888 KBPH:ConnectusServicesLtdMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2021-04-01 2021-09-30 0001164888 KBPH:DeepBlueMedicalAdvancesIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-09-30 0001164888 KBPH:DeepBlueMedicalAdvancesIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-04-01 2021-09-30 0001164888 KBPH:EumentisThereapeuticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-09-30 0001164888 KBPH:EumentisThereapeuticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-04-01 2021-09-30 0001164888 KBPH:FemtoDXIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-09-30 0001164888 KBPH:FemtoDXIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-04-01 2021-09-30 0001164888 KBPH:HealionicsCorporationMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredMember 2021-09-30 0001164888 KBPH:HealionicsCorporationMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredMember 2021-04-01 2021-09-30 0001164888 KBPH:ILumenScientificIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredPlusWarrantsMember 2021-09-30 0001164888 KBPH:ILumenScientificIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredPlusWarrantsMember 2021-04-01 2021-09-30 0001164888 KBPH:ILumenScientificIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredPlusWarrantsOneMember 2021-09-30 0001164888 KBPH:ILumenScientificIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredPlusWarrantsOneMember 2021-04-01 2021-09-30 0001164888 KBPH:InhalonBiopharmaIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2021-09-30 0001164888 KBPH:InhalonBiopharmaIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2021-04-01 2021-09-30 0001164888 KBPH:LightLineMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteMember 2021-09-30 0001164888 KBPH:LightLineMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteMember 2021-04-01 2021-09-30 0001164888 KBPH:LightLineMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteOneMember 2021-09-30 0001164888 KBPH:LightLineMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteOneMember 2021-04-01 2021-09-30 0001164888 KBPH:LightLineMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2021-09-30 0001164888 KBPH:LightLineMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2021-04-01 2021-09-30 0001164888 KBPH:LightLineMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredPlusWarrantsMember 2021-09-30 0001164888 KBPH:LightLineMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredPlusWarrantsMember 2021-04-01 2021-09-30 0001164888 KBPH:LowellTherapeuticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-09-30 0001164888 KBPH:LowellTherapeuticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-04-01 2021-09-30 0001164888 KBPH:LowellTherapeuticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredStockOneMember 2021-04-01 2021-09-30 0001164888 KBPH:LowellTherapeuticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesBPreferredStockMember 2021-09-30 0001164888 KBPH:LowellTherapeuticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesBPreferredStockMember 2021-04-01 2021-09-30 0001164888 KBPH:MakaniScienceIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2021-09-30 0001164888 KBPH:MakaniScienceIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2021-04-01 2021-09-30 0001164888 KBPH:MicronicTechnologiesIncMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedOnePreferredPlusWarrantsMember 2021-09-30 0001164888 KBPH:MicronicTechnologiesIncMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedOnePreferredPlusWarrantsMember 2021-04-01 2021-09-30 0001164888 KBPH:NeuroflowIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedTwoPreferredMember 2021-09-30 0001164888 KBPH:NeuroflowIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedTwoPreferredMember 2021-04-01 2021-09-30 0001164888 KBPH:NeuroflowIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesBPreferredStockMember 2021-09-30 0001164888 KBPH:NeuroflowIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesBPreferredStockMember 2021-04-01 2021-09-30 0001164888 KBPH:NewViewSurgicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredMember 2021-09-30 0001164888 KBPH:NewViewSurgicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredMember 2021-04-01 2021-09-30 0001164888 KBPH:NewViewSurgicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredOneMember 2021-09-30 0001164888 KBPH:NewViewSurgicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredOneMember 2021-04-01 2021-09-30 0001164888 KBPH:OrionBiotechnologyIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-09-30 0001164888 KBPH:OrionBiotechnologyIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-04-01 2021-09-30 0001164888 KBPH:OtomagneticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredPlusWarrantsMember 2021-09-30 0001164888 KBPH:OtomagneticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredPlusWarrantsMember 2021-04-01 2021-09-30 0001164888 KBPH:PartheousIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-09-30 0001164888 KBPH:PartheousIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-04-01 2021-09-30 0001164888 KBPH:PromaxolIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesBOnePreferredConvertedNoteMember 2021-09-30 0001164888 KBPH:PromaxoIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesBOnePreferredConvertedNoteMember 2021-04-01 2021-09-30 0001164888 KBPH:SealRockTherapeuticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteMember 2021-09-30 0001164888 KBPH:SealRockTherapeuticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteMember 2021-04-01 2021-09-30 0001164888 KBPH:ShyftFKACraterGroupIncMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredMember 2021-09-30 0001164888 KBPH:ShyftFKACraterGroupIncMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredMember 2021-04-01 2021-09-30 0001164888 KBPH:ShyftFKACraterGroupIncMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-09-30 0001164888 KBPH:ShyftFKACraterGroupIncMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredConvertedNoteMember 2021-04-01 2021-09-30 0001164888 KBPH:ShyftFKACraterGroupIncMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredConvertedNoteMember 2021-09-30 0001164888 KBPH:ShyftFKACraterGroupIncMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredConvertedNoteMember 2021-04-01 2021-09-30 0001164888 KBPH:TrellisBioscienceLLCMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesBPreferredPlusWarrantsMember 2021-09-30 0001164888 KBPH:TrellisBioscienceLLCMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesBPreferredPlusWarrantsMember 2021-04-01 2021-09-30 0001164888 KBPH:TrellisBioscienceLLCMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesBPreferredPlusWarrantsOneMember 2021-09-30 0001164888 KBPH:TrellisBioscienceLLCMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesBPreferredPlusWarrantsOneMember 2021-04-01 2021-09-30 0001164888 KBPH:TrellisBioscienceLLCMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesBPreferredPlusWarrantsTwoMember 2021-09-30 0001164888 KBPH:TrellisBioscienceLLCMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesBPreferredPlusWarrantsTwoMember 2021-04-01 2021-09-30 0001164888 KBPH:ValfixMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2021-09-30 0001164888 KBPH:ValfixMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2021-04-01 2021-09-30 0001164888 KBPH:VesteckIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-09-30 0001164888 KBPH:VesteckIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredConvertedNoteMember 2021-04-01 2021-09-30 0001164888 KBPH:VisgenxIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedOnePreferredConvertedNoteMember 2021-09-30 0001164888 KBPH:VisgenxIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedOnePreferredConvertedNoteMember 2021-04-01 2021-09-30 0001164888 KBPH:VisgenxIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteMember 2021-09-30 0001164888 KBPH:VisgenxIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteMember 2021-04-01 2021-09-30 0001164888 KBPH:VisgenxIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteOneMember 2021-09-30 0001164888 KBPH:VisgenxIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteOneMember 2021-04-01 2021-09-30 0001164888 KBPH:PreferredInvestmentsMember 2021-09-30 0001164888 KBPH:PreferredInvestmentsMember country:US 2021-09-30 0001164888 KBPH:PreferredInvestmentsMember country:CA 2021-09-30 0001164888 KBPH:PreferredInvestmentsMember KBPH:RestOfWorldMember 2021-09-30 0001164888 KBPH:BendaRXCorpMember KBPH:LifeScienceMember KBPH:CommonStockInvestmentsMember us-gaap:CommonStockMember 2021-09-30 0001164888 KBPH:BendaRXCorpMember KBPH:LifeScienceMember KBPH:CommonStockInvestmentsMember us-gaap:CommonStockMember 2021-04-01 2021-09-30 0001164888 KBPH:BendaRXCorpMember KBPH:LifeScienceMember KBPH:CommonStockInvestmentsMember KBPH:CommonStockOneMember 2021-09-30 0001164888 KBPH:BendaRXCorpMember KBPH:LifeScienceMember KBPH:CommonStockInvestmentsMember KBPH:CommonStockOneMember 2021-04-01 2021-09-30 0001164888 KBPH:BoardwalkTechMember KBPH:TechnologyMember KBPH:CommonStockInvestmentsMember us-gaap:CommonStockMember 2021-09-30 0001164888 KBPH:BoardwalkTechMember KBPH:TechnologyMember KBPH:CommonStockInvestmentsMember us-gaap:CommonStockMember 2021-04-01 2021-09-30 0001164888 KBPH:BoardwalkTechMember KBPH:TechnologyMember KBPH:CommonStockInvestmentsMember KBPH:CommonStockOneMember 2021-09-30 0001164888 KBPH:BoardwalkTechMember KBPH:TechnologyMember KBPH:CommonStockInvestmentsMember KBPH:CommonStockOneMember 2021-04-01 2021-09-30 0001164888 KBPH:KuantsolIncMember KBPH:TechnologyMember KBPH:CommonStockInvestmentsMember us-gaap:CommonStockMember 2021-09-30 0001164888 KBPH:KuantsolIncMember KBPH:TechnologyMember KBPH:CommonStockInvestmentsMember us-gaap:CommonStockMember 2021-04-01 2021-09-30 0001164888 KBPH:SanabyHealthSponsorLLCMember KBPH:LifeScienceMember KBPH:CommonStockInvestmentsMember us-gaap:CommonStockMember 2021-09-30 0001164888 KBPH:SanabyHealthSponsorLLCMember KBPH:LifeScienceMember KBPH:CommonStockInvestmentsMember us-gaap:CommonStockMember 2021-04-01 2021-09-30 0001164888 KBPH:CommonStockInvestmentMember 2021-09-30 0001164888 KBPH:CommonStockInvestmentsMember country:US 2021-09-30 0001164888 KBPH:CommonStockInvestmentsMember country:CA 2021-09-30 0001164888 KBPH:CommonStockInvestmentsMember KBPH:RestOfWorldMember 2021-09-30 0001164888 KBPH:CommonStockInvestmentsMember 2021-09-30 0001164888 KBPH:InfinidomeLtdMember KBPH:TechnologyMember KBPH:SafeInvestmentsMember KBPH:SafeMember 2021-09-30 0001164888 KBPH:InfinidomeLtdMember KBPH:TechnologyMember KBPH:SafeInvestmentsMember KBPH:SafeOneMember 2021-09-30 0001164888 KBPH:MadorraIncMember KBPH:SafeInvestmentsMember KBPH:SafeInvestmentsMember KBPH:SafeMember 2021-09-30 0001164888 KBPH:MitreMedicalCorpMember KBPH:LifeScienceMember KBPH:SafeInvestmentsMember KBPH:SafeMember 2021-09-30 0001164888 KBPH:MitreMedicalCorpMember KBPH:LifeScienceMember KBPH:SafeInvestmentsMember KBPH:SafeOneMember 2021-09-30 0001164888 KBPH:OrionBiotechnologyIncMember KBPH:LifeScienceMember KBPH:SafeInvestmentsMember KBPH:SafeMember 2021-09-30 0001164888 KBPH:PolymertalIncMember KBPH:TechnologyMember KBPH:SafeInvestmentsMember KBPH:SafeMember 2021-09-30 0001164888 KBPH:SafeInvestmentsMember 2021-09-30 0001164888 KBPH:SafeInvestmentsMember country:US 2021-09-30 0001164888 KBPH:SafeInvestmentsMember country:CA 2021-09-30 0001164888 KBPH:SafeInvestmentsMember KBPH:RestOfWorldMember 2021-09-30 0001164888 KBPH:EnduralockLLCMember KBPH:TechnologyMember KBPH:OtherInvestmentMember KBPH:SeriesAOneOwnershipUnitsMember 2021-09-30 0001164888 KBPH:EnduralockLLCMember KBPH:TechnologyMember KBPH:OtherInvestmentMember KBPH:SeriesAOneOwnershipUnitsMember 2021-04-01 2021-09-30 0001164888 KBPH:EnduralockLLCMember KBPH:TechnologyMember KBPH:OtherInvestmentMember KBPH:SeriesAOneOwnershipUnitsOneMember 2021-09-30 0001164888 KBPH:EnduralockLLCMember KBPH:TechnologyMember KBPH:OtherInvestmentMember KBPH:SeriesAOneOwnershipUnitsOneMember 2021-04-01 2021-09-30 0001164888 KBPH:ExodosLifeSciencesLPMember KBPH:LifeScienceMember KBPH:OtherInvestmentMember KBPH:SeriesAOneOwnershipUnitsMember 2021-09-30 0001164888 KBPH:GreenSunMedicalLLCMember KBPH:LifeScienceMember KBPH:OtherInvestmentMember KBPH:ClassAOnePreferredOwnershipUnitsMember 2021-09-30 0001164888 KBPH:GreenSunMedicalLLCMember KBPH:LifeScienceMember KBPH:OtherInvestmentMember KBPH:ClassAOnePreferredOwnershipUnitsMember 2021-04-01 2021-09-30 0001164888 KBPH:GreenSunMedicalLLCMember KBPH:LifeScienceMember KBPH:OtherInvestmentMember KBPH:ClassAOnePreferredOwnershipUnitsOneMember 2021-09-30 0001164888 KBPH:GreenSunMedicalLLCMember KBPH:LifeScienceMember KBPH:OtherInvestmentMember KBPH:ClassAOnePreferredOwnershipUnitsOneMember 2021-04-01 2021-09-30 0001164888 KBPH:GreenSunMedicalLLCMember KBPH:LifeScienceMember KBPH:OtherInvestmentMember KBPH:ClassAOnePreferredOwnershipUnitsTwoMember 2021-09-30 0001164888 KBPH:GreenSunMedicalLLCMember KBPH:LifeScienceMember KBPH:OtherInvestmentMember KBPH:ClassAOnePreferredOwnershipUnitsTwoMember 2021-04-01 2021-09-30 0001164888 KBPH:GreenSunMedicalLLCMember KBPH:LifeScienceMember KBPH:OtherInvestmentMember KBPH:ClassAOnePreferredOwnershipUnitsThreeMember 2021-09-30 0001164888 KBPH:GreenSunMedicalLLCMember KBPH:LifeScienceMember KBPH:OtherInvestmentMember KBPH:ClassAOnePreferredOwnershipUnitsThreeMember 2021-04-01 2021-09-30 0001164888 KBPH:RisoCapitalFundILPMember KBPH:TechnologyMember KBPH:OtherInvestmentMember KBPH:OwnershipUnitsMember 2021-09-30 0001164888 KBPH:RisoCapitalFundILPMember KBPH:TechnologyMember KBPH:OtherInvestmentMember KBPH:OwnershipUnitsOneMember 2021-09-30 0001164888 KBPH:OtherInvestmentMember 2021-09-30 0001164888 KBPH:OtherInvestmentMember country:US 2021-09-30 0001164888 KBPH:OtherInvestmentMember country:CA 2021-09-30 0001164888 KBPH:OtherInvestmentMember KBPH:RestOfWorldMember 2021-09-30 0001164888 country:US 2021-09-30 0001164888 country:CA 2021-09-30 0001164888 KBPH:RestOfWorldMember 2021-09-30 0001164888 KBPH:AcheliosTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneMember 2021-03-31 0001164888 KBPH:AcheliosTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneMember 2020-04-01 2021-03-31 0001164888 KBPH:AcheliosTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneOneMember 2021-03-31 0001164888 KBPH:AcheliosTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneOneMember 2020-04-01 2021-03-31 0001164888 KBPH:AcheliosTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneTwoMember 2021-03-31 0001164888 KBPH:AcheliosTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneTwoMember 2020-04-01 2021-03-31 0001164888 KBPH:AvisiTechnologiesIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueJulyTwoThousandTwentyTwoMember 2021-03-31 0001164888 KBPH:AvisiTechnologiesIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueJulyTwoThousandTwentyTwoMember 2020-04-01 2021-03-31 0001164888 KBPH:BasepawsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteOnePercentageDueAprilTwoThousandTwentyMember 2021-03-31 0001164888 KBPH:BasepawsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteOnePercentageDueAprilTwoThousandTwentyMember 2020-04-01 2021-03-31 0001164888 KBPH:BeamSemiConductorIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueAprilTwoThousandTwentyTwoMember 2021-03-31 0001164888 KBPH:BeamSemiConductorIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueAprilTwoThousandTwentyTwoMember 2020-04-01 2021-03-31 0001164888 KBPH:BeamSemiConductorIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueMarchTwoThousandTwentyOneMember 2021-03-31 0001164888 KBPH:BeamSemiConductorIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueMarchTwoThousandTwentyOneMember 2020-04-01 2021-03-31 0001164888 KBPH:CorinnovaIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyFourMember 2021-03-31 0001164888 KBPH:CorinnovaIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyFourMember 2020-04-01 2021-03-31 0001164888 KBPH:CyberdonticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueSeptemberTwoThousandTwentyTwoMember 2021-03-31 0001164888 KBPH:CyberdonticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueSeptemberTwoThousandTwentyTwoMember 2020-04-01 2021-03-31 0001164888 KBPH:CyberdonticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueFebruaryTwoThousandTwentyThreeMember 2021-03-31 0001164888 KBPH:CyberdonticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueFebruaryTwoThousandTwentyThreeMember 2020-04-01 2021-03-31 0001164888 KBPH:CyberdonticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteZeroPercentageOnDueDateMember 2021-03-31 0001164888 KBPH:DeepBlueMedicalAdvancesIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueJuneTwoThousandTwentyTwoMember 2021-03-31 0001164888 KBPH:DeepBlueMedicalAdvancesIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueJuneTwoThousandTwentyTwoMember 2020-04-01 2021-03-31 0001164888 KBPH:EveryKeyIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteFivePercentageDueDecemberTwoThousandTwentyThreeMember 2021-03-31 0001164888 KBPH:EveryKeyIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteFivePercentageDueDecemberTwoThousandTwentyThreeMember 2020-04-01 2021-03-31 0001164888 KBPH:IdenticalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteTwoPercentageDueMayTwoThousandTwentyTwoMember 2021-03-31 0001164888 KBPH:IdenticalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteTwoPercentageDueMayTwoThousandTwentyTwoMember 2020-04-01 2021-03-31 0001164888 KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteTwelvePercentageDueOctoberTwoThousandTwentyMember 2021-03-31 0001164888 KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteTwelvePercentageDueOctoberTwoThousandTwentyMember 2020-04-01 2021-03-31 0001164888 KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteTwelvePercentageDueJulyTwoThousandTwentyOneMember 2021-03-31 0001164888 KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteTwelvePercentageDueJulyTwoThousandTwentyOneMember 2020-04-01 2021-03-31 0001164888 KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteTwelvePercentageDueFebruaryTwoThousandTwentyTwoMember 2021-03-31 0001164888 KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteTwelvePercentageDueFebruaryTwoThousandTwentyTwoMember 2020-04-01 2021-03-31 0001164888 KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteTwelvePercentageDueDecemberTwoThousandTwentyTwoMember 2021-03-31 0001164888 KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteTwelvePercentageDueDecemberTwoThousandTwentyTwoMember 2020-04-01 2021-03-31 0001164888 KBPH:KianaAnalyticsMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteThreePercentageDueDecemberTwoThousandTwentyTwoMember 2021-03-31 0001164888 KBPH:KianaAnalyticsMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteThreePercentageDueDecemberTwoThousandTwentyTwoMember 2020-04-01 2021-03-31 0001164888 KBPH:KiotechMedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyMember 2021-03-31 0001164888 KBPH:KiotechMedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyMember 2020-04-01 2021-03-31 0001164888 KBPH:KiotechMedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueNovemberTwoThousandTwentyTwoMember 2021-03-31 0001164888 KBPH:KiotechMedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueNovemberTwoThousandTwentyTwoMember 2020-04-01 2021-03-31 0001164888 KBPH:LifewaveBiomedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyMember 2021-03-31 0001164888 KBPH:LifewaveBiomedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyMember 2020-04-01 2021-03-31 0001164888 KBPH:LifewaveBiomedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyOnlyMember 2021-03-31 0001164888 KBPH:LifewaveBiomedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyOnlyMember 2020-04-01 2021-03-31 0001164888 KBPH:NavauxIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyThreeMember 2021-03-31 0001164888 KBPH:NavauxIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyThreeMember 2020-04-01 2021-03-31 0001164888 KBPH:NeuroFoutyTwoIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueDecemberTwoThousandTwentyThreeMember 2021-03-31 0001164888 KBPH:NeuroFoutyTwoIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueDecemberTwoThousandTwentyThreeMember 2020-04-01 2021-03-31 0001164888 KBPH:OctagonTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteFivePercentageDueJuneTwoThousandTwentyOneMember 2021-03-31 0001164888 KBPH:OctagonTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteFivePercentageDueJuneTwoThousandTwentyOneMember 2020-04-01 2021-03-31 0001164888 KBPH:OctagonTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteFivePercentageDueJuneTwoThousandTwentyOneOnlyMember 2021-03-31 0001164888 KBPH:OctagonTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteFivePercentageDueJuneTwoThousandTwentyOneOnlyMember 2020-04-01 2021-03-31 0001164888 KBPH:PerikineticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueMayTwoThousandTwentyTwoMember 2021-03-31 0001164888 KBPH:PerikineticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueMayTwoThousandTwentyTwoMember 2020-04-01 2021-03-31 0001164888 KBPH:PreviewMedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSevenPercentageDueJanuaryTwoThousandTwentyThreeMember 2021-03-31 0001164888 KBPH:PreviewMedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSevenPercentageDueJanuaryTwoThousandTwentyThreeMember 2020-04-01 2021-03-31 0001164888 KBPH:SageMedicCorpMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueAprilTwoThousandTwentyOnePlusWarrantsMember 2021-03-31 0001164888 KBPH:SageMedicCorpMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueAprilTwoThousandTwentyOnePlusWarrantsMember 2020-04-01 2021-03-31 0001164888 KBPH:SageMedicCorpMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueDecemberTwoThousandTwentyTwoPlusWarrantsMember 2021-03-31 0001164888 KBPH:SageMedicCorpMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueDecemberTwoThousandTwentyTwoPlusWarrantsMember 2020-04-01 2021-03-31 0001164888 KBPH:SensingElectromagneticPlusCorpMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteFullyReservedMember 2021-03-31 0001164888 KBPH:SensingElectromagneticPlusCorpMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteFullyReservedOneMember 2021-03-31 0001164888 KBPH:ValfixMedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDecemberTwoThousandTwentyOneMember 2021-03-31 0001164888 KBPH:ValfixMedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDecemberTwoThousandTwentyOneMember 2020-04-01 2021-03-31 0001164888 KBPH:XpanIncMember KBPH:LifeScienceMember us-gaap:CorporateNoteSecuritiesMember KBPH:ConvertibleNoteEightPercentageMarchTwoThousandTwentyTwoMember 2021-03-31 0001164888 KBPH:XpanIncMember KBPH:LifeScienceMember us-gaap:CorporateNoteSecuritiesMember KBPH:ConvertibleNoteEightPercentageMarchTwoThousandTwentyTwoMember 2020-04-01 2021-03-31 0001164888 KBPH:XpanIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageJuneTwoThousandTwentyTwoMember 2021-03-31 0001164888 KBPH:XpanIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageJuneTwoThousandTwentyTwoMember 2020-04-01 2021-03-31 0001164888 KBPH:XpanIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageJuneTwoThousandTwentyTwoOnlyMember 2021-03-31 0001164888 KBPH:XpanIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageJuneTwoThousandTwentyTwoOnlyMember 2020-04-01 2021-03-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember 2021-03-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember country:US 2021-03-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember country:CA 2021-03-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:RestOfWorldMember 2021-03-31 0001164888 KBPH:AltisBiosystemsMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2020-04-01 2021-03-31 0001164888 KBPH:AltisBiosystemsMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2021-03-31 0001164888 KBPH:AstrocytePharmaceuticalsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2020-04-01 2021-03-31 0001164888 KBPH:AstrocytePharmaceuticalsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-03-31 0001164888 KBPH:CnoteGroupIncMember KBPH:FintechMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedTwoPreferredMember 2020-04-01 2021-03-31 0001164888 KBPH:CnoteGroupIncMember KBPH:FintechMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedTwoPreferredMember 2021-03-31 0001164888 KBPH:CnoteGroupIncMember KBPH:FintechMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedThreePreferredMember 2020-04-01 2021-03-31 0001164888 KBPH:CnoteGroupIncMember KBPH:FintechMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedThreePreferredMember 2021-03-31 0001164888 KBPH:CoLabsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredMember 2020-04-01 2021-03-31 0001164888 KBPH:CoLabsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredMember 2021-03-31 0001164888 KBPH:ConnectusServicesLtdMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2020-04-01 2021-03-31 0001164888 KBPH:ConnectusServicesLtdMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2021-03-31 0001164888 KBPH:DeepBlueMedicalAdvancesIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2020-04-01 2021-03-31 0001164888 KBPH:DeepBlueMedicalAdvancesIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-03-31 0001164888 KBPH:EumentisThereapeuticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2020-04-01 2021-03-31 0001164888 KBPH:EumentisThereapeuticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-03-31 0001164888 KBPH:FemtoDXIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2020-04-01 2021-03-31 0001164888 KBPH:FemtoDXIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-03-31 0001164888 KBPH:ILumenScientificIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredPlusWarrantsMember 2020-04-01 2021-03-31 0001164888 KBPH:ILumenScientificIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredPlusWarrantsMember 2021-03-31 0001164888 KBPH:ILumenScientificIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredPlusWarrantsOneMember 2020-04-01 2021-03-31 0001164888 KBPH:ILumenScientificIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredPlusWarrantsOneMember 2021-03-31 0001164888 KBPH:InhalonBiopharmaIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2020-04-01 2021-03-31 0001164888 KBPH:InhalonBiopharmaIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2021-03-31 0001164888 KBPH:LightLineMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteMember 2020-04-01 2021-03-31 0001164888 KBPH:LightLineMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteMember 2021-03-31 0001164888 KBPH:LightLineMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteOneMember 2020-04-01 2021-03-31 0001164888 KBPH:LightLineMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteOneMember 2021-03-31 0001164888 KBPH:LightLineMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2020-04-01 2021-03-31 0001164888 KBPH:LightLineMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2021-03-31 0001164888 KBPH:LightLineMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredPlusWarrantsMember 2020-04-01 2021-03-31 0001164888 KBPH:LightLineMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredPlusWarrantsMember 2021-03-31 0001164888 KBPH:LowellTherapeuticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2020-04-01 2021-03-31 0001164888 KBPH:LowellTherapeuticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-03-31 0001164888 KBPH:LowellTherapeuticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredStockOneMember 2020-04-01 2021-03-31 0001164888 KBPH:LowellTherapeuticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredStockOneMember 2021-03-31 0001164888 KBPH:MicronicTechnologiesIncMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedOnePreferredPlusWarrantsMember 2020-04-01 2021-03-31 0001164888 KBPH:MicronicTechnologiesIncMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedOnePreferredPlusWarrantsMember 2021-03-31 0001164888 KBPH:NeuroflowIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedTwoPreferredMember 2020-04-01 2021-03-31 0001164888 KBPH:NeuroflowIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedTwoPreferredMember 2021-03-31 0001164888 KBPH:NeuroflowIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesBPreferredStockMember 2020-04-01 2021-03-31 0001164888 KBPH:NeuroflowIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesBPreferredStockMember 2021-03-31 0001164888 KBPH:NewViewSurgicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredMember 2020-04-01 2021-03-31 0001164888 KBPH:NewViewSurgicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredMember 2021-03-31 0001164888 KBPH:OtomagneticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredPlusWarrantsMember 2020-04-01 2021-03-31 0001164888 KBPH:OtomagneticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredPlusWarrantsMember 2021-03-31 0001164888 KBPH:PromaxoMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesBOnePreferredConvertedNoteMember 2020-04-01 2021-03-31 0001164888 KBPH:PromaxoMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesBOnePreferredConvertedNoteMember 2021-03-31 0001164888 KBPH:SealRockTherapeuticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteMember 2020-04-01 2021-03-31 0001164888 KBPH:SealRockTherapeuticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteMember 2021-03-31 0001164888 KBPH:ShyftFKACraterGroupIncMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredMember 2020-04-01 2021-03-31 0001164888 KBPH:ShyftFKACraterGroupIncMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredMember 2021-03-31 0001164888 KBPH:ShyftFKACraterGroupIncMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredConvertedNoteMember 2020-04-01 2021-03-31 0001164888 KBPH:ShyftFKACraterGroupIncMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredConvertedNoteMember 2021-03-31 0001164888 KBPH:ShyftFKACraterGroupIncMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredConvertedNoteMember 2020-04-01 2021-03-31 0001164888 KBPH:ShyftFKACraterGroupIncMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredConvertedNoteMember 2021-03-31 0001164888 KBPH:TrellisBioscienceLLCMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesBPreferredPlusWarrantsMember 2020-04-01 2021-03-31 0001164888 KBPH:TrellisBioscienceLLCMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesBPreferredPlusWarrantsMember 2021-03-31 0001164888 KBPH:TrellisBioscienceLLCMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesBPreferredPlusWarrantsOneMember 2020-04-01 2021-03-31 0001164888 KBPH:TrellisBioscienceLLCMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesBPreferredPlusWarrantsOneMember 2021-03-31 0001164888 KBPH:TrellisBioscienceLLCMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesBPreferredPlusWarrantsTwoMember 2020-04-01 2021-03-31 0001164888 KBPH:TrellisBioscienceLLCMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesBPreferredPlusWarrantsTwoMember 2021-03-31 0001164888 KBPH:ValfixMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2020-04-01 2021-03-31 0001164888 KBPH:ValfixMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2021-03-31 0001164888 KBPH:VisgenxIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedOnePreferredConvertedNoteMember 2020-04-01 2021-03-31 0001164888 KBPH:VisgenxIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedOnePreferredConvertedNoteMember 2021-03-31 0001164888 KBPH:VisgenxIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteMember 2020-04-01 2021-03-31 0001164888 KBPH:VisgenxIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteMember 2021-03-31 0001164888 KBPH:VisgenxIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteOneMember 2020-04-01 2021-03-31 0001164888 KBPH:VisgenxIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteOneMember 2021-03-31 0001164888 KBPH:PreferredInvestmentsMember 2021-03-31 0001164888 KBPH:PreferredInvestmentsMember country:US 2021-03-31 0001164888 KBPH:PreferredInvestmentsMember country:CA 2021-03-31 0001164888 KBPH:PreferredInvestmentsMember KBPH:RestOfWorldMember 2021-03-31 0001164888 KBPH:BendaRXCorpMember KBPH:LifeScienceMember KBPH:CommonStockInvestmentsMember us-gaap:CommonStockMember 2020-04-01 2021-03-31 0001164888 KBPH:BendaRXCorpMember KBPH:LifeScienceMember KBPH:CommonStockInvestmentsMember us-gaap:CommonStockMember 2021-03-31 0001164888 KBPH:BendaRXCorpMember KBPH:LifeScienceMember KBPH:CommonStockInvestmentsMember KBPH:CommonStockOneMember 2020-04-01 2021-03-31 0001164888 KBPH:BendaRXCorpMember KBPH:LifeScienceMember KBPH:CommonStockInvestmentsMember KBPH:CommonStockOneMember 2021-03-31 0001164888 KBPH:BoardwalkTechMember KBPH:LifeScienceMember KBPH:CommonStockInvestmentsMember us-gaap:CommonStockMember 2020-04-01 2021-03-31 0001164888 KBPH:BoardwalkTechMember KBPH:LifeScienceMember KBPH:CommonStockInvestmentsMember us-gaap:CommonStockMember 2021-03-31 0001164888 KBPH:CommonStockInvestmentsMember 2021-03-31 0001164888 KBPH:CommonStockInvestmentsMember country:US 2021-03-31 0001164888 KBPH:CommonStockInvestmentsMember country:CA 2021-03-31 0001164888 KBPH:CommonStockInvestmentsMember KBPH:RestOfWorldMember 2021-03-31 0001164888 KBPH:InfinidomeLtdMember KBPH:TechnologyMember KBPH:SafeInvestmentsMember KBPH:SafeMember 2021-03-31 0001164888 KBPH:InfinidomeLtdMember KBPH:TechnologyMember KBPH:SafeInvestmentsMember KBPH:SafeOneMember 2021-03-31 0001164888 KBPH:MitreMedicalCorpMember KBPH:LifeScienceMember KBPH:SafeInvestmentsMember KBPH:SafeMember 2021-03-31 0001164888 KBPH:MitreMedicalCorpMember KBPH:LifeScienceMember KBPH:SafeInvestmentsMember KBPH:SafeOneMember 2021-03-31 0001164888 KBPH:OrionBiotechnologyIncMember KBPH:LifeScienceMember KBPH:SafeInvestmentsMember KBPH:SafeMember 2021-03-31 0001164888 KBPH:SafeInvestmentsMember 2021-03-31 0001164888 KBPH:SafeInvestmentsMember country:US 2021-03-31 0001164888 KBPH:SafeInvestmentsMember country:CA 2021-03-31 0001164888 KBPH:SafeInvestmentsMember KBPH:RestOfWorldMember 2021-03-31 0001164888 KBPH:EnduralockLLCMember KBPH:TechnologyMember KBPH:OtherInvestmentMember KBPH:SeriesAOneOwnershipUnitsMember 2020-04-01 2021-03-31 0001164888 KBPH:EnduralockLLCMember KBPH:TechnologyMember KBPH:OtherInvestmentMember KBPH:SeriesAOneOwnershipUnitsMember 2021-03-31 0001164888 KBPH:EnduralockLLCMember KBPH:TechnologyMember KBPH:OtherInvestmentMember KBPH:SeriesAOneOwnershipUnitsOneMember 2020-04-01 2021-03-31 0001164888 KBPH:EnduralockLLCMember KBPH:TechnologyMember KBPH:OtherInvestmentMember KBPH:SeriesAOneOwnershipUnitsOneMember 2021-03-31 0001164888 KBPH:ExodosLifeSciencesLPMember KBPH:LifeScienceMember KBPH:OtherInvestmentMember KBPH:ClassAOnePreferredOwnershipUnitsMember 2021-03-31 0001164888 KBPH:GreenSunMedicalLLCMember KBPH:LifeScienceMember KBPH:OtherInvestmentMember KBPH:ClassAOnePreferredOwnershipUnitsMember 2020-04-01 2021-03-31 0001164888 KBPH:GreenSunMedicalLLCMember KBPH:LifeScienceMember KBPH:OtherInvestmentMember KBPH:ClassAOnePreferredOwnershipUnitsMember 2021-03-31 0001164888 KBPH:GreenSunMedicalLLCMember KBPH:LifeScienceMember KBPH:OtherInvestmentMember KBPH:ClassAOnePreferredOwnershipUnitsOneMember 2020-04-01 2021-03-31 0001164888 KBPH:GreenSunMedicalLLCMember KBPH:LifeScienceMember KBPH:OtherInvestmentMember KBPH:ClassAOnePreferredOwnershipUnitsOneMember 2021-03-31 0001164888 KBPH:GreenSunMedicalLLCMember KBPH:LifeScienceMember KBPH:OtherInvestmentMember KBPH:ClassAOnePreferredOwnershipUnitsTwoMember 2020-04-01 2021-03-31 0001164888 KBPH:GreenSunMedicalLLCMember KBPH:LifeScienceMember KBPH:OtherInvestmentMember KBPH:ClassAOnePreferredOwnershipUnitsTwoMember 2021-03-31 0001164888 KBPH:RisoCapitalFundILPMember KBPH:TechnologyMember KBPH:OtherInvestmentMember KBPH:OwnershipUnitsMember 2021-03-31 0001164888 KBPH:OtherInvestmentMember 2021-03-31 0001164888 KBPH:OtherInvestmentMember country:US 2021-03-31 0001164888 KBPH:OtherInvestmentMember country:CA 2021-03-31 0001164888 KBPH:OtherInvestmentMember KBPH:RestOfWorldMember 2021-03-31 0001164888 country:US 2021-03-31 0001164888 country:CA 2021-03-31 0001164888 KBPH:RestOfWorldMember 2021-03-31 0001164888 2018-03-31 0001164888 srt:MaximumMember 2021-09-30 0001164888 srt:ChiefExecutiveOfficerMember 2021-01-01 2021-01-02 0001164888 srt:ChiefExecutiveOfficerMember 2021-05-01 2021-05-31 0001164888 srt:ChiefExecutiveOfficerMember 2021-07-01 2021-09-30 0001164888 srt:ChiefExecutiveOfficerMember 2021-04-01 2021-09-30 0001164888 srt:ChiefExecutiveOfficerMember 2020-04-01 2020-09-30 0001164888 2021-10-01 0001164888 KBPH:ConsultantsAndAdvisorsMember 2021-07-01 2021-09-30 0001164888 KBPH:ConsultantsAndAdvisorsMember 2020-07-01 2020-09-30 0001164888 KBPH:ConsultantsAndAdvisorsMember 2021-04-01 2021-09-30 0001164888 KBPH:ConsultantsAndAdvisorsMember 2020-04-01 2020-09-30 0001164888 KBPH:CommonStockIssuedMember 2021-07-01 2021-09-30 0001164888 KBPH:CommonStockIssuedMember 2021-04-01 2021-09-30 0001164888 KBPH:CommonStockSubscribedNotIssuedMember 2021-07-01 2021-09-30 0001164888 KBPH:CommonStockSubscribedNotIssuedMember 2021-04-01 2021-09-30 0001164888 KBPH:SeriesAPreferredStocksMember 2021-07-01 2021-09-30 0001164888 KBPH:SeriesAPreferredStocksMember 2021-04-01 2021-09-30 0001164888 KBPH:SeriesBPreferredStocksMember 2021-07-01 2021-09-30 0001164888 KBPH:SeriesBPreferredStocksMember 2021-04-01 2021-09-30 0001164888 us-gaap:EmployeeStockOptionMember 2021-07-01 2021-09-30 0001164888 us-gaap:EmployeeStockOptionMember 2021-04-01 2021-09-30 0001164888 us-gaap:WarrantMember 2021-07-01 2021-09-30 0001164888 us-gaap:WarrantMember 2021-04-01 2021-09-30 0001164888 KBPH:CommonStockIssuedMember 2020-07-01 2020-09-30 0001164888 KBPH:CommonStockIssuedMember 2020-04-01 2020-09-30 0001164888 KBPH:SeriesAPreferredStocksMember 2020-07-01 2020-09-30 0001164888 KBPH:SeriesAPreferredStocksMember 2020-04-01 2020-09-30 0001164888 KBPH:SeriesBPreferredStocksMember 2020-07-01 2020-09-30 0001164888 KBPH:SeriesBPreferredStocksMember 2020-04-01 2020-09-30 0001164888 us-gaap:EmployeeStockOptionMember 2020-07-01 2020-09-30 0001164888 us-gaap:EmployeeStockOptionMember 2020-04-01 2020-09-30 0001164888 us-gaap:WarrantMember 2020-07-01 2020-09-30 0001164888 us-gaap:WarrantMember 2020-04-01 2020-09-30 0001164888 us-gaap:PreferredStockMember 2021-09-30 0001164888 us-gaap:PreferredStockMember 2021-03-31 0001164888 us-gaap:CommonStockMember 2021-09-30 0001164888 us-gaap:CommonStockMember 2021-03-31 0001164888 KBPH:SafeMember 2021-09-30 0001164888 KBPH:SafeMember 2021-03-31 0001164888 KBPH:OtherOwnershipUnitsMember 2021-09-30 0001164888 KBPH:OtherOwnershipUnitsMember 2021-03-31 0001164888 KBPH:InvestmentFairValueMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:BasepawsIncMember 2021-09-30 0001164888 KBPH:InvestmentFairValueMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:BasepawsIncMember 2021-07-01 2021-09-30 0001164888 KBPH:InvestmentFairValueMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:PromaxoIncMember 2021-09-30 0001164888 KBPH:InvestmentFairValueMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:PromaxoIncMember 2021-07-01 2021-09-30 0001164888 srt:WeightedAverageMember KBPH:PromaxoIncMember KBPH:InvestmentFairValueMember us-gaap:ConvertibleDebtSecuritiesMember 2021-09-30 0001164888 KBPH:InvestmentFairValueMember KBPH:ConvertibleDebtSecuritiesOtherMember 2021-09-30 0001164888 KBPH:InvestmentFairValueMember KBPH:ConvertibleDebtSecuritiesOtherMember 2021-07-01 2021-09-30 0001164888 srt:MinimumMember KBPH:InvestmentFairValueMember KBPH:ConvertibleDebtSecuritiesOtherMember 2021-09-30 0001164888 srt:MaximumMember KBPH:InvestmentFairValueMember KBPH:ConvertibleDebtSecuritiesOtherMember 2021-09-30 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesMember KBPH:ShyftMovingIncMember 2021-09-30 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesMember KBPH:ShyftMovingIncMember 2021-07-01 2021-09-30 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesMember KBPH:SealRockTherapeuticsIncMember 2021-09-30 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesMember KBPH:SealRockTherapeuticsIncMember 2021-07-01 2021-09-30 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesMember KBPH:FemtoDXIncMember 2021-09-30 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesMember KBPH:FemtoDXIncMember 2021-07-01 2021-09-30 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesMember KBPH:PromaxoIncMember 2021-09-30 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesMember KBPH:PromaxoIncMember 2021-07-01 2021-09-30 0001164888 srt:MinimumMember KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesMember KBPH:PromaxoIncMember 2021-09-30 0001164888 srt:MaximumMember KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesMember KBPH:PromaxoIncMember 2021-09-30 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesOtherMember 2021-09-30 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesOtherMember 2021-07-01 2021-09-30 0001164888 KBPH:InvestmentFairValueMember KBPH:CommonStockInPrivateCompaniesMember 2021-09-30 0001164888 KBPH:InvestmentFairValueMember KBPH:CommonStockInPrivateCompaniesMember 2021-07-01 2021-09-30 0001164888 KBPH:InvestmentFairValueMember KBPH:SafeMember 2021-09-30 0001164888 KBPH:InvestmentFairValueMember KBPH:SafeMember 2021-07-01 2021-09-30 0001164888 KBPH:InvestmentFairValueMember us-gaap:OtherInvestmentsMember 2021-09-30 0001164888 KBPH:InvestmentFairValueMember us-gaap:OtherInvestmentsMember 2021-07-01 2021-09-30 0001164888 KBPH:InvestmentFairValueMember 2021-09-30 0001164888 KBPH:InvestmentFairValueMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:KitotechMedicalIncMember 2021-03-31 0001164888 KBPH:InvestmentFairValueMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:KitotechMedicalIncMember 2020-04-01 2021-03-31 0001164888 KBPH:InvestmentFairValueMember us-gaap:ConvertibleDebtSecuritiesMember 2021-03-31 0001164888 KBPH:InvestmentFairValueMember us-gaap:ConvertibleDebtSecuritiesMember 2020-04-01 2021-03-31 0001164888 srt:MinimumMember KBPH:InvestmentFairValueMember KBPH:ConvertibleDebtSecuritiesOtherMember 2021-03-31 0001164888 srt:MaximumMember KBPH:InvestmentFairValueMember KBPH:ConvertibleDebtSecuritiesOtherMember 2021-03-31 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesMember KBPH:FemtoDXIncMember 2021-03-31 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesMember KBPH:FemtoDXIncMember 2020-04-01 2021-03-31 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesMember KBPH:NeuroflowIncMember 2021-03-31 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesMember KBPH:NeuroflowIncMember 2020-04-01 2021-03-31 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesOtherMember 2021-03-31 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesOtherMember 2020-04-01 2021-03-31 0001164888 KBPH:InvestmentFairValueMember KBPH:CommonStockInPrivateCompaniesMember 2021-03-31 0001164888 KBPH:InvestmentFairValueMember KBPH:CommonStockInPrivateCompaniesMember 2020-04-01 2021-03-31 0001164888 KBPH:InvestmentFairValueMember KBPH:SafeMember 2021-03-31 0001164888 KBPH:InvestmentFairValueMember KBPH:SafeMember 2020-04-01 2021-03-31 0001164888 KBPH:InvestmentFairValueMember us-gaap:OtherInvestmentsMember 2021-03-31 0001164888 KBPH:InvestmentFairValueMember us-gaap:OtherInvestmentsMember 2020-04-01 2021-03-31 0001164888 KBPH:InvestmentFairValueMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel1Member us-gaap:ConvertibleDebtSecuritiesMember 2021-09-30 0001164888 us-gaap:FairValueInputsLevel2Member us-gaap:ConvertibleDebtSecuritiesMember 2021-09-30 0001164888 us-gaap:FairValueInputsLevel3Member us-gaap:ConvertibleDebtSecuritiesMember 2021-09-30 0001164888 us-gaap:FairValueInputsLevel1Member us-gaap:PreferredStockMember 2021-09-30 0001164888 us-gaap:FairValueInputsLevel2Member us-gaap:PreferredStockMember 2021-09-30 0001164888 us-gaap:FairValueInputsLevel3Member us-gaap:PreferredStockMember 2021-09-30 0001164888 us-gaap:FairValueInputsLevel1Member KBPH:CommonStockInPrivateCompaniesMember 2021-09-30 0001164888 us-gaap:FairValueInputsLevel2Member KBPH:CommonStockInPrivateCompaniesMember 2021-09-30 0001164888 us-gaap:FairValueInputsLevel3Member KBPH:CommonStockInPrivateCompaniesMember 2021-09-30 0001164888 KBPH:CommonStockInPrivateCompaniesMember 2021-09-30 0001164888 us-gaap:FairValueInputsLevel1Member KBPH:SafeMember 2021-09-30 0001164888 us-gaap:FairValueInputsLevel2Member KBPH:SafeMember 2021-09-30 0001164888 us-gaap:FairValueInputsLevel3Member KBPH:SafeMember 2021-09-30 0001164888 us-gaap:FairValueInputsLevel1Member us-gaap:OtherInvestmentsMember 2021-09-30 0001164888 us-gaap:FairValueInputsLevel2Member us-gaap:OtherInvestmentsMember 2021-09-30 0001164888 us-gaap:FairValueInputsLevel3Member us-gaap:OtherInvestmentsMember 2021-09-30 0001164888 us-gaap:OtherInvestmentsMember 2021-09-30 0001164888 us-gaap:FairValueInputsLevel1Member KBPH:PrivatePortfolioCompaniesMember 2021-09-30 0001164888 us-gaap:FairValueInputsLevel2Member KBPH:PrivatePortfolioCompaniesMember 2021-09-30 0001164888 us-gaap:FairValueInputsLevel3Member KBPH:PrivatePortfolioCompaniesMember 2021-09-30 0001164888 KBPH:PrivatePortfolioCompaniesMember 2021-09-30 0001164888 us-gaap:FairValueInputsLevel1Member KBPH:CommonStockInPublicCompaniesMember 2021-09-30 0001164888 us-gaap:FairValueInputsLevel2Member KBPH:CommonStockInPublicCompaniesMember 2021-09-30 0001164888 us-gaap:FairValueInputsLevel3Member KBPH:CommonStockInPublicCompaniesMember 2021-09-30 0001164888 KBPH:CommonStockInPublicCompaniesMember 2021-09-30 0001164888 us-gaap:FairValueInputsLevel1Member 2021-09-30 0001164888 us-gaap:FairValueInputsLevel2Member 2021-09-30 0001164888 us-gaap:FairValueInputsLevel3Member 2021-09-30 0001164888 us-gaap:FairValueInputsLevel1Member us-gaap:ConvertibleDebtSecuritiesMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel2Member us-gaap:ConvertibleDebtSecuritiesMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel3Member us-gaap:ConvertibleDebtSecuritiesMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel1Member us-gaap:PreferredStockMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel2Member us-gaap:PreferredStockMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel3Member us-gaap:PreferredStockMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel1Member KBPH:CommonStockInPrivateCompaniesMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel2Member KBPH:CommonStockInPrivateCompaniesMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel3Member KBPH:CommonStockInPrivateCompaniesMember 2021-03-31 0001164888 KBPH:CommonStockInPrivateCompaniesMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel1Member KBPH:SafeMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel2Member KBPH:SafeMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel3Member KBPH:SafeMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel1Member us-gaap:OtherInvestmentsMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel2Member us-gaap:OtherInvestmentsMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel3Member us-gaap:OtherInvestmentsMember 2021-03-31 0001164888 us-gaap:OtherInvestmentsMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel1Member KBPH:PrivatePortfolioCompaniesMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel2Member KBPH:PrivatePortfolioCompaniesMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel3Member KBPH:PrivatePortfolioCompaniesMember 2021-03-31 0001164888 KBPH:PrivatePortfolioCompaniesMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel1Member KBPH:CommonStockInPublicCompaniesMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel2Member KBPH:CommonStockInPublicCompaniesMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel3Member KBPH:CommonStockInPublicCompaniesMember 2021-03-31 0001164888 KBPH:CommonStockInPublicCompaniesMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel1Member 2021-03-31 0001164888 us-gaap:FairValueInputsLevel2Member 2021-03-31 0001164888 us-gaap:FairValueInputsLevel3Member 2021-03-31 0001164888 country:US 2021-04-01 2021-09-30 0001164888 country:CA 2021-04-01 2021-09-30 0001164888 KBPH:RestOfWorldMember 2021-04-01 2021-09-30 0001164888 country:US 2020-03-31 0001164888 country:CA 2020-03-31 0001164888 KBPH:RestOfWorldMember 2020-03-31 0001164888 country:US 2020-04-01 2020-09-30 0001164888 country:CA 2020-04-01 2020-09-30 0001164888 KBPH:RestOfWorldMember 2020-04-01 2020-09-30 0001164888 country:US 2020-09-30 0001164888 country:CA 2020-09-30 0001164888 KBPH:RestOfWorldMember 2020-09-30 0001164888 KBPH:FintechMember 2021-03-31 0001164888 KBPH:TechnologyMember 2021-03-31 0001164888 KBPH:LifeScienceMember 2021-03-31 0001164888 KBPH:FintechMember 2021-04-01 2021-09-30 0001164888 KBPH:TechnologyMember 2021-04-01 2021-09-30 0001164888 KBPH:LifeScienceMember 2021-04-01 2021-09-30 0001164888 KBPH:FintechMember 2021-09-30 0001164888 KBPH:TechnologyMember 2021-09-30 0001164888 KBPH:LifeScienceMember 2021-09-30 0001164888 KBPH:FintechMember 2020-03-31 0001164888 KBPH:TechnologyMember 2020-03-31 0001164888 KBPH:LifeScienceMember 2020-03-31 0001164888 KBPH:FintechMember 2020-04-01 2020-09-30 0001164888 KBPH:TechnologyMember 2020-04-01 2020-09-30 0001164888 KBPH:LifeScienceMember 2020-04-01 2020-09-30 0001164888 KBPH:FintechMember 2020-09-30 0001164888 KBPH:TechnologyMember 2020-09-30 0001164888 KBPH:LifeScienceMember 2020-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember 2021-04-01 2021-09-30 0001164888 us-gaap:PreferredStockMember 2021-04-01 2021-09-30 0001164888 us-gaap:CommonStockMember 2021-04-01 2021-09-30 0001164888 KBPH:SafeMember 2021-04-01 2021-09-30 0001164888 KBPH:OtherOwnershipUnitsMember 2021-04-01 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember 2020-03-31 0001164888 us-gaap:PreferredStockMember 2020-03-31 0001164888 us-gaap:CommonStockMember 2020-03-31 0001164888 KBPH:SafeMember 2020-03-31 0001164888 KBPH:OtherOwnershipUnitsMember 2020-03-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember 2020-04-01 2020-09-30 0001164888 us-gaap:PreferredStockMember 2020-04-01 2020-09-30 0001164888 us-gaap:CommonStockMember 2020-04-01 2020-09-30 0001164888 KBPH:SafeMember 2020-04-01 2020-09-30 0001164888 KBPH:OtherOwnershipUnitsMember 2020-04-01 2020-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember 2020-09-30 0001164888 us-gaap:PreferredStockMember 2020-09-30 0001164888 us-gaap:CommonStockMember 2020-09-30 0001164888 KBPH:SafeMember 2020-09-30 0001164888 KBPH:OtherOwnershipUnitsMember 2020-09-30 0001164888 us-gaap:SeriesAPreferredStockMember 2021-04-01 2021-09-30 0001164888 us-gaap:SeriesAPreferredStockMember 2021-06-30 0001164888 KBPH:SeriesAOnePreferredStockMember 2021-09-30 0001164888 KBPH:SeriesAOnePreferredStockMember 2021-07-01 2021-09-30 0001164888 KBPH:SeriesAOneAndSeriesATwoPreferredStockMember us-gaap:IPOMember 2021-07-01 2021-09-30 0001164888 KBPH:SeriesAOnePreferredStockMember 2021-04-01 2021-09-30 0001164888 KBPH:SeriesATwoPreferredStockMember 2021-04-01 2021-09-30 0001164888 us-gaap:SeriesBPreferredStockMember 2021-04-01 2021-09-30 0001164888 us-gaap:CommonStockMember us-gaap:SeriesBPreferredStockMember 2021-03-02 0001164888 KBPH:SeriesBOnePreferredStockMember 2021-02-28 2021-03-02 0001164888 KBPH:SeriesBOneAndSeriesBTwoPreferredStockMember us-gaap:IPOMember 2021-02-28 2021-03-02 0001164888 KBPH:SeriesBOnePreferredStockMember 2021-04-01 2021-09-30 0001164888 KBPH:SeriesBTwoPreferredStockMember 2021-04-01 2021-09-30 0001164888 KBPH:SeriesBOnePreferredStockMember 2021-07-01 2021-09-30 0001164888 KBPH:SeriesBThreePreferredStockMember 2021-09-30 0001164888 KBPH:SeriesBThreePreferredStockMember 2021-09-29 2021-09-30 0001164888 us-gaap:CommonStockMember KBPH:AmendmentofPreferredStockMember 2021-07-01 2021-09-30 0001164888 us-gaap:CommonStockMember KBPH:AmendmentofPreferredStockMember 2021-04-01 2021-09-30 0001164888 us-gaap:CommonStockMember KBPH:AmendmentofPreferredStockMember 2021-03-31 0001164888 KBPH:TwoThousandAndEighteenStockOptionAndIncentivePlanMember 2018-04-28 2018-04-30 0001164888 KBPH:TwoThousandNineteenStockOptionAndIncentivePlanMember 2019-07-31 0001164888 KBPH:TwoThousandNineteenStockOptionAndIncentivePlanMember 2019-07-29 2019-07-31 0001164888 KBPH:TwoThousandAndTwentyStockOptionAndIncentivePlanMember 2020-12-31 0001164888 KBPH:NonQualifiedStockOptionsMember 2021-07-01 2021-09-30 0001164888 KBPH:NonQualifiedStockOptionsMember 2020-07-01 2020-09-30 0001164888 KBPH:NonQualifiedStockOptionsMember 2021-04-01 2021-09-30 0001164888 KBPH:NonQualifiedStockOptionsMember 2020-04-01 2020-09-30 0001164888 srt:MinimumMember 2021-03-31 0001164888 srt:MaximumMember 2021-03-31 0001164888 srt:MinimumMember 2021-04-01 2021-09-30 0001164888 srt:MaximumMember 2021-04-01 2021-09-30 0001164888 srt:MinimumMember 2020-04-01 2021-03-30 0001164888 srt:MaximumMember 2020-04-01 2021-03-30 0001164888 2020-04-01 2021-03-30 0001164888 us-gaap:WarrantMember 2020-03-31 0001164888 us-gaap:WarrantMember 2020-04-01 2020-09-30 0001164888 us-gaap:WarrantMember 2020-09-30 0001164888 us-gaap:WarrantMember 2019-04-01 2020-03-31 0001164888 us-gaap:WarrantMember 2021-03-31 0001164888 us-gaap:WarrantMember 2021-04-01 2021-09-30 0001164888 us-gaap:WarrantMember 2021-09-30 0001164888 us-gaap:WarrantMember 2020-04-01 2021-03-31 0001164888 2021-01-01 2021-09-30 0001164888 KBPH:SeriesBThreePreferredStockMember us-gaap:SubsequentEventMember 2021-10-05 0001164888 us-gaap:SubsequentEventMember KBPH:SeriesBThreePreferredStockMember 2021-11-12 2021-11-13 0001164888 us-gaap:SubsequentEventMember 2021-11-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure KBPH:Integer

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES

EXCHANGE ACT OF 1934

For the quarterly period ended ~~June~~September 30, 2021

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES

EXCHANGE ACT OF 1934

For the transition period from: _____________ to _____________

KYTO TECHNOLOGY AND LIFE SCIENCE, INC.

(Exact name of registrant as specified in its charter)

DELAWARE	000-50390	65-1086538
delaware	000-50390	65-1086538
(State or Other Jurisdiction	(Commission	(I.R.S. Employer
of Incorporation)	File Number)	Identification No.)

13050 Paloma Road, Los Altos Hills, CA 94022

(Address of Principal Executive Office) (Zip Code)

(650) 204 7896

(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Title of each class		Trading Symbol		Exchange
Common stock		KBPH		OTC QB

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (ss. 232.405 of this chapter) during the preceding 12 (or for such shorter period that the registrant was required to submit such files). ~~☐Yes~~ ☒ Yes No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☒
Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). ☐ Yes ☒ No

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

13,287,621 Common Shares - $.01 Par Value - as of ~~September~~November 2815, 2021

KYTO Technology and Life Science, Inc.

For the quarterly period ended ~~June~~September 30, 2021

INDEX

	PART I. FINANCIAL INFORMATION
Item 1.	Financial Statements	3
	Condensed Statements of Asset and Liabilities as of June 30, 2021 (Unaudited) and March 31, 2021	3
	Condensed Statements of Asset and Liabilities as of September 30, 2021 (Unaudited) and March 31, 2021	3
	Unaudited Condensed Statements of Operations for the Three Months Ended June 30, 2021 and 2020	4
	Unaudited Condensed Statements of Operations for the Three Months and Six Months Ended September 30, 2021 and 2020	4
	Unaudited Condensed Statements of Changes in Net Assets for the Three Months Ended June 30, 2021 and 2020	5
	Unaudited Condensed Statements of Changes in Net Assets for the Three Months and Six Months Ended September 30, 2021 and 2020	5
	Unaudited Condensed Statements of Cash Flows for the Three Months Ended June 30, 2021 and 2020	6
	Unaudited Condensed Statements of Cash Flows for the Six Months Ended September 30, 2021 and 2020	7
	Condensed Schedule of Investments as of June 30, 2021 (Unaudited) and March 31, 2021	7
	Condensed Schedule of Investments as of September 30, 2021 (Unaudited) and March 31, 2021	9
	Notes to Unaudited Interim Condensed Financial Statements	1214
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations.	2528
Item 3.	Quantitative and Qualitative Disclosures About Market Risk.	2932
Item 4.	Controls and Procedures.	2932
	PART II. OTHER INFORMATION
Item 1.	Legal Proceedings.	3033
Item 1A.	Risk Factors.	3033
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds.	3033
Item 3.	Defaults Upon Senior Securities.	3033
Item 4.	Mine Safety Disclosures	3033
Item 5.	Other Information	3033
Item 6.	Exhibits	3033
	Signatures	3235

PART I - FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

Kyto Technology and Life Science, Inc.

Condensed Statements of Assets and Liabilities

	June 30,			March 31,
	September 30,			March 31,
	2021			2021
	(Unaudited)
ASSETS
Investments at fair value (cost of $6,952,145 and $5,686,545, respectively)	$	8,140,007		$	6,821,407
Investments at fair value (cost of $7,904,636 and $5,686,545, respectively)	$	10,442,813		$	6,821,407
Cash		~~481~~316,~~506~~124			1,437,868
Deferred offering costs		170,889			169,891
Other current assets		230,434			169,891
Total Assets	$	810,~~792~~989,~~402~~371		$	8,429,166
LIABILITIES
Liabilities
Accounts payable and accrued liabilities	$	~~182~~84,~~951~~477		$	193,141
Accrued liabilities - related parties		7287,~~205~~000			51,420
Common stock subscription liability		-			1,191,442
Total Liabilities		~~255~~171,~~156~~477			1,436,003
Commitments and Contingencies (Note 3)		-			-
Net Assets
Preferred stock authorized but not designated, $.01 par value 19,800,000 shares, none issued and outstanding as of June 30, 2021 and March 31, 2021, respectively		-			-
Preferred stock authorized but not designated, $.01 par value 19,800,000 shares, none issued and outstanding as of September 30, 2021 and March 31, 2021, respectively		-			-
Series A preferred convertible stock, $.01 par value, 4,200,000 shares designated, 4,200,000 issued and outstanding as of June 30, 2021 and March 31, 2021, respectively		42,001			42,001
Series A (including Series A-1 and A-2) preferred convertible stock, $0.01 par value, 4,200,000 shares designated, 4,200,000 issued and outstanding as of September 30, 2021 and March 31, 2021, respectively, aggregate liquidation preference of $6,720,000 at September 30, 2021 and March 31, 2021, respectively		42,001			42,001
Series B preferred convertible stock, $0.01 par value, 6,000,000 shares designated, 4,320,156 and 3,628,906 issued and outstanding as of June 30, 2021 and March 31, 2021, respectively		43,202			36,289
Series B (including Series B-1 and B-2) preferred convertible stock, $0.01 par value, 6,000,000 shares designated, 5,911,406 and 3,628,906 issued and outstanding as of September 30, 2021 and March 31, 2021, respectively, aggregate liquidation preference of $9,458,250 at September 30, 2021 and $5,806,250 at March 31, 2021, respectively		59,114			36,289
Common stock, $.01 par value, 40,000,000 shares authorized, 13,268,871 and 9,983,082 issued and outstanding as of June 30, 2021 and March 31 2021, respectively		132,689			99,831
Preferred stock, value		-			-
Additional paid-in capital		41,610,332			39,772,228
Common stock, $.01 par value, 40,000,000 shares authorized, 13,287,621 and 9,983,082 issued and outstanding as of September 30, 2021 and March 31 2021, respectively		132,876			99,831
Accumulated deficit		(33,290,978	)		(32,957,186	)
Additional paid-in capital		42,878,748			39,772,228
Total Net Assets		8,537,246			6,993,163
Accumulated deficit		(32,294,845	)		(32,957,186	)
Total Liabilities and Net Assets	$	8,792,402		$	8,429,166
Total Net Assets		10,817,894			6,993,163
Total Liabilities and Net Assets	$	10,989,371		$	8,429,166

The accompanying notes are an integral part of these condensed interim financial statements.

Kyto Technology and Life Science, Inc.

Condensed Statements of Operations

(Unaudited)

	For the three months ended June 30,
	2021			2020			2021			2020
	2021			2020
	For the Three months ended September 30,						For the Six months ended September 30,
INVESTMENT INCOME
	2021			2020			2021			2020
Interest and other income	$	-		$	-
INVESTMENT INCOME
Total investment income		-			-
Interest and other income	$	-		$	-		$	-		$	500
EXPENSES
Total investment income		-			-			-			500
Professional fees		166,954			12,938
EXPENSES
Other operating expenses		219,838			25,930
Professional fees		107,201			63,605			273,359			76,543
Total expenses		386,792			38,868
Other operating expenses		245,519			96,506			466,027			122,936
Net investment loss		(386,792	)		(38,868	)
Interest and non operating expenses		1,596			-			1,588			-
Net change in unrealized gain from investments		53,000			-
Total expenses		354,316			160,111			740,974			199,479
Net decrease in net assets resulting from operations	$	(333,792	)	$	(38,868	)
Net investment loss		(354,316	)		(160,111	)		(740,974	)		(198,979	)
Loss per Common Share, Basic and Fully diluted
Net change in unrealized gain from investments		1,350,449			478,248			1,403,315			478,248
Net decrease in net assets resulting from operations per common share	$	(0.03	)	$	(0.01	)
Net increase in net assets resulting from operations	$	996,133		$	318,137		$	662,341		$	279,269
Weighted average common shares outstanding		13,268,871			5,836,832
Basic earnings per Common Share,
Net increase in net assets resulting from operations per common share	$	0.08		$	0.05		$	0.05		$	0.05
Weighted average common shares outstanding		13,271,996			5,836,832			13,269,764			5,836,832
Fully-diluted earnings per Common Share,
Net increase in net assets resulting from operations per common share	$	0.04		$	0.02		$	0.03		$	0.02
Weighted average common shares outstanding		27,338,695			17,987,040			26,263,218			17,058,856

The accompanying notes are an integral part of these condensed interim financial statements.

Kyto Technology and Life Science, Inc.

Condensed Statements of Changes in Net Assets for the Three and Six months ended September 30, 2021

( Unaudited)

			Preferred A				Preferred B				Common		Additional
	Preferred A		Stock		Preferred B		Stock		Common		Stock		Paid-in		Accumulated
	Preferred A (Including Series A-1, A-2)		Preferred A Stock (Including Series A-1, A-2)		Preferred B (Including Series B-1, B-2)		Preferred B (Including Series B-1, B-2) Stock		Common		Common Stock		Additional Paid-in		Accumulated
	Shares		Amount		Shares		Amount		Shares		Amount		Capital		Deficit			Total
Balance, March 31, 2020		4,200,000	$	42,001		812,500	$	8,125		5,836,832	$	58,368	$	35,943,369	$	(33,384,252	)	$	2,667,611
Three months ended September 30, 2021
Net decrease in net assets resulting from operations																(38,868	)		(38,868	)
Sale of Series B Preferred stock at $0.80 per share						468,750		4,063						370,937					375,000
Compensation expense from stock options														1,048					1,048
Balance, June 30, 2020		4,200,000	$	42,001		1,281,250	$	12,188		5,836,832	$	58,368	$	36,315,354	$	(33,423,120	)	$	3,004,791
Balance, March 31, 2021		4,200,000	$	42,001		3,628,906	$	36,289		9,983,082	$	99,831	$	39,772,228	$	(32,957,186	)	$	6,993,163
Net decrease in net assets resulting from operations																(333,792	)		(333,792	)
Sale of Series B Preferred stock at $0.80 per share						691,250		6,913						546,089					553,002
Sale of common stock at $0.40 per share										3,285,789		32,858		1,281,458					1,314,316
Compensation expense from stock options														10,557					10,557
Balance, June 30, 2021		4,200,000	$	42,001		4,320,156	$	43,202		13,268,871	$	132,689	$	41,610,332	$	(33,290,978	)	$	8,537,246
Net increase in net assets resulting from operations																996,133			996,133
Sale of Series B-1 Preferred stock at $0.80 per share		-		-		1,591,250		15,912						1,257,088					1,273,000
Sale of common stock at $0.40 per share
Sale of common stock at $0.40 per share, shares
Exercise of stock options										18,750		187		431					618
Compensation expense from stock options														10,897					10,897
Balance, September 30, 2021		4,200,000	$	42,001		5,911,406	$	59,114		13,287,621	$	132,876	$	42,878,748	$	(32,294,845	)	$	10,817,894
Six months ended September 30, 2021
Balance, March 31, 2021		4,200,000	$	42,001		3,628,906	$	36,289		9,983,082	$	99,831	$	39,772,228	$	(32,957,186	)	$	6,993,163
Net increase in net assets resulting from operations																662,341			662,341
Sale of Series B-1 Preferred stock at $0.80 per share		-		-		2,282,500		22,825						1,803,176					1,826,001
Sale of common stock at $0.40 per share										3,285,789		32,858		1,281,459					1,314,317
Exerrcise of stock options										18,750		187		431					618
Compensation expense from stock options														21,454					21,454
Balance, September 30, 2021		4,200,000	$	42,001		5,911,406	$	59,114		13,287,621	$	132,876	$	42,878,748	$	(32,294,845	)	$	10,817,894

The accompanying notes are an integral part of these condensed interim financial statements.

Kyto Technology and Life Science, Inc.

Condensed Statements of ~~Cash~~Changes ~~Flows~~in Net Assets for the Three and Six months ended September 30, 2020

( Unaudited)

	Three months ended June 30,
	Preferred A			Preferred A Stock			Preferred B		Preferred B Stock		Common		Common Stock		Additional Paid-in		Accumulated
	2021			2020
	Shares			Amount			Shares		Amount		Shares		Amount		Capital		Deficit			Total
Operating activities:
Three months ended September 30, 2020
Net decrease in net assets resulting from operations	$	(333,792	)	$	(38,868	)
Balance, June 30, 2020		42,000,000		$	42,001			1,281,250	$	12,188		5,836,832	$	58,368	$	36,315,354	$	(33,423,120	)	$	3,004,791
Adjustments to reconcile net decrease in net assets resulting from operations to net cash used in operating activities
Net increase in net assets resulting from operations		-			-			-		-		-		-		-		318,137			318,137
Net change in unrealized gain on investments		(53,000	)		-
Sale of Series B Preferred stock at $0.80 per share		-			-			1,056,250		11,187		-		-		883,813		-			895,000
Stock option compensation expenses		10,557			1,048
Compensation expense from stock options		-			-			-		-		-		-		12,803		-			12,803
Change in operating assets and liabilities
Balance, September 30, 2020		42,000,000		$	42,001			2,337,500	$	23,375		5,836,832	$	58,368	$	37,211,970	$	(33,104,983	)	$	4,230,731
Other current assets		-			500
Six months ended September 30, 2020
Deferred fundraising expenses		(998	)		-
Balance, March 31, 2020		42,000,000		$	42,001			812,500	$	8,125		5,836,832	$	58,368	$	35,943,369	$	(33,384,252	)	$	2,667,611
Accounts payable and accrued liabilities		(10,190	)		2,643
Balance		42,000,000		$	42,001			812,500	$	8,125		5,836,832	$	58,368	$	35,943,369	$	(33,384,252	)	$	2,667,611
Accrued liabilities to related parties		20,785			2,250
Net increase in net assets resulting from operations		-			-			-		-		-		-		-		279,269			279,269
Purchase of investments		(1,265,600	)		(250,000	)
Sale of Series B Preferred stock at $0.80 per share		-			-			1,525,000		15,250		-		-		1,254,750		-			1,270,000
Net cash used in operating activities		(1,632,238	)		(282,427	)
Compensation expense from stock options		-			-			-		-		-		-		13,851		-			13,851
Cash flows from financing activities:
Balance, September 30, 2020		42,000,000		$	42,001			2,337,500	$	23,375		5,836,832	$	58,368	$	37,211,970	$	(33,104,983	)	$	4,230,731
Sale of Common Stock		122,874			-
Balance		42,000,000		$	42,001			2,337,500	$	23,375		5,836,832	$	58,368	$	37,211,970	$	(33,104,983	)	$	4,230,731
Sale of Series B Preferred stock		553,002			375,000
Net cash provided by financing activities		675,876			375,000
Net increase/(decrease) in cash		(956,362	)		92,573
Cash, beginning of period		1,437,868			33,756
Cash, end of period	$	481,506		$	126,329
Supplemental cash flow information
Interest paid	$	-		$	-
Taxes paid	$	800		$	800
Supplemental schedule of noncash financing activities:
Conversion of common stock subscription liability to common stock	$	1,191,442		$	-

The accompanying notes are an integral part of these condensed interim financial statements.

Kyto Technology and Life Science, Inc.

Condensed ~~Schedule~~Statements of ~~Investments~~Cash ~~as of June 30, 2021~~Flows

(Unaudited)

Portfolio Company	Industry		Investment	Cost			Fair value		% of net assets (a)
	2021			2020
Convertible loan investments
	Six months months ended September 30,
Abfero Pharmaceuticals Inc	Life science		Convertible Note, 6% due, December 2022	$	100,000		$	101,118		1.2	%
	2021			2020
Achelios Therapeutics Inc.	Life science		Convertible Note, 8% due, December 2021		100,000			123,167		1.4	%
Operating activities:
Achelios Therapeutics Inc.	Life science		Convertible Note, 8% due December 2021		25,000			29,532		0.3	%
Net increase in net assets resulting from operations	$	662,341		$	279,269
Achelios Therapeutics Inc.	Life science		Convertible Note, 8% due December 2021		50,000			55,578		0.7	%
Adjustments to reconcile net increase (decrease) in net assets resulting from operations to net cash used in operating activities
Achelios Therapeutics Inc.	Life science		Convertible Note Sidecar, 25% discount. No interest		50,000			50,000		0.6	%
Net change in unrealized gain on investments		(1,403,315	)		(478,248	)
AOA DX Inc	Life science		Convertible Note, 4%, due May 2024		100,000			100,559		1.2	%
Stock option compensation expense		21,454			13,851
Avisi Technologies Inc	Life science		Convertible Note, 8% due July 2022		50,000			53,671		0.6	%
Change in operating assets and liabilities
Basepaws Inc	Life science		Convertible Note, 1% due April 2020		50,000			162,444		1.9	%
Other current assets		(60,543	)		500
Beam Semiconductor Inc	Technology		Convertible Note, 8% due April 2022		150,000			174,033		2.0	%
Accounts payable and accrued liabilities		(108,664	)		15,064
Beam Semiconductor Inc	Technology		Convertible Note, 8% due March 2021		50,000			55,282		0.6	%
Accrued liabilities to related parties		35,580			-
Beam Semiconductor Inc	Technology		Convertible Note, 8% due March 2022		100,000			101,688		1.2	%
Purchase of investments		(2,218,091	)		(740,000	)
Corinnova Inc	Life science		Convertible Note, 6% due December 2024		100,000			103,699		1.2	%
Net cash used in operating activities		(3,071,238	)		(909,564	)
Cyberdontics Inc	Life science		Convertible Note, 8% due September 2022		30,000			34,366		0.4	%
Cash flows from financing activities:
Cyberdontics Inc	Life science		Convertible Note, 8% due February 2023		35,000			38,751		0.5	%
Sale of Common stock in connection with preference rights (see Note 6)		122,875			-
Cyberdontics Inc	Life science		Convertible Note, 0% no due date		35,000			36,995		0.4	%
Sale of Common stock from exercise of options stock		618			-
Deep Blue Medical Advances Inc	Life science		Convertible Note, 6% due June 2022		50,000			51,595		0.6	%
Sale of Series B-1 Preferred stock		1,826,001			1,270,000
Every Key Inc	Technology		Convertible Note, 5% due December 2023		100,000			107,767		1.3	%
Receipt of SBA loan		-			1,000
Identical Inc	Life science		Convertible Note, 2% due May 2022		100,000			101,271		1.2	%
Advances from related party		-			2,250
INBay Technology Inc	Technology		Convertible Note, 12% due October 2020		50,000			66,077		0.8	%
Net cash provided by financing activities		1,949,494			1,273,250
INBay Technology Inc	Technology		Convertible Note, 12% due July 2021		30,000			37,121		0.4	%
Net increase/(decrease) in cash		(1,121,744	)		363,686
INBay Technology Inc	Technology		Convertible Note, 12% due February 2022		50,000			58,137		0.7	%
Cash, beginning of period		1,437,868			33,756
INBay Technology Inc	Technology		Convertible Note, 12% due December 2022		40,000			42,748		0.5	%
Cash, end of period	$	316,124		$	397,442
INBay Technology Inc	Technology		Convertible Note, 12% due December 2023		50,000			51,414		0.6	%
Supplemental cash flow information
Iris R&D Group Inc	Technology		Convertible Note, 8% May 2023		50,000			50,438		0.6	%
Interest paid	$	1,588		$	-
Kiana Analytics Inc	Technology		Convertible Note, 3% December 2022		100,000			101,570		1.2	%
Taxes paid	$	800		$	800
Kitotech Medical Inc	Life science		Convertible Note, 6% due December 2020		100,000			244,629		2.9	%
Supplemental schedule of noncash financing activities:
Kitotech Medical Inc	Life science		Convertible Note, 6% due November 2022		75,000			84,761		1.0	%
Conversion of common stock subscription liability to common stock	$	1,191,442		$	-
Lifewave Biomedical Inc	Life science		Convertible Note, 6% due December 2020		30,000			33,279		0.4	%
Lifewave Biomedical Inc	Life science		Convertible Note, 6% due December 2020		70,000			75,857		0.9	%
Lifewave Biomedical Inc	Life science		Convertible Note, 6% due December 2021		50,000			50,403		0.6	%
mmTron Inc	Technology		Convertible Note, 4% due April 2023		100,000			100,022		1.2	%
Navaux Inc	Life science		Convertible Note, 6% due December 2023		60,000			61,933		0.7	%
Neuro42 Inc.	Life science		Convertible Note, 8% due December 2023		50,000			51,556		0.6	%
Octagon Therapeutics Inc	Life science		Convertible Note, 5% due June 2021		50,000			51,719		0.6	%
Octagon Therapeutics Inc	Life science		Convertible Note, 5% due June 2021		50,000			51,589		0.6	%
Perikinetics Inc	Life science		Convertible Note, 6% due May 2022		100,000			103,814		1.2	%
Preview Medical Inc	Life science		Convertible Note, 7% due January 2023		100,000			103,184		1.2	%
SageMedic Corp	Life science		Convertible Note, 8% April 2021 plus warrants		50,000			58,877		0.7	%
SageMedic Corp	Life science		Convertible Note, 8% December 2022 plus warrants		75,000			78,436		0.9	%
Sensing Electromagnetic Plus Corp	Technology		Convertible Note, Fully reserved		50,000			1		0.0	%
Sensing Electromagnetic Plus Corp	Technology		Convertible Note, Fully reserved		11,048			1		0.0	%
Single Pass Inc	Life science		Convertible Note, 6% April 2024		50,000			50,214		0.6	%
Valfix Medical Inc	Life science		Convertible Note, 8% December 2021		50,000			53,507		0.6	%
Xpan Inc	Life science		Convertible Note, 8% due March 2022		50,000			55,293		0.6	%
Xpan Inc	Life science		Convertible Note, 8% due June 2022		25,000			27,044		0.3	%
Xpan Inc	Life science		Convertible Note, 8% due June 2022		25,000			27,035		0.3	%
Total convertible loan investments				$	2,866,048		$	3,252,175		38.1	%
United States				$	2,046,048		$	2,342,246		27.4	%
Canada					470,000			525,419		6.2	%
Rest of World					350,000			384,510		4.5	%
Total convertible loan investments				$	2,866,048		$	3,252,175		38.1	%

Continued on next page

The accompanying notes are an integral part of these condensed interim financial statements.

Continued from previous page

Kyto Technology and Life Science, Inc.

Condensed Schedule of Investments as of ~~June~~September 30, 2021

(Unaudited)

~~Portfolio Company~~	~~Industry~~Portfolio Company		~~Investment~~	Industry	~~Cost~~	Investment	Cost	~~Fair value~~		Fair value	~~% of net assets (a)~~			% of net assets (a)
Preferred stock investments
Convertible loan investments
Altis Biosystems	Life science		22,028 shares of Series Seed Preferred		$	50,000		$	50,000			0.6	%
	Abfero Pharmaceuticals Inc			Life science		Convertible Note, 6% due, December 2022	$	100,000		$	102,630				0.9	%
Astrocyte Pharmaceuticals Inc	Life science		260,756 shares of Series A Preferred			100,000			104,778			1.2	%
( i )	Achelios Therapeutics Inc.			Life science		Convertible Note, 8% due, December 2021		100,000			125,184				1.2	%
Cnote Group, Inc	Fintech		84,655 shares of series Seed-2 Preferred (converted SAFE)			51,500			59,783			0.7	%
( i )	Achelios Therapeutics Inc.			Life science		Convertible Note, 8% due December 2021		25,000			30,036				0.3	%
Cnote Group, Inc	Fintech		93,807 shares of Series Seed-3 Preferred (converted note)			50,000			66,247			0.8	%
( i )	Achelios Therapeutics Inc.			Life science		Convertible Note, 8% due December 2021		50,000			56,586				0.5	%
Colabs Inc	Life science		147,058 shares of Series A-1 Preferred			50,000			50,000			0.6	%
( i )	Achelios Therapeutics Inc.			Life science		Convertible Note Sidecar, 25% discount. No interest		50,000			50,000				0.5	%
Connectus Services Ltd	Technology		31,348 shares of Series Seed Preferred			100,000			100,000			1.2	%
	AOA DX Inc			Life science		Convertible Note, 4%, due May 2024		100,000			101,567				0.9	%
Deep Blue Medical Advances Inc	Life science		10,474 shares of Series A Preferred			49,996			49,996			0.6	%
	Avisi Technologies Inc			Life science		Convertible Note, 8% due July 2022		50,000			54,679				0.5	%
Eumentis Thereapeutics Inc	Life science		85,009 shares of Series A Preferred			100,000			100,000			1.2	%
	Basepaws Inc			Life science		Convertible Note, 1% due April 2020		50,000			201,663				1.9	%
FemtoDX Inc	Life science		42,436 shares of Series A Preferred			100,000			159,835			1.9	%
( i )	Beam Semiconductor Inc	*		Technology		Convertible Note, 8% due April 2022		150,000			177,058				1.6	%
Healionics Corporation	Life science		35,075 of Series A-1 Preferred			100,000			100,000			1.2	%
( i )	Beam Semiconductor Inc	*		Technology		Convertible Note, 8% due March 2021		50,000			56,290				0.5	%
i-Lumen Scientific Inc.	Life science		50,000 shares of Series A Preferred plus warrants			50,000			50,000			0.6	%
( i )	Beam Semiconductor Inc	*		Technology		Convertible Note, 8% due March 2022		100,000			103,704				1.0	%
i-Lumen Scientific Inc.	Life science		50,000 shares of Series A Preferred plus warrants			50,000			50,000			0.6	%
	CoLabs Inc			Life science		Convertible Note, 6% due February 2023		50,000			50,304				0.5	%
Inhalon Biopharma Inc	Life science		18,843 shares of Series Seed Preferred			99,997			99,997			1.2	%
	Corinnova Inc			Life science		Convertible Note, 6% due December 2024		100,000			105,211				1.0	%
Light Line Medical Inc	Life science		62,849 shares of Series Seed Preferred (converted note)			30,000			38,031			0.4	%
	Corinnova Inc			Life science		Convertible Note, 6% due December 2024		50,000			50,164				0.5	%
Light Line Medical Inc	Life science		141,871 shares of Series Seed Preferred (converted note)			70,000			106,049			1.2	%
*	Cyberdontics Inc	*		Life science		Convertible Note, 8% due September 2022		30,000			34,971				0.3	%
Light Line Medical Inc	Life science		40,323 shares of Series Seed preferred			25,000			25,000			0.3	%
*	Cyberdontics Inc	*		Life science		Convertible Note, 8% due February 2023		35,000			39,457				0.4	%
Light Line Medical Inc	Life science		72,464 shares of Series A Preferred plus warants			50,000			50,000			0.6	%
*	Cyberdontics Inc	*		Life science		Convertible Note, 0% no due date		35,000			37,700				0.3	%
Lowell Therapeutics Inc	Life science		20,000 shares of Series A Preferred			50,000			50,000			0.6	%
	Deep Blue Medical Advances Inc			Life science		Convertible Note, 6% due June 2022		50,000			52,351				0.5	%
Lowell Therapeutics Inc	Life science		20,000 shares of Series A Preferred			50,000			50,000			0.6	%
	Every Key Inc			Technology		Convertible Note, 5% due December 2023		100,000			109,027				1.0	%
Makani Science Inc	Life science		172,413 shares of Series Seed Preferred			50,000			50,000			0.6	%
	Identical Inc			Life science		Convertible Note, 2% due May 2022		100,000			101,775				0.9	%
Micronic Technologies Inc	Technology		51,929 shares of Series Seed-1 Preferred plus warrants			100,000			100,000			1.2	%
*	INBay Technology Inc			Technology		Convertible Note, 12% due October 2020		50,000			67,589				0.6	%
Neuroflow Inc	Life science		98,684 shares of Series Seed -2 Preferred			150,000			224,998			2.6	%
*	INBay Technology Inc			Technology		Convertible Note, 12% due July 2021		30,000			38,028				0.4	%
Neuroflow Inc	Life science		20,429 shares of Series B Preferred			100,000			212,497			2.5	%
*	INBay Technology Inc			Technology		Convertible Note, 12% due February 2022		50,000			59,649				0.6	%
New View Surgical, Inc.	Life science		53,825 shares of Series A-1 Preferred			75,000			75,000			0.9	%
*	INBay Technology Inc			Technology		Convertible Note, 12% due December 2022		40,000			43,958				0.4	%
Orion Biotechnology Inc	Life science		5,824 shares of Series A Preferred			100,000			100,000			1.2	%
*	INBay Technology Inc			Technology		Convertible Note, 12% due December 2023		50,000			52,926				0.5	%
Otomagnetics Inc	Life science		16,538 shares of Series A-1 Preferred plus warrants			100,000			100,000			1.2	%
*	Iris R&D Group Inc			Technology		Convertible Note, 8% May 2023		50,000			51,447				0.5	%
Promaxo	Life science		104,248 shares of Series B-1 Preferred, (converted note)			250,000			531,738			6.2	%
	Kiana Analytics Inc			Technology		Convertible Note, 3% December 2022		100,000			102,326				0.9	%
Seal Rock Therapeutics, Inc.	Life science		68,075 shares of Series Seed Preferred, (converted note)			78,000			80,329			0.9	%
	Kitotech Medical Inc			Life science		Convertible Note, 6% due December 2020		100,000			246,141				2.3	%
Shyft (FKA Crater Group Inc)	Technology		42,657 shares of Series A-1 Preferred (converted note)			51,500			97,940			1.1	%
	Kitotech Medical Inc			Life science		Convertible Note, 6% due November 2022		75,000			85,896				0.8	%
Shyft (FKA Crater Group Inc)	Technology		28,147 shares of Series A Preferred (converted note)			50,000			64,626			0.8	%
	Lifewave Biomedical Inc			Life science		Convertible Note, 6% due December 2020		30,000			33,733				0.3	%
Shyft (FKA Crater Group Inc)	Technology		21,774 shares of Series A-1 Preferred (plus warrants)			50,000			50,000			0.6	%
	Lifewave Biomedical Inc			Life science		Convertible Note, 6% due December 2020		70,000			76,916				0.7	%
Trellis Bioscience LLC	Life science		50,000 shares of Series B Preferred plus warrants			50,000			50,000			0.6	%
	Lifewave Biomedical Inc			Life science		Convertible Note, 6% due December 2021		50,000			51,159				0.5	%
Trellis Bioscience LLC	Life science		50,000 shares of Series B Preferred plus warrants			50,000			50,000			0.6	%
	Lowell Therapeutics Inc			Life science		Convertible Note, 8% no due date		27,491			27,955				0.3	%
Trellis Bioscience LLC	Life science		100,000 shares of Series B Preferred plus warrants			100,000			100,000			1.2	%
	mmTron Inc			Technology		Convertible Note, 4% due April 2023		100,000			101,030				0.9	%
Valfix Medical Inc	Life science		27,217 shares of Series Seed Preferred			50,000			50,000			0.6	%
	Navaux Inc			Life science		Convertible Note, 6% due December 2023		60,000			62,841				0.6	%
Visgenx Inc	Life science		7,833 shares of Series Seed-1 Preferred (converted note)			30,000			46,352			0.5	%
	Neuro42 Inc.			Life science		Convertible Note, 8% due December 2023		50,000			52,564				0.5	%
Visgenx Inc	Life science		4,132 shares of Series Seed Preferred (converted note)			25,000			25,648			0.3	%
	Octagon Therapeutics Inc			Life science		Convertible Note, 5% due June 2021		50,000			52,349				0.5	%
Visgenx Inc	Life science		2,480 shares of Series Seed Preferred (converted note)			15,003			15,393			0.2	%
	Octagon Therapeutics Inc			Life science		Convertible Note, 5% due June 2021		50,000			52,219				0.5	%
Total Preferred stock investments					$	2,700,997		$	3,384,237			39.6	%
	Perikinetics Inc			Life science		Convertible Note, 6% due May 2022		100,000			105,326				1.0	%
United States					$	2,450,997		$	3,134,237			36.7	%
	Preview Medical Inc			Life science		Convertible Note, 7% due January 2023		100,000			104,948				1.0	%
Canada						200,000			200,000			2.3	%
	Promaxo Inc			Life science		Convertible note, 5% due July 2022		100,000			183,876				1.7	%
Rest of World						50,000			50,000			0.6	%
	Rheos Inc			Life science		Convertible note, 8% due August 2026		100,000			101,074				0.9	%
Total Preferred stock investments					$	2,700,997		$	3,384,237			39.6	%
	Saccharo Inc			Life science		Convertible note, 7% due September 2022		50,000			50,815				0.5	%
Common stock investments
	SageMedic Corp			Life science		Convertible Note, 8% April 2021 plus warrants		50,000			59,885				0.6	%
BendaRX Corp	Life science		12,500 Common shares		$	100,000		$	150,000			1.8	%
	SageMedic Corp			Life science		Convertible Note, 8% December 2022 plus warrants		75,000			79,948				0.7	%
BendaRX Corp	Life science		12,500 Common shares			100,000			150,000			1.8	%
	Sensing Electromagnetic Plus Corp			Technology		Convertible Note, Fully reserved		50,000			1				0.0	%
Boardwalk Tech	Technology		75,000 Common shares			65,600			65,600			0.8	%
	Sensing Electromagnetic Plus Corp			Technology		Convertible Note, Fully reserved		11,048			1				0.0	%
Boardwalk Tech	Technology		150,000 Common shares			73,500			91,995			1.1	%
	Single Pass Inc			Life science		Convertible Note, 6% April 2024		50,000			50,970				0.5	%
Sanaby Health Sponsor LLC	Life science		50,000 Common shares			100,000			100,000			1.2	%
*	Valfix Medical Inc	*		Life science		Convertible Note, 8% December 2021		50,000			54,515				0.5	%
Total Common stock investments					$	439,100		$	557,595			5.4	%
*	Xpan Inc	*		Life science		Convertible Note, 8% due March 2022		50,000			56,301				0.5	%
United States					$	239,100		$	257,595			3.0	%
*	Xpan Inc	*		Life science		Convertible Note, 8% due June 2022		25,000			27,548				0.3	%
Canada						200,000			300,000			3.5	%
*	Xpan Inc	*		Life science		Convertible Note, 8% due June 2022		25,000			27,542				0.3	%
Rest of World						-			-			0.0	%
Total convertible loan investments							$	3,243,539		$	3,801,833				35.1	%
Total Common stock investments					$	439,100		$	557,595			6.5	%
	United States						$	2,423,539		$	2,873,150				26.6	%
SAFE investments
	Canada							470,000			537,116				5.0	%
Infinidome Ltd	Technology		SAFE		$	50,000		$	50,000			0.6	%
	Rest of World							350,000			391,567				3.6	%
Infinidome Ltd	Technology		SAFE			50,000			50,000			0.6	%
Total convertible loan investments							$	3,243,539		$	3,801,833				35.1	%
Madorra Inc	Life science		SAFE			100,000			100,000			1.2	%
Mitre Medical Corp	Life science		SAFE			75,000			75,000			0.9	%
Mitre Medical Corp	Life science		SAFE			50,000			50,000			0.6	%
Orion Biotechnology Inc.	Life science		SAFE			100,000			100,000			1.2	%
Total SAFE investments					$	425,000		$	425,000			5.0	%
United States						125,000			125,000			1.5	%
Canada						100,000			100,000			1.2	%
Rest of World						200,000			200,000			2.3	%
Total SAFE investments					$	425,000		$	425,000			5.0	%

Continued on next page

The accompanying notes are an integral part of these condensed interim financial statements.

Continued from previous page

Kyto Technology and Life Science, Inc.

Condensed Schedule of Investments as of ~~June~~September 30, 2021

(Unaudited)

~~Portfolio Company~~	~~Industry~~Portfolio Company		~~Investment~~Industry	~~Cost~~Investment		Cost		~~Fair value~~		Fair value		~~% of net assets (a)~~	% of net assets (a)
Other investments
Preferred stock investments
Enduralock LLC	Technology		34.1 Series A-1 Ownership Units	$	30,000			$	30,000			0.4%
	Altis Biosystems		Life science	22,028 shares of Series Seed Preferred		$	50,000			$	50,000		0.5	%
Enduralock LLC	Technology		39.7 Series A-1 Ownership Units		35,000				35,000			0.4%
	Astrocyte Pharmaceuticals Inc		Life science	260,756 shares of Series A Preferred			100,000				100,000		0.9	%
Exodos Life Sciences LP	Life science		Class A-1 Preferred Ownership Units		206,000				206,000			2.4%
	Cnote Group, Inc		Fintech	84,655 shares of series Seed-2 Preferred (converted SAFE)			51,500				59,783		0.6	%
Green Sun Medical LLC	Life science		2,193 Class A-1 Ownership units		50,000				50,000			0.6%
	Cnote Group, Inc		Fintech	93,807 shares of Series Seed-3 Preferred (converted note)			50,000				66,247		0.6	%
Green Sun Medical LLC	Life science		1,096 Class A-1 Ownership units		25,000				25,000			0.3%
	Colabs Inc		Life science	147,058 shares of Series A-1 Preferred			50,000				50,000		0.5	%
Green Sun Medical LLC	Life science		1,096 Class A-1 Ownership units		25,000				25,000			0.3%
*	Connectus Services Ltd	*	Technology	31,348 shares of Series Seed Preferred			100,000				100,000		0.9	%
Green Sun Medical LLC	Life science		4,386 Class A-1 Ownership units		100,000				100,000			1.2%
	Deep Blue Medical Advances Inc		Life science	10,474 shares of Series A Preferred			49,996				49,997		0.5	%
Riso Capital Fund I, LP	Technology		Ownership units		50,000				50,000			0.6%
	Eumentis Thereapeutics Inc		Life science	85,009 shares of Series A Preferred			100,000				100,000		0.9	%
Total other investments				$	521,000			$	521,000			6.1%
	FemtoDX Inc		Life science	42,436 shares of Series A Preferred			100,000				290,046		2.7	%
	United States			$	521,000			$	521,000			6.1%
	Healionics Corporation		Life science	35,075 of Series A-1 Preferred			100,000				100,000		0.9	%
	Canada				-				-			0.0%
	i-Lumen Scientific Inc.		Life science	50,000 shares of Series A Preferred plus warrants			50,000				50,000		0.5	%
	Rest of World				-				-			0.0%
	i-Lumen Scientific Inc.		Life science	50,000 shares of Series A Preferred plus warrants			50,000				50,000		0.5	%
Total other investments				$	521,000			$	521,000			14.5%
	Inhalon Biopharma Inc		Life science	18,843 shares of Series Seed Preferred			99,997				99,997		0.9	%
Total investments
	Light Line Medical Inc		Life science	62,849 shares of Series Seed Preferred (converted note)			30,000				38,031		0.4	%
United States					5,382,145				6,380,078			74.7%
	Light Line Medical Inc		Life science	141,871 shares of Series Seed Preferred (converted note)			70,000				106,049		1.0	%
Canada					970,000				1,125,419			13.2%
	Light Line Medical Inc		Life science	40,323 shares of Series Seed preferred			25,000				25,000		0.2	%
Rest of World					600,000				634,510			7.4%
	Light Line Medical Inc		Life science	72,464 shares of Series A Preferred plus warrants			50,000				50,000		0.5	%
Total other investments				$	6,952,145			$	8,140,007			95.3%
	Lowell Therapeutics Inc		Life science	20,000 shares of Series A Preferred			50,000				50,000		0.5	%
(a) based on total net assets of	$	8,537,246
	Lowell Therapeutics Inc		Life science	20,000 shares of Series A Preferred			50,000				50,000		0.5	%
	Lowell Therapeutics Inc		Life science	25,000 shares of Series B Preferred			100,000				100,000		0.9	%
	Makani Science Inc		Life science	172,413 shares of Series Seed Preferred			50,000				50,000		0.5	%
	Micronic Technologies Inc		Technology	51,929 shares of Series Seed-1 Preferred plus warrants			100,000				100,000		0.9	%
	Neuroflow Inc		Life science	98,684 shares of Series Seed -2 Preferred			150,000				224,998		2.1	%
	Neuroflow Inc		Life science	20,429 shares of Series B Preferred			100,000				212,497		2.0	%
	New View Surgical, Inc.		Life science	53,825 shares of Series A-1 Preferred			75,000				75,000		0.7	%
	New View Surgical, Inc.		Life science	58,220 shares of Series A-1 Preferred			100,000				100,000		0.9	%
*	Orion Biotechnology Inc	*	Life science	5,824 shares of Series A Preferred			100,000				100,000		0.9	%
	Otomagnetics Inc		Life science	16,538 shares of Series A-1 Preferred			100,000				100,000		0.9	%
	Partheous Inc		Life science	50,000 shares of Series A Preferred			50,000				50,000		0.5	%
	Promaxo		Life science	104,248 shares of Series B-1 Preferred, (converted note)			250,000				1,034,684		9.6	%
	Seal Rock Therapeutics, Inc.		Life science	68,075 shares of Series Seed Preferred, (converted note)			78,000				199,112		1.8	%
	Shyft (FKA Crater Group Inc)		Technology	42,657 shares of Series A-1 Preferred (converted note)			51,500				107,059		1.0	%
	Shyft (FKA Crater Group Inc)		Technology	28,147 shares of Series A Preferred (converted note)			50,000				91,771		0.8	%
	Shyft (FKA Crater Group Inc)		Technology	21,774 shares of Series A-1 Preferred (plus warrants)			50,000				70,990		0.7	%
( i )	Trellis Bioscience LLC		Life science	50,000 shares of Series B Preferred plus warrants			50,000				50,000		0.5	%
( i )	Trellis Bioscience LLC		Life science	50,000 shares of Series B Preferred plus warrants			50,000				50,000		0.5	%
( i )	Trellis Bioscience LLC		Life science	100,000 shares of Series B Preferred plus warrants			100,000				100,000		0.9	%
*	Valfix Medical Inc	*	Life science	27,217 shares of Series Seed Preferred			50,000				50,000		0.5	%
	Vesteck Inc		Life science	34,783 shares of Series A preferred			100,000				100,000		0.9	%
	Visgenx Inc		Life science	7,833 shares of Series Seed-1 Preferred (converted note)			30,000				46,352		0.4	%
	Visgenx Inc		Life science	4,132 shares of Series Seed Preferred (converted note)			25,000				25,648		0.2	%
	Visgenx Inc		Life science	2,480 shares of Series Seed Preferred (converted note)			15,003				15,392		0.1	%
Total Preferred stock investments						$	3,050,997			$	4,538,653		42.0	%
	United States					$	2,800,997			$	4,288,653		39.6	%
	Canada						200,000				200,000		1.8	%
	Rest of World						50,000				50,000		0.5	%
Total Preferred stock investments						$	3,050,997			$	4,538,653		42.0	%
Common stock investments
*	BendaRX Corp	*	Life science	12,500 Common shares		$	100,000			$	150,000		1.4	%
*	BendaRX Corp	*	Life science	12,500 Common shares			100,000				150,000		1.4	%
	Boardwalk Tech		Technology	75,000 Common shares			65,600				65,600		0.6	%
	Boardwalk Tech		Technology	150,000 Common shares			73,500				91,995		0.9	%
	Kuantsol Inc		Technology	133.333 Common shares			25,000				25,000		0.2	%
	Sanaby Health Sponsor LLC		Life science	50,000 Common shares			100,000				473,732		4.4	%
Total Common stock investments						$	464,100			$	956,327		4.2	%
	United States					$	264,100			$	656,327		6.1	%
	Canada						200,000				300,000		2.8	%
	Rest of World						-				-
Total Common stock investments						$	464,100			$	956,327		8.8	%
		*
SAFE investments
*	Infinidome Ltd	*	Technology	SAFE		$	50,000			$	50,000		0.5	%
*	Infinidome Ltd	*	Technology	SAFE			50,000				50,000		0.5	%
*	Madorra Inc	*	Life science	SAFE			100,000				100,000		0.9	%
	Mitre Medical Corp		Life science	SAFE			75,000				75,000		0.7	%
	Mitre Medical Corp		Life science	SAFE			50,000				50,000		0.5	%
*	Orion Biotechnology Inc.	*	Life science	SAFE			100,000				100,000		0.9	%
*	Polymertal Ltd	*	Technology	SAFE			150,000				150,000		1.4	%
Total SAFE investments						$	575,000			$	575,000		5.3	%
	United States						125,000				125,000		1.2	%
	Canada						100,000				100,000		0.9	%
	Rest of World						350,000				350,000		3.2	%
Total SAFE investments						$	575,000			$	575,000		5.3	%

Continued on next page

The accompanying notes are an integral part of these condensed interim financial statements.

Continued from previous page

Kyto Technology and Life Science, Inc.

Condensed Schedule of Investments as of September 30, 2021

(Unaudited)

	Portfolio Company		Industry	Investment	Cost		Fair value		% of net assets (a)
Other investments
	Enduralock LLC		Technology	34.1 Series A-1 Ownership Units	$	30,000	$	30,000		0.3	%
	Enduralock LLC		Technology	39.7 Series A-1 Ownership Units		35,000		35,000		0.3	%
( i )	Exodos Life Sciences LP		Life science	Class A-1 Preferred Ownership Units		206,000		206,000		1.9	%
	Green Sun Medical LLC		Life science	2,193 Class A-1 Ownership units		50,000		50,000		0.5	%
	Green Sun Medical LLC		Life science	1,096 Class A-1 Ownership units		25,000		25,000		0.2	%
	Green Sun Medical LLC		Life science	1,096 Class A-1 Ownership units		25,000		25,000		0.2	%
	Green Sun Medical LLC		Life science	4,386 Class A-1 Ownership units		100,000		100,000		0.9	%
	Riso Capital Fund I, LP		Technology	Ownership units		50,000		50,000		0.5	%
	Riso Capital Fund I, LP		Technology	Ownership units		50,000		50,000		0.5	%
Total other investments					$	571,000	$	571,000		5.3	%
	United States				$	571,000	$	571,000		5.3	%
	Canada					-		-
	Rest of World					-		-
Total other investments					$	571,000	$	571,000		5.3	%

Total investments					$	7,904,636	$	10,442,813		96.5	%
	United States				$	6,184,636	$	8,514,130		78.7	%
	Canada					970,000		1,137,116		10.5	%
	Rest of World					750,000		791,567		7.3	%
Total investments					$	7,904,636	$	10,442,813		96.5	%
	(a) based on total net assets of	$	10,817,894

( i ) Kyto representatives sit on the Board of Directors of these companies.

* These companies are headquartered outside of the US.

The accompanying notes are an integral part of these condensed interim financial statements.

Kyto Technology and Life Science, Inc.

Condensed Schedule of Investments as of March 31, 2021

(Unaudited)

~~Portfolio Company~~

~~Industry~~

Portfolio Company

~~Investment~~

~~Cost~~

Industry

~~Fair value~~

Investment

~~% of net assets (b)~~

Cost

Fair value

% of net assets (a)

Convertible loan investments

Achelios Therapeutics Inc.

Life science

Convertible Note, 8% due, December 2021

100,000

121,173

1.7

(i)

Achelios Therapeutics Inc.

Life science

Convertible Note, 8% due, December 2021

100,000

121,173

1.7

Achelios Therapeutics Inc.

Life science

Convertible Note, 8% due December 2021

25,000

29,033

0.4

(i)

Achelios Therapeutics Inc.

Life science

Convertible Note, 8% due December 2021

25,000

29,033

0.4

Achelios Therapeutics Inc.

Life science

Convertible Note, 8% due December 2021

50,000

54,581

0.8

(i)

Achelios Therapeutics Inc.

Life science

Convertible Note, 8% due December 2021

50,000

54,581

0.8

~~Avisi Technologies Inc~~

~~Life science~~

Avisi Technologies Inc

~~Convertible Note, 8% due July 2022~~

~~50,000~~

Life science

~~52,674~~

Convertible Note, 8% due July 2022

~~0.8~~

%50,000

52,674

0.8

~~Basepaws Inc~~

~~Life science~~

Basepaws Inc

~~Convertible Note, 1% due April 2020~~

~~50,000~~

Life science

~~162,319~~

Convertible Note, 1% due April 2020

~~2.3~~

%50,000

162,319

2.3

Beam Semiconductor Inc

Technology

Convertible Note, 8% due April 2022

150,000

171,041

2.4

(i)

Beam Semiconductor Inc

Technology

Convertible Note, 8% due April 2022

150,000

171,041

2.4

Beam Semiconductor Inc

Technology

Convertible Note, 8% due March 2021

50,000

54,285

0.8

(i)

Beam Semiconductor Inc

Technology

Convertible Note, 8% due March 2021

50,000

54,285

0.8

~~Corinnova Inc~~

~~Life science~~

Corinnova Inc

~~Convertible Note, 6% due December 2024~~

~~100,000~~

Life science

~~102,318~~

Convertible Note, 6% due December 2024

~~1.5~~

%100,000

102,318

1.5

~~Cyberdontics Inc~~

~~Life science~~

Cyberdontics Inc

~~Convertible Note, 8% due September 2022~~

~~30,000~~

Life science

~~33,768~~

Convertible Note, 8% due September 2022

~~0.5~~

%30,000

33,768

0.5

~~Cyberdontics Inc~~

~~Life science~~

Cyberdontics Inc

~~Convertible Note, 8% due February 2023~~

~~35,000~~

Life science

~~38,053~~

Convertible Note, 8% due February 2023

~~0.5~~

%35,000

38,053

0.5

~~Cyberdontics Inc~~

~~Life science~~

Cyberdontics Inc

~~Convertible Note, 0% no due date~~

~~35,000~~

Life science

~~36,296~~

Convertible Note, 0% no due date

~~0.5~~

%35,000

36,296

0.5

~~Deep Blue Medical Advances Inc~~

~~Life science~~

Deep Blue Medical Advances Inc

~~Convertible Note, 6% due June 2022~~

~~50,000~~

Life science

~~50,863~~

Convertible Note, 6% due June 2022

~~0.7~~

%50,000

50,863

0.7

~~Every Key Inc~~

~~Technology~~

Every Key Inc

~~Convertible Note, 5% due December 2023~~

~~100,000~~

Technology

~~106,521~~

Convertible Note, 5% due December 2023

~~1.5~~

%100,000

106,521

1.5

~~Identical Inc~~

~~Life science~~

Identical Inc

~~Convertible Note, 2% due May 2022~~

~~100,000~~

Life science

~~100,844~~

Convertible Note, 2% due May 2022

~~1.4~~

%100,000

100,844

1.4

~~INBay Technology Inc~~

~~Technology~~

INBay Technology Inc

~~Convertible Note, 12% due October 2020~~

~~50,000~~

Technology

~~59,721~~

Convertible Note, 12% due October 2020

~~0.9~~

%50,000

59,721

0.9

~~INBay Technology Inc~~

~~Technology~~

INBay Technology Inc

~~Convertible Note, 12% due July 2021~~

~~30,000~~

Technology

~~34,149~~

Convertible Note, 12% due July 2021

~~0.5~~

%30,000

34,149

0.5

~~INBay Technology Inc~~

~~Technology~~

INBay Technology Inc

~~Convertible Note, 12% due February 2022~~

~~50,000~~

Technology

~~56,641~~

Convertible Note, 12% due February 2022

~~0.8~~

%50,000

56,641

0.8

~~INBay Technology Inc~~

~~Technology~~

INBay Technology Inc

~~Convertible Note, 12% due December 2022~~

~~40,000~~

Technology

~~41,552~~

Convertible Note, 12% due December 2022

~~0.6~~

%40,000

41,552

0.6

~~Kiana Analytics Inc~~

~~Technology~~

Kiana Analytics Inc

~~Convertible Note, 3% December 2022~~

~~100,000~~

Technology

~~100,847~~

Convertible Note, 3% December 2022

~~1.4~~

%100,000

100,847

1.4

~~Kitotech Medical Inc~~

~~Life science~~

Kitotech Medical Inc

~~Convertible Note, 6% due December 2020~~

~~100,000~~

Life science

~~243,133~~

Convertible Note, 6% due December 2020

~~3.5~~

%100,000

243,133

3.5

~~Kitotech Medical Inc~~

~~Life science~~

Kitotech Medical Inc

~~Convertible Note, 6% due November 2022~~

~~75,000~~

Life science

~~83,738~~

Convertible Note, 6% due November 2022

~~1.2~~

%75,000

83,738

1.2

~~Lifewave Biomedical Inc~~

~~Life science~~

Lifewave Biomedical Inc

~~Convertible Note, 6% due December 2020~~

~~30,000~~

Life science

~~32,831~~

Convertible Note, 6% due December 2020

~~0.5~~

%30,000

32,831

0.5

~~Lifewave Biomedical Inc~~

~~Life science~~

Lifewave Biomedical Inc

~~Convertible Note, 6% due December 2020~~

~~70,000~~

Life science

~~74,810~~

Convertible Note, 6% due December 2020

~~1.1~~

%70,000

74,810

1.1

~~Navaux Inc~~

~~Life science~~

Navaux Inc

~~Convertible Note, 6% due December 2023~~

~~60,000~~

Life science

~~61,036~~

Convertible Note, 6% due December 2023

~~0.9~~

%60,000

61,036

0.9

~~Neuro42 Inc.~~

~~Life science~~

Neuro42 Inc.

~~Convertible Note, 8% due December 2023~~

~~50,000~~

Life science

~~50,559~~

Convertible Note, 8% due December 2023

~~0.7~~

%50,000

50,559

0.7

~~Octagon Therapeutics Inc~~

~~Life science~~

Octagon Therapeutics Inc

~~Convertible Note, 5% due June 2021~~

~~50,000~~

Life science

~~51,110~~

Convertible Note, 5% due June 2021

~~0.7~~

%50,000

51,110

0.7

~~Octagon Therapeutics Inc~~

~~Life science~~

Octagon Therapeutics Inc

~~Convertible Note, 5% due June 2021~~

~~50,000~~

Life science

~~50,966~~

Convertible Note, 5% due June 2021

~~0.7~~

%50,000

50,966

0.7

~~Perikinetics Inc~~

~~Life science~~

Perikinetics Inc

~~Convertible Note, 6% due May 2022~~

~~100,000~~

Life science

~~102,318~~

Convertible Note, 6% due May 2022

~~1.5~~

%100,000

102,318

1.5

~~Preview Medical Inc~~

~~Life science~~

Preview Medical Inc

~~Convertible Note, 7% due January 2023~~

~~100,000~~

Life science

~~101,918~~

Convertible Note, 7% due January 2023

~~1.5~~

%100,000

101,918

1.5

~~SageMedic Corp~~

~~Life science~~

SageMedic Corp

~~Convertible Note, 8% April 2021 plus warrants~~

~~50,000~~

Life science

~~57,879~~

Convertible Note, 8% April 2021 plus warrants

~~0.8~~

%50,000

57,879

0.8

~~SageMedic Corp~~

~~Life science~~

SageMedic Corp

~~Convertible Note, 8% December 2022 plus warrants~~

~~75,000~~

Life science

~~77,088~~

Convertible Note, 8% December 2022 plus warrants

~~1.1~~

%75,000

77,088

1.1

~~Sensing Electromagnetic Plus Corp~~

~~Technology~~

Sensing Electromagnetic Plus Corp

~~Convertible Note, Fully reserved~~

~~50,000~~

Technology

Convertible Note, Fully reserved

~~0.0~~

%50,000

0.0

~~Sensing Electromagnetic Plus Corp~~

~~Technology~~

Sensing Electromagnetic Plus Corp

~~Convertible Note, Fully reserved~~

~~11,048~~

Technology

Convertible Note, Fully reserved

~~0.0~~

%11,048

0.0

~~Valfix Medical Inc~~

~~Life science~~

Valfix Medical Inc

~~Convertible Note, 8% December 2021~~

~~50,000~~

Life science

~~52,510~~

Convertible Note, 8% December 2021

~~0.8~~

%50,000

52,510

0.8

~~Xpan Inc~~

~~Life science~~

Xpan Inc

~~Convertible Note, 8% due March 2022~~

~~50,000~~

Life science

~~54,296~~

Convertible Note, 8% due March 2022

~~0.8~~

%50,000

54,296

0.8

~~Xpan Inc~~

~~Life science~~

Xpan Inc

~~Convertible Note, 8% due June 2022~~

~~25,000~~

Life science

~~26,545~~

Convertible Note, 8% due June 2022

~~0.4~~

%25,000

26,545

0.4

~~Xpan Inc~~

~~Life science~~

Xpan Inc

~~Convertible Note, 8% due June 2022~~

~~25,000~~

Life science

~~26,540~~

Convertible Note, 8% due June 2022

~~0.4~~

%25,000

26,540

0.4

Total Convertible loan investments

~~2,216,048~~

~~2,553,954~~

~~36.5~~$

%2,216,048

2,553,954

36.5

~~United States~~

United States

~~1,596,048~~

~~1,868,557~~

~~26.7~~$

%1,596,048

1,868,557

26.7

~~Canada~~

Canada

~~370,000~~

~~407,561~~

~~5.8~~

%370,000

407,561

5.8

~~Rest of World~~

Rest of World

~~250,000~~

~~277,836~~

~~4.0~~

%250,000

277,836

4.0

Total Convertible loan investments

~~2,216,048~~

~~2,553,954~~

~~36.5~~$

%2,216,048

2,553,954

36.5

Continued on next page

The accompanying notes are an integral part of these condensed interim financial statements.

1011

Continued from previous page

Kyto Technology and Life Science, Inc.

Condensed Schedule of Investments as of March 31, 2021 - continued

(Unaudited)

Preferred stock investments
~~Altis Biosystems~~		~~Life~~Altis ~~science~~Biosystems		~~22,028 shares of Series Seed Preferred~~	Life science	$	5022,~~000~~028 shares of Series Seed Preferred	$	$50,000	~~50,000~~	$	50,000	~~0.7~~	%	0.7	%
~~Astrocyte Pharmaceuticals Inc~~		~~Life~~Astrocyte ~~science~~Pharmaceuticals Inc		~~260,756 shares of Series A Preferred~~	Life science		~~100~~260,~~000~~756 shares of Series A Preferred		100,000	~~100,000~~		100,000	~~1.4~~	%	1.4	%
~~Cnote Group, Inc~~		~~Fintech~~Cnote Group, Inc		~~84,655 shares of series Seed-2 Preferred (converted SAFE)~~	Fintech		5184,~~500~~655 shares of series Seed-2 Preferred (converted SAFE)		51,500	~~59,783~~		59,783	~~0.9~~	%	0.9	%
~~Cnote Group, Inc~~		~~Fintech~~Cnote Group, Inc		~~93,807 shares of Series Seed-3 Preferred (converted note)~~	Fintech		5093,~~000~~807 shares of Series Seed-3 Preferred (converted note)		50,000	~~66,247~~		66,247	~~0.9~~	%	0.9	%
~~Colabs Inc~~		~~Life~~Colabs ~~science~~Inc		~~147,058 shares of Series A-1 Preferred~~	Life science		50147,~~000~~058 shares of Series A-1 Preferred		50,000	~~50,000~~		50,000	~~0.7~~	%	0.7	%
~~Connectus Services Ltd~~		~~Technology~~Connectus Services Ltd	*	~~31,348 shares of Series Seed Preferred~~	Technology		~~100~~31,~~000~~348 shares of Series Seed Preferred		100,000	~~100,000~~		100,000	~~1.4~~	%	1.4	%
~~Deep Blue Medical Advances Inc~~		~~Life~~Deep ~~science~~Blue Medical Advances Inc		~~10,474 shares of Series A Preferred~~	Life science		4910,~~997~~474 shares of Series A Preferred		49,997	~~49,997~~		49,997	~~0.7~~	%	0.7	%
~~Eumentis Thereapeutics Inc~~		~~Life~~Eumentis ~~science~~Thereapeutics Inc		~~85,009 shares of Series A Preferred~~	Life science		~~100~~85,~~000~~009 shares of Series A Preferred		100,000	~~100,000~~		100,000	~~1.4~~	%	1.4	%
~~FemtoDX Inc~~		~~Life~~FemtoDX ~~science~~Inc		~~42,436 shares of Series A Preferred~~	Life science		~~100~~42,~~000~~436 shares of Series A Preferred		100,000	~~159,835~~		159,835	~~2.3~~	%	2.3	%
~~i-Lumen Scientific Inc.~~		~~Life~~i-Lumen ~~science~~Scientific Inc.		~~50,000 shares of Series A Preferred plus warrants~~	Life science		50,000 shares of Series A Preferred plus warrants		50,000	~~50,000~~		50,000	~~0.7~~	%	0.7	%
~~i-Lumen Scientific Inc.~~		~~Life~~i-Lumen ~~science~~Scientific Inc.		~~50,000 shares of Series A Preferred plus warrants~~	Life science		50,000 shares of Series A Preferred plus warrants		50,000	~~50,000~~		50,000	~~0.7~~	%	0.7	%
~~Inhalon Biopharma Inc~~		~~Life~~Inhalon ~~science~~Biopharma Inc		~~18,843 shares of Series Seed Preferred~~	Life science		9918,~~997~~843 shares of Series Seed Preferred		99,997	~~99,997~~		99,997	~~1.4~~	%	1.4	%
~~Light Line Medical Inc~~		~~Life~~Light ~~science~~Line Medical Inc		~~62,849 shares of Series Seed Preferred (converted note)~~	Life science		3062,~~000~~849 shares of Series Seed Preferred (converted note)		30,000	~~38,031~~		38,031	~~0.5~~	%	0.5	%
~~Light Line Medical Inc~~		~~Life~~Light ~~science~~Line Medical Inc		~~141,871 shares of Series Seed Preferred (converted note)~~	Life science		70141,~~000~~871 shares of Series Seed Preferred (converted note)		70,000	~~106,049~~		106,049	~~1.5~~	%	1.5	%
~~Light Line Medical Inc~~		~~Life~~Light ~~science~~Line Medical Inc		~~40,323 shares of Series Seed preferred~~	Life science		2540,~~000~~323 shares of Series Seed preferred		25,000	~~25,000~~		25,000	~~0.4~~	%	0.4	%
~~Light Line Medical Inc~~		~~Life~~Light ~~science~~Line Medical Inc		~~72,464 shares of Series A Preferred plus warants~~	Life science		5072,~~000~~464 shares of Series A Preferred plus warants		50,000	~~50,000~~		50,000	~~0.7~~	%	0.7	%
~~Lowell Therapeutics Inc~~		~~Life~~Lowell ~~science~~Therapeutics Inc		~~20,000 shares of Series A Preferred~~	Life science		5020,000 shares of Series A Preferred		50,000	~~50,000~~		50,000	~~0.7~~	%	0.7	%
~~Lowell Therapeutics Inc~~		~~Life~~Lowell ~~science~~Therapeutics Inc		~~20,000 shares of Series A Preferred~~	Life science		5020,000 shares of Series A Preferred		50,000	~~50,000~~		50,000	~~0.7~~	%	0.7	%
~~Micronic Technologies Inc~~		~~Technology~~Micronic Technologies Inc		~~51,929 shares of Series Seed-1 Preferred plus warrants~~	Technology		~~100~~51,~~000~~929 shares of Series Seed-1 Preferred plus warrants		100,000	~~100,000~~		100,000	~~1.4~~	%	1.4	%
~~Neuroflow Inc~~		~~Life~~Neuroflow ~~science~~Inc		~~98,684 shares of Series Seed -2 Preferred~~	Life science		~~150~~98,~~000~~684 shares of Series Seed -2 Preferred		150,000	~~224,998~~		224,998	~~3.2~~	%	3.2	%
~~Neuroflow Inc~~		~~Life~~Neuroflow ~~science~~Inc		~~20,429 shares of Series B Preferred~~	Life science		~~100~~20,~~000~~429 shares of Series B Preferred		100,000	~~212,497~~		212,497	~~3.0~~	%	3.0	%
~~New View Surgical, Inc.~~		~~Life~~New ~~science~~View Surgical, Inc.		~~53,825 shares of Series A-1 Preferred~~	Life science		7553,~~000~~825 shares of Series A-1 Preferred		75,000	~~75,000~~		75,000	~~1.1~~	%	1.1	%
~~Otomagnetics Inc~~		~~Life~~Otomagnetics ~~science~~Inc		~~16,538 shares of Series A-1 Preferred plus warrants~~	Life science		~~100~~16,~~000~~538 shares of Series A-1 Preferred plus warrants		100,000	~~100,000~~		100,000	~~1.4~~	%	1.4	%
~~Promaxo~~		~~Life science~~Promaxo		~~104,248 shares of Series B-1 Preferred, (converted note)~~	Life science		~~250~~104,~~000~~248 shares of Series B-1 Preferred, (converted note)		250,000	~~531,738~~		531,738	~~7.6~~	%	7.6	%
~~Seal Rock Therapeutics, Inc.~~		~~Life~~Seal ~~science~~Rock Therapeutics, Inc.		~~68,075 shares of Series Seed Preferred, (converted note)~~	Life science		7868,~~000~~075 shares of Series Seed Preferred, (converted note)		78,000	~~80,329~~		80,329	~~1.1~~	%	1.1	%
~~Shyft (FKA Crater Group Inc)~~		~~Technology~~Shyft (FKA Crater Group Inc)		~~42,657 shares of Series A-1 Preferred~~	Technology		5142,~~500~~657 shares of Series A-1 Preferred		51,500	~~97,940~~		97,940	~~1.4~~	%	1.4	%
~~Shyft (FKA Crater Group Inc)~~		~~Technology~~Shyft (FKA Crater Group Inc)		~~28,147 shares of Series A Preferred (converted note)~~	Technology		5028,~~000~~147 shares of Series A Preferred (converted note)		50,000	~~64,626~~		64,626	~~0.9~~	%	0.9	%
~~Shyft (FKA Crater Group Inc)~~		~~Technology~~Shyft (FKA Crater Group Inc)		~~21,774 shares of Series A-1 Preferred (converted note)~~	Technology		5021,~~000~~774 shares of Series A-1 Preferred (converted note)		50,000	~~50,000~~		50,000	~~0.7~~	%	0.7	%
Trellis Bioscience LLC		Life science		50,000 shares of Series B Preferred plus warrants			50,000			50,000			0.7	%
(i)		Trellis Bioscience LLC			Life science		50,000 shares of Series B Preferred plus warrants		50,000			50,000			0.7	%
Trellis Bioscience LLC		Life science		50,000 shares of Series B Preferred plus warrants			50,000			50,000			0.7	%
(i)		Trellis Bioscience LLC			Life science		50,000 shares of Series B Preferred plus warrants		50,000			50,000			0.7	%
Trellis Bioscience LLC		Life science		100,000 shares of Series B Preferred plus warrants			100,000			100,000			1.4	%
(i)		Trellis Bioscience LLC			Life science		100,000 shares of Series B Preferred plus warrants		100,000			100,000			1.4	%
~~Valfix Medical Inc~~		~~Life~~Valfix ~~science~~Medical Inc	*	~~27,217 shares of Series Seed Preferred~~	Life science		5027,~~000~~217 shares of Series Seed Preferred		50,000	~~50,000~~		50,000	~~0.7~~	%	0.7	%
~~Visgenx Inc~~		~~Life~~Visgenx ~~science~~Inc		~~7,833 shares of Series Seed-1 Preferred (converted note)~~	Life science		307,~~000~~833 shares of Series Seed-1 Preferred (converted note)		30,000	~~46,352~~		46,352	~~0.7~~	%	0.7	%
~~Visgenx Inc~~		~~Life~~Visgenx ~~science~~Inc		~~4,132 shares of Series Seed Preferred (converted note)~~	Life science		254,~~000~~132 shares of Series Seed Preferred (converted note)		25,000	~~25,648~~		25,648	~~0.4~~	%	0.4	%
~~Visgenx Inc~~		~~Life~~Visgenx ~~science~~Inc		~~2,480 shares of Series Seed Preferred (converted note)~~	Life science		152,~~003~~480 shares of Series Seed Preferred (converted note)		15,003	~~15,392~~		15,392	~~0.2~~	%	0.2	%
Total Preferred stock investments						$	~~2,450,997~~	$	$2,450,998	~~3,129,458~~	$	3,129,458	~~44.8~~	%	44.8	%
~~United States~~		United States				$	~~2,300,997~~	$	$2,300,998	~~2,979,458~~	$	2,979,458	~~42.6~~	%	42.6	%
~~Canada~~		Canada					~~100,000~~		100,000	~~100,000~~		100,000	~~1.4~~	%	1.4	%
~~Rest of World~~		Rest of World					~~50,000~~		50,000	~~50,000~~		50,000	~~0.7~~	%	0.7	%
Total Preferred stock investments						$	~~2,450,997~~	$	$2,450,998	~~3,129,458~~	$	3,129,458	~~44.8~~	%	44.8	%
Common stock investments
~~BendaRX Corp~~		~~Life~~BendaRX ~~science~~Corp	*	~~12,500 Common shares~~	Life science	$	~~100~~12,~~000~~500 Common shares	$	$100,000	~~150,000~~	$	150,000	~~2.1~~	%	2.1	%
~~BendaRX Corp~~		~~Life~~BendaRX ~~science~~Corp	*	~~12,500 Common shares~~	Life science		~~100~~12,~~000~~500 Common shares		100,000	~~150,000~~		150,000	~~2.1~~	%	2.1	%
~~Boardwalk Tech~~		~~Technology~~Boardwalk Tech		~~150,000 Common shares~~	Technology		73150,~~500~~000 Common shares		73,500	~~91,995~~		91,995	~~1.3~~	%	1.3	%
Total common stock investments						$	~~273,500~~	$	$273,500	~~391,995~~	$	391,995	~~5.6~~	%	5.6	%
~~United States~~		United States				$	~~73,500~~	$	$73,500	~~91,995~~	$	91,995	~~1.3~~	%	1.3	%
~~Canada~~		Canada					~~200,000~~		200,000	~~300,000~~		300,000	~~4.3~~	%	4.3	%
~~Rest of World~~		Rest of World					-		-	-		-	~~0.0~~	%
Total common stock investments						$	~~273,500~~	$	$273,500	~~391,995~~	$	391,995	~~5.6~~	%	5.6	%
SAFE investments
~~Infinidome Ltd~~		~~Technology~~Infinidome Ltd	*	~~SAFE~~	Technology	$	~~50,000~~SAFE	$	$50,000	~~50,000~~	$	50,000	~~0.7~~	%	0.7	%
~~Infinidome Ltd~~		~~Technology~~Infinidome Ltd	*	~~SAFE~~	Technology		~~50,000~~SAFE		50,000	~~50,000~~		50,000	~~0.7~~	%	0.7	%
~~Mitre Medical Corp~~		~~Life~~Mitre ~~science~~Medical Corp		~~SAFE~~	Life science		~~75,000~~SAFE		75,000	~~75,000~~		75,000	~~1.1~~	%	1.1	%
~~Mitre Medical Corp~~		~~Life~~Mitre ~~science~~Medical Corp		~~SAFE~~	Life science		~~50,000~~SAFE		50,000	~~50,000~~		50,000	~~0.7~~	%	0.7	%
~~Orion Biotechnology Inc.~~		~~Life~~Orion ~~science~~Biotechnology Inc.	*	~~SAFE~~	Life science		~~100,000~~SAFE		100,000	~~100,000~~		100,000	~~1.4~~	%	1.4	%
Total SAFE investments						$	~~325,000~~	$	$325,000	~~325,000~~	$	325,000	~~4.6~~	%	4.6	%
~~United States~~		United States				$	~~125,000~~	$	$125,000	~~125,000~~	$	125,000	~~1.8~~	%	1.8	%
~~Canada~~		Canada					~~100,000~~		100,000	~~100,000~~		100,000	~~1.4~~	%	1.4	%
~~Rest of World~~		Rest of World					~~100,000~~		100,000	~~100,000~~		100,000	~~1.4~~	%	1.4	%
Total SAFE investments						$	~~325,000~~	$	$325,000	~~325,000~~	$	325,000	~~4.6~~	%	4.6	%
Other investments
Enduralock LLC		Technology		34.1 Series A-1 Ownership Units		$	30,000		$	30,000			0.4	%
Enduralock LLC		Technology		39.7 Series A-1 Ownership Units			35,000			35,000			0.5	%
Exodos Life Sciences LP		Life science		Class A-1 Preferred Ownership Units			206,000			206,000			2.9	%
Green Sun Medical LLC		Life science		2,193 Class A-1 Ownership units			50,000			50,000			0.7	%
Green Sun Medical LLC		Life science		1,096 Class A-1 Ownership units			25,000			25,000			0.4	%
Green Sun Medical LLC		Life science		1,096 Class A-1 Ownership units			25,000			25,000			0.4	%
Riso Capital Fund I, LP		Technology		Ownership units			50,000			50,000			0.7	%
Total other investments						$	421,000		$	421,000			6.0	%
United States						$	421,000		$	421,000			6.0	%
Canada							-			-			0.0	%
Rest of World							-			-			0.0	%
Total Other investments						$	421,000		$	421,000			6.0	%
Total investments						$	5,686,545		$	6,821,407			97.5	%
United States						$	4,516,545		$	5,486,010			78.4	%
Canada							770,000			907,561			13.0	%
Rest of World							400,000			427,836			6.1	%
Total investments						$	5,686,545		$	6,821,407			97.5	%
( b ) based on total net assets of	$	6,993,163

Continued on next page

The accompanying notes are an integral part of these condensed interim financial statements.

1112

Continued from previous page

Kyto Technology and Life Science, Inc.

Condensed Schedule of Investments as of March 31, 2021 - continued

(Unaudited)

Preferred stock investments
Other investments
	Enduralock LLC		Technology	34.1 Series A-1 Ownership Units	$	30,000	$	30,000	0.4	%
	Enduralock LLC		Technology	39.7 Series A-1 Ownership Units		35,000		35,000	0.5	%
(i)	Exodos Life Sciences LP		Life science	Class A-1 Preferred Ownership Units		206,000		206,000	2.9	%
	Green Sun Medical LLC		Life science	2,193 Class A-1 Ownership units		50,000		50,000	0.7	%
	Green Sun Medical LLC		Life science	1,096 Class A-1 Ownership units		25,000		25,000	0.4	%
	Green Sun Medical LLC		Life science	1,096 Class A-1 Ownership units		25,000		25,000	0.4	%
	Riso Capital Fund I, LP		Technology	Ownership units		50,000		50,000	0.7	%
Total other investments					$	421,000	$	421,000	6.0	%
	United States				$	421,000	$	421,000	6.0	%
	Canada					-		-
	Rest of World					-		-
Total Other investments					$	421,000	$	421,000	6.0	%

Total investments					$	5,686,545	$	6,821,407	97.5	%
	United States				$	4,516,546	$	5,486,011	78.4	%
	Canada					770,000		907,560	13.0	%
	Rest of World					400,000		427,836	6.1	%
Total investments					$	5,686,545	$	6,821,407	97.5	%

	(a) based on total net assets of	$	6,993,163

( i )	Kyto representatives sit on the Board of Directors of these companies.
*	These companies are headquartered outside of the US.
	The accompanying notes are an integral part of these condensed interim financial statements.

KYTO TECHNOLOGY AND LIFE SCIENCE INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

~~June~~September 30, 2021

NOTE 1 – DESCRIPTION OF BUSINESS

Kyto Technology and Life Science, Inc. (the “Company”) was formed as a Florida corporation on March 5, 1999 under the name of B Twelve, Inc. In August, 2002, the Company changed its name from B Twelve, Inc. to Kyto BioPharma Inc. and in May 2018, the name was changed again to Kyto Technology and Life Science, Inc. In July 2019, the Company was re-incorporated as a Delaware company. The Company operates virtually, from public locations or the homes of its officers, and does not currently lease any office space.

The Company was originally formed to acquire and develop proprietary drugs for the treatment of cancer, arthritis, and other autoimmune diseases and had been evaluating a number of strategies. As of March 31, 2018, the Company had accumulated a deficit of $32,380,746 from all prior operations. In April 2018, the Board adopted a new business plan focused on the development of early-stage technology and life science businesses through early-stage investment funding. The Company has recruited a number of experienced investment consultants from a network that includes angel investors, corporate managers, sophisticated early-stage investors and successful entrepreneurs with experience across a number of technology and life science products and markets, and relies on input from these advisors in conducting due diligence and making investment decisions. In order to offset the risk in early-stage investing, the Company works with angel investment groups and other sophisticated investors and participates only after these groups have completed due diligence and committed to invest, in effect becoming lead investors. The Company then completes its own due diligence and invests under identical terms as the lead investors. The Company will do follow-on investments in existing portfolio companies, assuming adequate progress, when portfolio companies initiate new financing rounds. The Company currently does not typically invest more than $250,000 in any single investment. Generally, the Company’s investments represent less than 5% ownership interests, and the Company therefore has no effective control or influence over the management or commercial decisions of the companies in which it invests. The Company plans to generate revenue from realized gains from the sale of the businesses in which it has invested, or some or all of its shareholdings in those cases where portfolio companies go public. Generally, it is expected that investments will be realized from an exit within a period of four to five years following initial investment. Such exits or liquidity events are outside the Company’s control and depend on merger and acquisition (“M&A”) transactions or an initial public offering (“IPO”) which may result in cash or equity proceeds. ~~Accordingly, it is difficult to forecast revenue, net income, and cash flow.~~ Other than making its initial and, potentially, follow-on investments in its portfolio companies, the Company does not provide any financial support to any of its investees.

The Company has one regular employee – the CEO, Mr, Paul Russo. Prior to December 31, 2020, Mr. Russo was acting as a consultant to the Company and did not receive contractual compensation for his services in the form of cash. As of January 1, 2021, Mr. Russo was engaged as an employee of the Company at a salary of $400,000 per annum of which 60% was is paid monthly from January to April 2021, ~~and~~then 75% from May 2021, with the balance being deferred to be paid once the Company lists and starts trading on the Nasdaq exchange. The full terms of Mr. Russo’s employment are described in ana ~~engagement letter filed on~~ Form 8-K filed on February 1, 2021, which was approved by the Compensation committee of the Board of Directors on that date. During the three months and six months ended ~~June~~September 30, 2021, Mr. Russo received gross pay of $8090,000 and ~~gross payroll~~$170,000, respectively. noNo consulting fees and no options were granted. to him during these periods. During the three months and six months ended ~~June~~September 30, 2020, Mr. Russo received no payroll or consulting fees , however in the three and nosix ~~options~~months ~~were~~ended September 30, 2020 he received a bonus of $50,000 and was granted options to ~~him~~purchase 215,000 shares of Common stock.

12The Company has created a portfolio of minority investments in early-stage start-up companies and derives its revenue opportunity from the sale of those investments. Such sales are outside the Company’s control and depend on M&A transactions or IPOs which may result in cash or equity proceeds. Accordingly, it is difficult to forecast revenue, net income, and cash flow. As of the date of this filing, the Company had approximately $485,000 of cash to cover its operating expenses, and new investment requirements and is continuing to raise additional funding on a recurring monthly basis. If successful, it will have sufficient funding for further investments and ongoing operations. However, there is no assurance that the Company will be able to raise sufficient cash to cover its requirements on attractive terms, if at all, and whether it will be able to continue as a going concern. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying condensed interim financial statements have been prepared assuming the Company will continue to operate as a going concern and do not include any adjustments that might result from the outcome of this uncertainty. Stay at home orders and general economic uncertainties arising out of the current Covid-19 epidemic have created additional delays and uncertainty. To date there has been no disruption to the Company’s business operations, although some of its portfolio investment companies report delays in their programs.

The Company has created a portfolio of minority investments in early-stage start-up companies and derives its revenue opportunity from the sale of those investments. Such sales are outside the Company’s control and depend on M&A transactions or IPOs which may result in cash or equity proceeds. Accordingly, it is difficult to forecast revenue, net income, and cash flow. As of the date of this filing, the Company had approximately $500,000 of cash to cover its operating expenses, and new investment requirements and is continuing to raise additional funding on a recurring monthly basis. If successful, it will have sufficient funding for further investments and ongoing operations. However, there is no assurance that the Company will be able to raise sufficient cash to cover its requirements on attractive terms, if at all, and whether it will be able to continue as a going concern. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying condensed interim financial statements have been prepared assuming the Company will continue to operate as a going concern and do not include any adjustments that might result from the outcome of this uncertainty. Stay at home orders and general economic uncertainties arising out of the current Covid-19 epidemic have created additional delays and uncertainty. To date there has been no disruption to the Company’s business operations, although some of its portfolio investment companies report delays in their programs.14

At March 31, 2020, management determined that the Company was an investment company for purposes of Accounting Standards Codification Topic 946, Financial Services—Investment Companies (ASC Topic 946) disclosure, and ~~committed~~adopted ~~to follow~~ the specialized accounting and reporting guidance contained therein. Accordingly, a new company, Kyto Investments, Inc. (“KI”) was incorporated in Delaware in December 2020 in preparation for a restructuring and an N-2 Registration Statement filed in March 2021 for review by the SEC. KI is an internally managed, closed-end investment company that has elected to be regulated as a business development company (“BDC”) under the Investment Company Act of 1940, as amended (the “1940 Act”). Immediately upon effectiveness of this N-2 Registration Statement, the Company will merge with KI and the Company will be the surviving entity. As of the completion of the merger, the Company will constitute a “successor issuer” for the purposes of Rule 414 under the Securities Act and may continue the current offering by filing post-effective amendments to the Registration Statements. Prior to the merger, the Company had fewer than 100 non affiliated investors and filed under the 1934 Act relying on exemption Rule 3( c )(1).

As a BDC, the Company will be required to comply with certain regulatory requirements. The Company also intends to elect to be treated for U.S. federal income tax purposes as a regulated investment company (“RIC”) under Subchapter M of the Internal Revenue Code of 1986, as amended (the “Code”). As a RIC, the Company is required to comply with additional regulatory requirements. The Company has prepared and submitted sequentially two N-2 Registration Statements to the SEC for review but has not yet received final approval of its registration as at the filing date of this report.

NOTE 2 - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES

(A) BASIS OF PRESENTATION

The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, these unaudited condensed financial statements do not include all of the information and disclosures required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments (consisting only of normal recurring adjustments), which the Company considers necessary, for a fair presentation of those financial statements. The results of operations and cash flows for the three months and six months ended ~~June~~September 30, 2021 may not necessarily be indicative of results that may be expected for any succeeding quarter or for the entire fiscal year. The condensed balance sheet as of March 31, 2021 was derived from the audited financial statements at that date, but does not include all the information and footnotes required by U.S. GAAP. The information contained in this Quarterly Report on Form 10-Q should be read in conjunction with the audited financial statements of the Company for the year ended March 31, 2021, included in the Annual Report on Form 10-K as filed with the Securities and Exchange Commission (the “SEC”) on August 10, 2021.

The Company’s condensed interim financial statements are prepared in accordance with U.S. ~~generally accepted accounting principles (~~GAAP), which requires the use of estimates, assumptions and the exercise of subjective judgment as to future uncertainties. Actual results could differ from those estimates, assumptions, and judgments. Significant items subject to such estimates will include determining the fair value of investments, revenue recognition, income tax uncertainties, stock-based compensation, and other contingencies.

The Company’s financial statements are prepared using the specialized accounting principles of ~~Accounting Standards Codification Topic 946, Financial Services—Investment Companies (~~ASC Topic 946). In accordance with this specialized accounting guidance, the Company recognizes and carries all of its investments at fair value with changes in fair value recognized in earnings. Additionally, the Company will not apply consolidation or equity method of accounting to its investments. The ~~Company~~carrying ~~carries~~amount ~~its~~of ~~liabilities~~the atCompany’s ~~amounts~~financial ~~payable, net~~instruments ofsuch ~~unamortized~~as ~~premiums~~cash orand ~~discounts.~~payables ~~The~~approximates ~~Company~~fair ~~does~~value ~~not~~due ~~currently plan~~ to ~~elect~~the toshort ~~carry~~maturity of ~~its~~such ~~liabilities at fair value~~instruments. Net assets are calculated as the carrying amounts of assets, including the fair value of investments, less the carrying amounts of its liabilities.

1315

(B) INVESTMENT TRANSACTIONS AND NET REALIZED AND UNREALIZED GAIN OR LOSS ON INVESTMENTS

The Company generates increases or decreases in its net assets from the sale of complete or partial investments following a merger or acquisition (“M&A”) transaction or restructuring or from the revaluation of portfolio company investments to recognize changes in their fair value, either upwards or downwards. As a minority, early-stage investor, the Company does not have the ability to manage the ~~timing~~ timing or acceptance of liquidity events that will realize its investments, nor the ability to predict when they may happen, although as a general guideline, it would expect such events to occur approximately four to five years after its investments are made. The Company ~~will record~~ records the ~~changes~~realized ingains ~~value~~and losses from investment activities upon completion of sale and receipt of net proceeds, after deducting related transaction ~~expenses~~ ~~as realized gains or losses~~expenses. Realized gains or losses on the sale of investments, or upon the determination that an investment balance, or portion thereof, is not recoverable, are calculated using the specific identification method. The Company measures realized ~~gains~~ gains or losses by calculating the difference between the net proceeds from the repayment or sale and the cost basis of the investment. ~~Net~~ Net change in unrealized appreciation or depreciation reflects the change in the fair values of the Company’s portfolio investments during the reporting period, including any reversal of previously recorded unrealized appreciation or depreciation when gains or losses are realized. The Company is in ~~regular~~periodic contact with the management of its portfolio investment companies to provide a basis for valuation changes ~~or impairment reviews~~. The Company does not expect to receive interest and principal repayments on its convertible notes and generally expects these notes to convert into equity securities upon completion of qualified subsequent financings. Accrued interest is ~~then~~ recorded as an adjustment to the fair value of the convertible notes.

The Company accounts for income taxes under the Financial Accounting Standards Accounting Standard Codification Topic 740 “Accounting for Income Taxes” (“Topic 740”). Under Topic 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under Topic 740, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period, which includes the enactment date.

(D) USE OF ESTIMATES

In preparing financial statements, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and revenues and expenses during the period presented. Actual results may differ from these estimates.

Significant estimates during the three months and six months ended ~~June~~September 30, 2021 and ~~June~~September 30, 2020 include the valuation of the investment portfolio, deferred tax assets, tax valuation allowance, stock options and warrants.

(E) CASH AND CASH EQUIVALENTS

The Company considers all highly liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents. There were no cash equivalents at ~~June~~September 30, 2021 and March 31, 2021, respectively.

(F) CONCENTRATIONS

The Company maintains its cash in bank checking and deposit accounts, which, at times, may exceed federally insured limits. As of ~~June~~ September 30, 2021, and March 31, 2021, the Company’s bank balance exceeded the federally insured limit by approximately $~~230~~70,000 and $1.2 million, respectively. The Company has not experienced any losses in such accounts through ~~June~~September 30, 2021.

(G) STOCK-BASED COMPENSATION

Financial Accounting Standards Board Accounting Standards Codification Topic 718, “Stock Compensation” requires generally that ~~all~~ all equity awards granted to employees and consultants be accounted for at fair value. This fair value is measured at grant date for ~~stock~~ stock settled awards, and at subsequent exercise or settlement for cash-settled awards. Under this method, the Company records an expense ~~equal~~ equal to the fair value of the options or warrants issued. The fair value is computed using the Black Scholes options pricing model. The Company granted ~~250~~consultants and advisors 490,000 and ~~120~~510,000 options toduring ~~consultants~~the three months ended September 30, 2021 and ~~advisors~~September 30, 2020, and 740,000 and 510,000 options during the ~~three~~six months ended ~~June~~September 30, 2021 and ~~June~~September 30, 2020, respectively.

(H) NET ~~LOSS~~EARNINGS PER COMMON SHARE

In accordance with Statement of Financial Accounting Standards Accounting Standard Codification Topic 260, “Earnings per Share”, basic earnings per common share is computed by dividing the net income less preferred dividends for the period by the weighted average ~~number~~ number of common shares outstanding. Diluted earnings per common share is computed by dividing net income less preferred dividends by the weighted average number of common shares outstanding including the effect of common stock equivalents. ~~Common stock equivalents,~~ consisting of preferred stock, stock options and warrants~~, have not been included in the calculation, as their effect is anti-dilutive for the periods presented~~. The following table sets out the number of shares used in calculating fully- diluted ~~EPS~~earnings per common share using the if-converted method.

Class of shares	Three months ended June 30, 2021
Common Stock		13,268,871
Common stock subscribed not issued		-
Series A preferred stock		4,200,000	*
Series B preferred stock		4,320,156	*
Options		2,759,250	*
Warrants		1,596,667	*
Total shares used in calculating fully-diluted EPS		13,268,871

Weighted Average method

*Number ~~These~~of shares ~~excluded~~used ~~from~~in ~~the~~calculating ~~calculation of~~ fully- diluted ~~EPS~~earnings asper ~~the~~common ~~result would be anti-dilutive.~~shares

SCHEDULE OF EARNINGS PER SHARE

	Three months ended September 30, 2021		Six months ended September 30, 2021
Common Stock		13,271,996		13,269,764
Common stock subscribed not issued		-		-
Series A preferred stock		4,200,000		4,200,000
Series B preferred stock		5,307,240		4,361,525
Options		2,962,792		2,835,262
Warrants		1,596,667		1,596,667

Total shares used in calculating fully-diluted earnings per common share		27,338,695		26,263,218

	Three months ended September 30, 2020		Six months ended September 30, 2020
Common Stock issued		5,836,832		5,836,832
Series A preferred stock		4,200,000		4,200,000
Series B preferred stock		1,830,208		1,250,595
Options		1,920,000		1,571,429
Warrants		4,200,000		4,200,000

Total shares used in calculating fully-diluted earnings per common share		17,987,040		17,058,856

(I ) INVESTMENT AND VALUATION OF INVESTMENT AT FAIR VALUE

The Company reviews the performance of its investments based on available information, including management reports, press releases, web site announcements and progress reports, third party equity updates, management interviews and, where accessible, financial reports, to determine their ~~current~~fair ~~and future potential value and liquidity~~values. In the event that ~~Management~~management considers the fair value of an investment to be ~~impaired,~~greater or less than the current ~~carrying~~book value, of the ~~investment~~difference will be ~~written~~reflected ~~down~~as byunrealized angains ~~impairment~~or ~~charge~~losses toin ~~reflect Management’s estimated valuation. The Company recognized impairment of one of its~~ investments ~~which was written down by $61,046~~ in ~~September~~the ~~2019.~~statements ~~The~~of ~~Company has not experienced any other impairment write-downs in any prior or subsequent periods~~operations.

The Company adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820, “Fair Value Measurements and Disclosures”, for assets and liabilities measured at fair value on a recurring basis. ASC ~~820~~ 820 establishes a common definition for fair value to be applied to existing USU.S. GAAP that require the use of fair value measurements ~~which~~ which establishes a framework for measuring fair value and expands disclosure about such fair value measurements.

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. Fair value is an exchange price notion under which fair value is the price in an orderly transaction between market participants to sell an asset or transfer a liability in the market in which the reporting entity would transact for the asset or liability.

The Company has established procedures to estimate the fair value of its investments which the Company’s board of directors has reviewed and approved. The Company ~~will~~uses ~~use~~ observable market data to estimate the fair value of investments to the extent that market data is available. In the absence of quoted market prices in active markets, or quoted market prices for similar assets or in markets that are not active, the Company ~~will~~uses ~~use~~ the valuation methodologies described below with unobservable data based on the best available information in the circumstances, which incorporates the Company’s assumptions about the factors that a market participant would use to value the asset.

For investments for which quoted market prices are not available, which ~~will~~ comprise most of our investment portfolio, fair value ~~will~~is be estimated by using the income, market, or back-solve approach. The income approach is based on the assumption that value is created by the expectation of future benefits discounted to a current value and the fair value estimate is the amount an investor would be willing to pay to receive those future benefits. The market approach compares recent comparable transactions to the investment. The back solve method involves comparing available data over a period of time and inferring a new valuation based on changes from a known starting point, for example the cost of an investment. Adjustments are made for any dissimilarity between the comparable transactions and the investments. ~~These~~ These valuation methodologies involve a significant degree of judgment on the part of our management and board.

In determining the appropriate fair value of an investment using these approaches, the most significant information and assumptions may include, as applicable: available current market data, including relevant and applicable comparable market transactions, applicable market yields and multiples, security covenants, call protection provisions, information rights, the nature and realizable value of any collateral, the investment’s ability to make payments, its earnings and discounted cash flows, the markets in which the company does business, comparisons of financial ratios of peer companies that are public, merger and acquisition comparables, the principal market and enterprise values, environmental factors, subsequent financings by the portfolio investment, among other factors.

The estimated fair values ~~will~~do not necessarily represent the amounts that may be ultimately realized due to the occurrence or nonoccurrence of future circumstances that cannot be reasonably determined. Because of the inherent uncertainty of the valuation of the investments, the estimate of fair values may differ significantly from the value that would have been used had a broader market for the investments existed.

The authoritative accounting guidance prioritizes the use of market-based inputs over entity-specific inputs and establishes a three-level hierarchy for fair value measurements based upon the transparency of inputs to the valuation. The three levels of valuation hierarchy are defined as follows:

Level 1: Observable inputs such as quoted market prices in active markets for identical assets or liabilities

Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data

Level 3: Unobservable inputs for which there is little or no market data, which require the use of the reporting entity’s own assumptions. Most of the Company’s investments are Level 3.

Critical accounting policies and practices are the policies that are both most important to the portrayal of our financial condition and results, and require management’s most difficult, subjective, or complex judgments, often as a result of the need to make estimates about matters that are inherently uncertain. These include estimates of the fair value of our Level 3 investments and other estimates that affect the reported amounts of assets and liabilities as of the date of the consolidated financial statements and the reported amounts of certain revenues and expenses during the reporting period. It is likely that changes in these estimates will occur in the near term. Our estimates are inherently subjective in nature and actual results could differ materially from such estimates. See “Note 1 – Significant Accounting Policies” to our financial statements as of March 31, 2021 as filed with the SEC on August 10, 2021, for further detail regarding our critical accounting policies and recently issued or adopted accounting pronouncements.18

16Critical accounting policies and practices are the policies that are both most important to the portrayal of the Company’s financial condition and results, and require management’s most difficult, subjective, or complex judgments, often as a result of the need to make estimates about matters that are inherently uncertain. These include estimates of the fair value of Level 3 investments and other estimates that affect the reported amounts of assets and liabilities as of the date of the consolidated financial statements and the reported amounts of certain revenues and expenses during the reporting period. It is likely that changes in these estimates will occur in the near term. The Company’s estimates are inherently subjective in nature and actual results could differ materially from such estimates. See “Note 1 – Significant Accounting Policies” to our financial statements as of March 31, 2021, as filed with the SEC on August 10, 2021, for further detail regarding our critical accounting policies and recently issued or adopted accounting pronouncements.

(J) RECENT ACCOUNTING PRONOUNCEMENTS

Management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying financial statements.

(K) ~~DEFERRED~~OTHER ~~OFFERING~~CURRENT ~~COSTS~~ASSETS

~~Since~~Other current assets principally include deferred offering costs. Since April 2019, the Company has conducted a series of sales of common and preferred stock to fund its ongoing investment program and cost of operations. Typically, it expects that ~~this~~raising capital through the sale of any series of securities, from start to finish, may take from six to nine months and in order to match the cost and benefits of this process, the Company adopted a policy of capitalizing direct expenses incurred in the course of ~~fund~~ raising capital, with the intention of netting accumulated expenses against proceeds from sale of equity, and reporting the net funds raised at the close. Direct expenses include legal fees, investor relations fees, investor roadshows and meeting expenses, and related filing and printing fees. At ~~June~~September 30, 2021 and March 31, 2021, the Company had deferred $~~170~~230,~~889~~434 and $169,891, respectively, of such expenses, relating to the preparation and filing of an N-2 Registration Statement.

NOTE 3 – COMMITMENTS AND CONTINGENCIES

The Company has no commitments or contingencies as of the date of this filing. The Company may be subject to litigation during the normal course of business but has not received any such claims to date.

NOTE 4 - RELATED PARTY TRANSACTIONS

At ~~June~~September 30, 2021 and March 31, 2021, the Company had accrued and owed $7287,~~205~~000 and $51,420, respectively, to officers of the Company ~~for~~ for deferred payroll and consulting service fees.

At ~~June~~September 30, 2021, officers or directors of the Company held board positions at ~~three~~four portfolio companies: ~~InBay~~Beam ~~Technology~~Semiconductor Inc., ~~Exodos~~Trellis Bioscience Inc., Exodos Life Sciences LP, and Achelios Therapeutics Inc.

NOTE 5 – INVESTMENTS

The following table summarizes the Company’s investment portfolio at ~~June~~September 30, 2021 and March 31, 2021.

	June 30, 2021				March 31, 2021
Number of portfolio companies		60				51
Fair value	$	8,140,007			$	6,821,407
Cost		6,952,145				5,686,545
% of portfolio at fair value
Convertible notes		3,252,175	40	%		2,553,954	37	%
Preferrred stock		3,384,237	42	%		3,129,458	46	%
Common stock		557,595	7	%		391,995	6	%
SAFE		425,000	5	%		325,000	5	%
Other ownership units		521,000	6	%		421,000	6	%
Total	$	8,140,007	100	%	$	6,821,407	100	%

SUMMARY OF INVESTMENT PORTFOLIO

	September 30, 2021				March 31, 2021
Number of portfolio companies		66				51
Fair value	$	10,442,813			$	6,821,407
Cost		7,904,636				5,686,545

% of portfolio at fair value
Convertible notes		3,801,833	36.4	%		2,553,954	37.4	%
Preferrred stock		4,538,653	43.5	%		3,129,458	45.9	%
Common stock		956,327	9.2	%		391,995	5.7	%
SAFE		575,000	5.5	%		325,000	4.8	%
Other ownership units		571,000	5.5	%		421,000	6.2	%
Total	$	10,442,813	100	%	$	6,821,407	100	%

~~Our~~A ~~investment~~SAFE ~~portfolio~~is ~~represents~~a ~~approximately~~Simple ~~95%~~Agreement offor ~~our~~Future ~~net~~Equity ~~assets~~in atthe ~~June~~form ~~30,~~of ~~2021~~a ~~and~~warrant ~~98%~~to atpurchase ~~March~~equity ~~31,~~stock ~~2021. Investments~~ in ~~early-stage start~~a upfuture ~~private~~priced operating entities are valued based on available metrics, such as relevant market multiples and comparable company valuations, company specific-financial data including subsequent financings, actual and projected results, and independent third-party valuation estimatesround.

As of June 30, 2021

Fair Value

Valuation Approach/ Technique

Unobservable Inputs

Range/ Weighted Average

Convertible notes

3,252,175

Market approach

Precedent and follow-on transactions

N/A

Preferred stock in private companies

3,384,237

Market approach

Precedent and follow-on transactions

N/A

Common stock in private companies

400,000

Market approach

Precedent and follow-on transactions

N/A

SAFE

425,000

Market approach

Precedent and follow-on transactions

N/A

Other investments

521,000

Market approach

Precedent and follow-on transactions

N/A

Total Investments

7,982,412

Our investment portfolio represents approximately 96% of our net assets at September 30, 2021 and 98% at March 31, 2021. Investments in early-stage start-up private operating entities are valued based on available metrics, such as relevant market multiples and comparable company valuations, company specific-financial data including subsequent financings, actual and projected results, and independent third-party valuation estimates.

As of March 31, 2021

Fair Value

Valuation Approach/ Technique

Unobservable Inputs

Range/ Weighted Average

Convertible notes

2,553,954

Market approach

Precedent and follow-on transactions

N/A

Preferred stock in private companies

3,129,458

Market approach

Precedent and follow-on transactions

N/A

Common stock in private companies

300,000

Market approach

Precedent and follow-on transactions

N/A

SAFE

325,000

Market approach

Precedent and follow-on transactions

N/A

Other investments

421,000

Market approach

Precedent and follow-on transactions

N/A

Total Investments

6,729,412

The following table presents fair value measurements of investments, by major class, as of June 30, 2021 and March 31, 2021, according to the fair value hierarchy:

	As of June 30, 2021
	Quoted prices in active markets for identical securities		Significant other observable inputs		Significant other inputs
Description	(Level 1)		(Level 2)		(Level 3)		Total
Investments at Fair Value
Private Portfolio Companies
Convertible notes	$	-	$	-	$	3,252,175	$	3,525,175
Preferred stock		-		-		3,384,237		3,384,237
Common stock		-		-		400,000		400,000
SAFEs		-		-		425,000		425,000
Other ownership interests		-		-		521,000		521,000
		-		-		7,982,412		7,982,412
Public Portfolio Companies
Common stock		157,595		-		-		157,595
Total Investments at Fair value	$	157,595	$	-	$	7,982,412	$	8,140,007

	As of March 31, 2021
Description	Level 1		Level 2		Level 3		Total
March 31, 2021
Investments at Fair Value
Private Portfolio Companies
Convertible notes	$	-	$	-	$	2,553,954	$	2,553,954
Preferred stock		-		-		3,129,458		3,129,458
Common stock						300,000		300,000
SAFEs		-		-		325,000		325,000
Other ownership interests		-		-		421,000		421,000
		-		-		6,729,412		6,729,412
Public Portfolio Companies
Common stock		91,995		-		-		91,995
Total Investments at Fair value	$	91,995	$	-	$	6,729,412	$	6,821,407

As of June 30, 2021 and March 31, 2021, all our investments were treated as Level 3 with the exception of one which was invested in common stock of a public company and treated as Level 1.

Significant Unobservable Inputs for Level 3 Assets and Liabilities

In accordance with FASB ASC 820, Fair Value Management, the tables ~~above~~below provide quantitative information about the Company’s fair value measurements of its Level 3 assets as of ~~June~~September 30, 2021 and March 31, 2021. In addition to the techniques and inputs noted in the tables above, according to the Company’s valuation policy, the Company may also use other valuation techniques and methodologies when determining the Company’s fair value measurements. The tables below are not meant to be all-inclusive, but rather provide information on the significant Level 3 inputs as they relate to the Company’s fair value measurements. To the extent an unobservable input is not reflected in the tables below, such input is deemed insignificant with respect to the Company’s Level 3 fair value measurements. Significant changes in the inputs in isolation would result in a significant change in the fair value measurement, depending on the materiality of the investment.

We focus on making our investments in the United States, Canada, and Israel. All investments are made and reported in US dollars. Assets that are denominated in foreign currencies are translated into U.S. dollars at closing rates of exchange on the date of valuation. Transactions during the year are translated at the rate of exchange prevailing on the date of the transaction. The Company does not isolate that portion of results of operations resulting from the changes in foreign exchange rates on securities from fluctuations resulting from changes in market prices of such securities. Such foreign currency translation gains and losses are included in the net realized gains or losses from investments and net changes in unrealized gain or losses from investments on the statement of operations.

	America		Canada		Rest of World		Total
Fair value March 31, 2021	$	5,486,011	$	907,560	$	427,836	$	6,821,407
New investments		865,600		200,000		200,000		1,265,600
Proceeds from sale of investments		-		-		-		-
Realized gains		-		-		-		-
Change in value of investments		28,467		17,859		6,674		53,000
Fair value June 30, 2021	$	6,380,078	$	1,125,419	$	634,510	$	8,140,007

	America		Canada		Rest of World		Total
Fair value beginning of year March 31, 2020	$	2,170,499	$	245,000	$	250,000	$	2,665,499
New investments		200,000		50,000		-		250,000
Proceeds from sale of investments		-		-		-		-
Realized gains		-		-		-		-
Change in value of investments		-		-		-		-
Fair value June 30, 2020	$	2,370,499	$	295,000	$	250,000	$	2,915,499

Working on the experience of our technical advisors, we limit our investments to fintech, technology, and life sciences.

	Fintech		Technology		Life science		Total
Fair value March 31, 2021	$	126,030	$	1,394,318	$	5,301,059	$	6,821,407
New investments		-		365,600		900,000		1,265,600
Proceeds from sale of investments		-		-		-		-
Realized gains		-		-		-		-
Change in value of investments		-		21,541		31,459		53,000
Fair value June 30, 2021	$	126,030	$	1,781,459	$	6,232,518	$	8,140,007

	Fintech		Technology		Life science		Total
Fair value March 31, 2020	$	101,500	$	685,002	$	1,878,997	$	2,665,499
New investments		-		-		250,000		250,000
Proceeds from sale of investments		-		-		-		-
Realized gains		-		-		-		-
Change in value of investments		-		-		-		-
Fair value June 30, 2020	$	101,500	$	685,002	$	2,128,997	$	2,915,499

We invest in early-stage private companies developing products or solutions in the fields of fintech, technology and life sciences. Typically, we are investing in interest bearing notes that may be convertible into equity securities upon the completion of qualified subsequent financings, preferred stock, SAFEs or other forms of ownership. Typically notes carry a two year term, and are then rolled over for additional periods if no other maturity triggers have been achieved. If a convertible note investment were, in our judgment, to become impaired, we would reverse the accrued interest and adjust the valuation to reflect management’s assessment of fair value. If a convertible note investment exceeds its maturity date we usually would request the portfolio company to document an extension, as well as consider whether the overdue note, along with all other available performance data and management reviews lead us to consider whether there should be an adjustment in fair value to reflect impairment of the investment.

	Convertible notes		Preferred stock		Common stock		SAFEs		Other ownership interests		Total
Fair value March 31, 2021	$	2,553,954	$	3,129,458	$	391,995	$	325,000	$	421,000	$	6,821,407
Conversions into preferred stock		-		-		-		-		-		-
New investments		650,000		250,000		165,600		100,000		100,000		1,265,600
Proceeds from sale of investments		-		-		-		-		-		-
Realized gains		-		-		-		-		-		-
Change in value of investments		48,221		4,779		-		-		-		53,000
Fair value June 30, 2021	$	3,252,175	$	3,384,237	$	557,595	$	425,000	$	521,000	$	8,140,007

The following table summarizes the valuation techniques and significant unobservable inputs used for investments that are categorized within Level 3 of the fair value hierarchy as of September 30, 2021 and March 31, 2021:

	Convertible notes		Preferred stock		Common stock		SAFEs		Other ownership interests		Total
Fair value March 31, 2020	$	1,528,002	$	701,497	$	126,500	$	73,500	$	236,000	$	2,665,499
Conversions into preferred stock		50,000		100,000		-		-		100,000		250,000
New investments		-		-		-		-		-		-
Proceeds from sale of investments		-		-		-		-		-		-
Realized gains		-		-		-		-		-		-
Change in value of investments		-		-		-		-		-		-
Fair value June 30, 2020	$	1,578,002	$	801,497	$	126,500	$	73,500	$	336,000	$	2,915,499

SCHEDULE OF INVESTMENTS

	As of September 30, 2021
	Fair Value		Valuation Approach/ Technique	Unobservable Inputs	Range/ Weighted Average

Convertible notes: Basepaws Inc	$	201,663	Market approach based on indicative term sheet and last round of financing	As if converted note and Series A term sheet of $37.5 million	50:50 weight
Convertible notes: Promaxo Inc		183,876	Market approach based on available comparables and financial performance	Conversion prospects, market yield, remaining maturity	5% yield
Convertible notes: Other		3,416,294	Market approach based on available comparables and financial performance	Conversion prospects, market yield, remaining maturity	1-12% yield
Preferred stock in private companies” Shyft Moving Inc		269,820	Market approach based on indicative term sheet and last round of financing	50/50 weighting to prior A-3 preferred and indicated pre Series B price. Forecast revenue from investor deck and 75% percentile for public company peer valuation ratios	Based on Series B valuation of $80 million
Preferred stock in private companies: Seal Rock Therapeutics Inc		199,112	Market approach based on indicative term sheet and last round of financing	50/50 weighting to prior Series seed preferred and indicated Note price. 75% percentile for public company peer valuation ratios	Based on new Note indication of $80 million
Preferred stock in private companies: Femto DX Inc		290,046	Market approach based on indicative term sheet and last round of financing	50/50 weighting to prior Series B-2 preferred price and public market. 75% percentile for public company peer valuation ratios	Based on Series B valuation of $170 million
Preferred stock in private companies: Promaxo Inc		1,034,984	Market approach based on available comparables and financial performance	a) Last round of financing for series B-2 price, 118% change in enterprise value @75th percentile b) revenue multiples 2021 13.3X 2022 9.3x	0%-168.3% 0.6x - 27.7x 0.5x - 59.4x
Preferred stock in private companies: Other		2,744,691	Market approach based on available comparables and financial performance	Market approach based on available information from portfolio companies	Various
Common stock in private companies		325,000	Market approach based on available comparables and financial performance	Historic or projected revenue and/or EBITDA multiples discounted for lack of marketability	Various
SAFE		575,000	Market approach based on available comparables and financial performance	Precedent and follow-on transactions adjusted for marketability	Various
Other investments		571,000	Market approach based on available comparables and financial performance	Precedent and follow-on transactions adjusted for marketability	Various
Total Investments	$	9,811,486

	As of March 31, 2021
	Fair Value		Valuation Approach/ Technique	Unobservable Inputs	Range/ Weighted Average

Convertible notes: Kitotech Medical Inc	$	326,871	Market approach based on available comparables and financial performance	Market cap of $28.51 million a, Public company 75th percentile As if converted 2020 note	Range : $28.514 million
Convertible notes		2,227,083	Market approach based on available comparables and financial performance	Conversion prospects, market yield, remaining maturity	1-12% yield
Preferred stock in private companies: Femto DX Inc		159,835	Market approach based on available comparables and financial performance	Based on Series B financing and public company peer multiples using 50:50 percentile	Market value of invested capital $58.66 million
Preferred stock in private companies: Neuroflow Inc		437,495	Market approach based on available comparables and financial performance	Based on Series Seed 2 and last round of financing - Series B	Market value of invested capital $57.98 million
Preferred stock in private companies: other		2,532,128	Market approach based on available comparables and financial performance	Market approach based on available information from portfolio companies	Various
Common stock in private companies		300,000	Market approach based on available comparables and financial performance	Historic or projected revenue and/or EBITDA multiples	Various
SAFE		325,000	Market approach based on available comparables and financial performance	Precedent and follow-on transactions adjusted for marketability	Various
Other investments		421,000	Market approach based on available comparables and financial performance	Precedent and follow-on transactions adjusted for marketability	Various
Total Investments	$	6,729,412

The following table presents fair value measurements of investments, by major class, as of September 30, 2021, and March 31, 2021, according to the fair value hierarchy:

	As of September 30, 2021
	Quoted prices in active markets for identical securities		Significant other observable inputs		Significant unobservable inputs
Description	(Level 1)		(Level 2)		(Level 3)		Total
Investments at Fair Value
Private Portfolio Companies
Convertible notes	$	-	$	-	$	3,801,833	$	3,801,833
Preferred stock		-		-		4,538,653		4,538,653
Common stock		-		-		325,000		325,000
SAFEs		-		-		575,000		575,000
Other ownership interests		-		-		571,000		571,000
		-		-		9,811,486		9,811,486
Public Portfolio Companies
Common stock		631,327		-		-		631,327

Total Investments at Fair value	$	631,327	$	-	$	9,811,486	$	10,442,813

	As of March 31, 2021
Description	Level 1		Level 2		Level 3		Total
March 31, 2021
Investments at Fair Value
Private Portfolio Companies
Convertible notes	$	-	$	-	$	2,553,954	$	2,553,954
Preferred stock		-		-		3,129,458		3,129,458
Common stock		-		-		300,000		300,000
SAFEs		-		-		325,000		325,000
Other ownership interests		-		-		421,000		421,000
		-		-		6,729,412		6,729,412

Public Portfolio Companies
Common stock		91,995		-		-		91,995

Total Investments at Fair value	$	91,995	$	-	$	6,729,412	$	6,821,407

As of September 30, 2021, and March 31, 2021, all our investments were treated as Level 3 with the exception of two which are invested in common stock of a public company and treated as Level 1.

We focus on making our investments in the United States, Canada, and Israel. All investments are made and reported in U.S. dollars. Assets that are denominated in foreign currencies are translated into U.S. dollars at closing rates of exchange on the date of valuation. Transactions during the year are translated at the rate of exchange prevailing on the date of the transaction. The Company does not isolate that portion of results of operations resulting from the changes in foreign exchange rates on securities from fluctuations resulting from changes in market prices of such securities. Such foreign currency translation gains and losses are included in the net realized gains or losses from investments and net changes in unrealized gain or losses from investments on the statement of operations.

	America		Canada		Rest of World		Total
Fair value beginning of year March 31, 2021	$	5,486,011	$	907,560	$	427,836	$	6,821,407
New investments		1,668,091		200,000		350,000		2,218,091
Proceeds from sale of investments		-		-		-		-
Realized gains		-		-		-		-
Net change in unrealized gains included in condensed Statements of Operations		1,360,028		29,556		13,731		1,403,315
Fair value end of six months September 30, 2021	$	8,514,130	$	1,137,116	$	791,567	$	10,442,813
Changes in unrealized gains or losses for the period included in Condensed Statement of Operations for assets held at the end of the reporting period.							$	1,403,315

	America		Canada		Rest of World		Total
Fair value beginning of year March 31, 2020	$	2,170,499	$	245,000	$	250,000	$	2,665,499
New investments		540,000		150,000		50,000		740,000
Proceeds from sale of investments		-		-		-		-
Realized gains		-		-		-		-
Net change in unrealized gains included in condensed Statements of Operations		438,953		21,947		17,348		478,248
Fair value end of six months September 30, 2020	$	3,149,452	$	416,947	$	317,348	$	3,883,747
Changes in unrealized gains or losses for the period included in Condensed Statement of Operations for assets held at the end of the reporting period.							$	478,248

Working on the experience of our technical advisors, we limit our investments to fintech, technology, and life sciences.

	Fintech		Technology		Life science		Total
Fair value beginning of year March 31, 2021	$	126,030	$	1,394,318	$	5,301,059	$	6,821,407
New investments		-		590,600		1,627,491		2,218,091
Proceeds from sale of investments		-		-		-		-
Realized gains		-		-		-		-
Net change in unrealized gains included in condensed Statements of Operations		-		45,531		1,357,784		1,403,315
Fair value end of six months September 30, 2021	$	126,030	$	2,030,449	$	8,286,334	$	10,442,813
Changes in unrealized gains or losses for the period included in Condensed Statement of Operations for assets held at the end of the reporting period.							$	1,403,315

	Fintech		Technology		Life science		Total
Fair value beginning of year March 31, 2020	$	101,500	$	685,002	$	1,878,997	$	2,665,499
New investments		-		-		740,000		740,000
Proceeds from sale of investments		-		-		-		-
Realized gains		-		-		-		-
Net change in unrealized gains included in condensed Statements of Operations		24,530		37,769		415,949		478,248
Fair value end of six months September 30, 2020	$	126,030	$	722,771	$	3,034,946	$	3,883,747
Changes in unrealized gains or losses for the period included in Condensed Statement of Operations for assets held at the end of the reporting period.							$	478,248

We invest in early-stage private companies developing products or solutions in the fields of fintech, technology and life sciences. Typically, we are investing in interest bearing notes that may be convertible into equity securities upon the completion of qualified subsequent financings, preferred stock, SAFEs or other forms of ownership. Typically notes carry a two-year term and are then rolled over for additional periods if no other maturity triggers have been achieved. If a convertible note investment were, in our judgment, to become impaired, we would reverse the accrued interest and adjust the valuation to reflect management’s assessment of fair value. If a convertible note investment exceeds its maturity date we would request the portfolio company to document an extension, as well as consider whether the overdue note, along with all other available performance data and management reviews lead us to consider whether there should be an adjustment in fair value of the investment. There were no transfers into or out of Level 3 during the three and six months ended September 30, 2021 and September 30, 2020.

	Convertible notes		Preferred stock		Common stock		SAFEs		Other ownership interests		Total

Fair value March 31, 2021	$	2,553,954	$	3,129,458	$	391,995	$	325,000	$	421,000	$	6,821,407
Conversions into preferred stock		-		-		-		-		-		-
New investments		1,027,491		600,000		190,600		250,000		150,000		2,218,091
Proceeds from sale of investments		-		-		-		-		-		-
Realized gains		-		-		-		-		-		-
Unrealized gains included in condensed Statements of Operations		220,388		809,195		373,732		-		-		1,403,315
Fair value September 30, 2021	$	3,801,833	$	4,538,653	$	956,327	$	575,000	$	571,000	$	10,442,813

	Convertible notes			Preferred stock		Common stock			SAFEs			Other ownership interests		Total

Fair value March 31, 2020	$	1,528,002		$	701,497	$	126,500		$	73,500		$	236,000	$	2,665,499
Conversions into preferred stock		(597,984	)		678,313		-			(80,329	)		-		-
New investments		100,000			440,000		100,000			-			100,000		740,000
Proceeds from sale of investments		-			-		-			-			-		-
Realized gains		-			-		-			-			-		-
Unrealized gains included in condensed Statements of Operations		178,986			279,433		(62,000	)		81,829			-		478,248
Fair value September 30, 2020	$	1,209,004		$	2,099,243	$	164,500		$	75,000		$	336,000	$	3,883,747

NOTE 6– EQUITY

(A)

PREFERRED STOCK

Series A

The Company has sold 4,200,000 Series A Stock Units (“Units”) consisting of one share of Series A Preferred Stock and one warrant to purchase a share of Common Stock at $0.80 per share. The Units were sold in a private placement to accredited investors. The Series A Preferred Stock will be converted into shares of Common Stock upon listing of the Company on Nasdaq or NYSE. In the event of any liquidation or winding up of the Company, the holders of the Series A shall be entitled to receive in preference to the holders of shares of Common Stock a per share amount equal to two times (2 X) their original purchase price plus any declared but unpaid dividends (the Liquidation Preference). All share issuances and obligations are recognized on the books and stock register.

On March 2, 2021, in preparation for an intended IPO, the Company made an offer to all its preferred shareholders to protect them against the possibility that the IPO price might be less than their preferred stock price. Accordingly, Series A-1 and Series A-2 Preferred Stock were created, and the holders of Series A Preferred Stock were granted an opportunity to purchase shares of Common Stock at $0.40 per share. If shareholders purchased at least $6,000 of Common Stock, their shares of Series A Preferred Stock were exchanged for Series A-1 which is guaranteed to convert into shares of Common Stock at the same price as the IPO price, and if shareholders purchased a pro-rated ~~amount~~ amount of Common Stock their Series A Preferred Stock were exchanged for Series A-2 Preferred Stock which in turn is convertible into ~~shares~~ shares of Common Stock at a discount of 10% to the IPO price. In all other respects the Series A-1 and Series A-2 Preferred Stock has the same rights and obligations as the Series A Preferred Stock. As of ~~June~~September 30, 2021, 1,437,500 shares of Series A Preferred Stock had been exchanged for Series A-1 Preferred Stock, and 2,212,500 shares of Series A Preferred Stock had been exchanged for Series A-2 Preferred Stock, respectively, leaving outstanding 550,000 shares of Series A Preferred Stock (“Series A”) designated at a par value of $0.01 per share.

2124

Series B

There ~~are~~were also 6,000,000 shares of Series B Preferred Stock (“Series B”) authorized designated at a par value of $0.01 per share. The Series B can be converted into shares of Common Stock upon listing of the Company on Nasdaq. In the event of any liquidation or winding up of the Company, the holders of the Series B shall be entitled to receive in preference to the holders of Common Shares and Series A Preferred Stock, a per share amount equal to two times (2 X) their original purchase price plus any declared but unpaid dividends (the Liquidation Preference). The holders of Series B shall be entitled to receive out of any funds of the Corporation at a time legally available for the declaration of dividends, dividends at a cumulative rate of 10% under such terms and conditions as the Board shall prescribe, provided, however, that in the event dividends shall be declared, dividends on issued and outstanding Series B shall be payable before any dividends shall be declared or paid upon or set apart for the Common Stock. ~~At June 30, 2021, the Company had sold 4,320,156 shares of Series B for proceeds of $3,456,124.~~

On March 2, 2021, in preparation for an intended future IPO, the Company made an offer to all its preferred shareholders to protect them against the possibility that the IPO price might be less than their preferred stock price. Accordingly, Series B-1 and Series B-2 Preferred Stock (“Series B-1” and “Series B-2”, respectively) were created, and the holders of the Series B were granted an opportunity to purchase shares of Common Stock at $0.40 per share. If shareholders purchased at least $6,000 of ~~common~~Common ~~stock~~Stock, their Series B were exchanged for Series B-1 which is guaranteed to convert into shares of Common Stock at the same price as the IPO price, and if shareholders purchased a pro-rated amount of ~~common~~Common ~~stock~~Stock their Series B were exchanged for Series B-2 which converts into shares of Common Stock at a discount of 10% to the IPO price. In all other respects, the Series B-1 and Series B-2 have the same rights and obligations as the Series B. At ~~June~~September 30, 2021, 1,~~857~~166,~~656~~406 shares of Series B had been exchanged for Series B-1, and 2,176,250 shares of of Series B had been exchanged for Series B-2, respectively, leaving outstanding 286,250 shares of Series B. During the three and six months ended September 30, 2021, the Company sold 1,591,250 and 2,282,500 shares of Series B-1 Preferred Stock for $1,273,000 and $1,826,001, respectively.

~~The~~As of September 30, 2021, the Company ~~sold~~authorized ~~691~~an additional 3,~~250~~000,000 shares of Series B stock designated as Series B-13 inPreferred (“Series B-3”) bringing Series B to a total of 9,000,000 authorized shares with a par value of $0.01 per share. The Certificate of Designation of the ~~three~~Series ~~months~~B-3 ~~ended~~shares ~~June~~was 30filed with the Delaware Secretary of State on October 5, 2021. The Series B-3 will be offered for $0.80 per share and isaccrue ~~still~~a ~~selling~~cumulative dividend of 10% per annum. The remaining terms and conditions are substantially the same as for all other Series B-1 shares, asincluding atmandatory conversion upon a majority vote of the ~~date~~Series B-3 shareholders, closing of a qualified financing of ~~this~~at ~~report~~least $10 million, or listing on a public stock exchange.

~~COMMON~~B) COMMON STOCK

The Company has authorized 40,000,000 shares of common stock at a par value of $0.01 per share. As of ~~June~~September 30, 2021, and March 31, 2021 a a total of 13,~~268~~287,~~871~~621 and 9,983,082 shares of the Company’s common stock were issued and outstanding, respectively. During the three months ended June 30, 2021, the Company issued 307,178 shares of Common Stock for $122,876 in connection with the amendment of preferred stock described in section A above. Also, during the year ended March 31, 2021 a total of 2,978,611 shares of Common Stock were subscribed under this program for a total consideration of $1,191,442 which was accrued as stock subscription liability at March 31, 2021, pending final closing of the round which occurred in April 2021, at which time these shares were recognized as fully-issued shares of common stock.

D)During ~~STOCK~~the ~~OPTIONS~~three and six months ended September 30, 2021, in connection with the amendment of Preferred Stock rights described in A above, the Company sold 3,285,789 shares of Common Stock for $1,314,317 of which $1,191,442 was received and accrued as subscription liability at March 31, 2021.

During each of the three and six months ended September 30, 2021, the Company issued 18,750 shares of Common Stock for $618, respectively, in connection with the exercise of stock options.

C) STOCK OPTIONS

In April 2018, the Board approved the introduction of the Kyto Technology and Life Science, Inc. Incentive Stock Option Plan (“the 2018 Plan”) reserving 2,697,085 shares for issuance to employees, consultants and directors, with the objective of securing the benefit of services for stock options rather than cash salaries.

In July 2019, the Board approved the introduction of the Kyto Technology and Life Science 2019 Stock Option and Incentive Plan (“2019 Plan”), and reserved 2 million shares for issuance to directors, officers, consultants and advisors. Options granted under the 2019 Plan expire May 21, 2029.

In December 2020, the Board approved the introduction of the Kyto Technology and Life Science 2020 Non Qualified Stock Option Plan (“2020 Plan”), and reserved 2 million shares for issuance to directors, officers, consultants and advisors. Options granted under the 2020 Plan expire December 16, 2030.

During the three months ended ~~June~~September 30, 2021, and ~~June~~September 30, 2020, the Company issued a total of ~~250~~490,000 and ~~120~~510,000 non-qualified stock options, respectively, to consultants and advisors vesting over terms of two years. During the corresponding six months ended September 30, 2021, and September 30, 2020, the Company issued a total of 740,000 and 630,000 non-qualified stock options, respectively.

	Number of options granted		Weighted average exercise price		Weighted average remaining life years
Outstanding March 31, 2021		2,634,250	$	0.05		8.13
Granted		250,000		0.07		9.82
Exercised		-		-		-
Cancelled		-		-		-
Outstanding June 30, 2021		2,884,250	$	0.05		8.53
Exercisable June 30, 2021		1,782,610	$	0.04		8.05

SCHEDULE OF OPTIONS VESTED

In connection with the grant of stock options the Company recognises the value of the related option expense using the Black Scholes model, with appropriate assumptions for option life, stock value, risk free interest rate, volatility, and cancellations.

	Number of options granted			Weighted average exercise price			Weighted average remaining life years
Outstanding March 31, 2021		2,634,250		$	0.05			8.13
Granted		740,000			0.07			9.42
Exercised		(18,750	)		(0.03	)		-
Cancelled		-			-			-
Outstanding September 30, 2021		3,355,500		$	0.06			8.63

Exercisable September 30, 2021		2,085,041		$	0.04			8.90

	June 30, 2021			March 31, 2021
Stock Price at grant date	$	0.070			$ 0.033 - $ 0.078
Exercise Price	$	0.070			$ 0.033 - $ 0.078
Term in Years		0 - 2.00			0 - 2.00
Volatility assumed		196	%		71% - 196%
Annual dividend rate		0.0	%		0.0	%
Risk free discount rate		0.12	%		0.12% - 2.0%

In connection with the grant of stock options the Company recognizes the value of the related option expense using the Black Scholes model, with appropriate assumptions for option life, stock value, risk free interest rate, volatility, and cancellations.

~~The compensation~~ SCHEDULE ~~expense~~OF ~~calculated~~FAIR atVALUE ~~time~~ASSUMPTIONS of- ~~grant~~STOCK is amortised over the vesting period for the options granted. During the three months ended June 30, 2021 and 2020, the Company amortized $10,557 and $1,048, respectively, as option expense. The intrinsic value of outstanding options at June 30, 2021 was $63,274, and $45,011 of the option expense upon grant remained unamortized at June 30, 2021 with a remaining vesting period of 1.39 years.OPTIONS

E) WARRANTS

	September 30, 2021			March 31, 2021
Stock Price at grant date	$	0.07		$	0.033 - $ 0.078
Exercise Price	$	0.07		$	0.033 - $ 0.078
Term in Years		0 - 2.00			0 - 2.00
Volatility assumed		196	%		71% - 196	%
Annual dividend rate		0.0	%		0.0	%
Risk free discount rate		0.12	%		0.12% - 2.0	%

InThe ~~conjunction~~compensation ~~with~~expense ~~the~~calculated ~~sale~~at time of ~~stock~~grant ~~Units,~~is ~~the~~recognized ~~Company~~over ~~issued~~the ~~4,200,000~~vesting ~~warrants~~period tofor ~~purchase~~the ~~common~~options ~~stock~~granted. atDuring athe ~~price~~three ofand six ~~$1.20~~months ~~per~~ended ~~share for~~September a30, ~~period~~2021 ofthe ~~three~~Company ~~years.~~recognized ~~The~~$10,897 and ~~Company~~$21,454, respectively, ~~values~~as ~~the~~stock-based ~~warrants~~compensation ~~using~~expense. For the ~~Black~~corresponding ~~Scholes~~three ~~model,~~and ~~with~~six ~~appropriate~~months ~~assumptions~~ended ~~for~~September ~~warrant life~~30, ~~stock value~~2020, ~~risk~~the ~~free~~Company ~~interest rate~~recognized $12,805 and ~~volatility~~ $13,851, respectively.

23The intrinsic value of outstanding options at September 30, 2021 was $62,580, and $56,987 of the option expense upon grant remained unrecognized at September 30, 2021 with a remaining vesting period of 1.44 years.

	Number of warrants		Weighted average exercise price		Weighted average remaining life in years
Outstanding March 31, 2021		1,596,667	$	1.20		1.4
Granted		-
Exercised		-				-
Cancelled		-				-
Outstanding June 30, 2021		1,596,667	$	1.20		1.1
Exercisable June 30, 2021		1,596,667	$	1.20		1.1

~~The~~D) ~~intrinsic value of outstanding warrants at June 30, 2021 was zero.~~WARRANTS

In conjunction with the sale of Series A Stock Units, the Company issued 4,200,000 warrants to purchase common stock at a price of $1.20 per share for a period of three years. The Company did not bifurcate the value of the warrants as the fair value of the warrant was determined to be de minimis. The Company has not issued any warrants since September, 2019. At September 30, 2021 and March 31, 2021 the fair value of the warrants was de minimis.

SCHEDULE OF WARRANTS

	Number of warrants			Weighted average exercise price		Weighted average remaining life in years
Outstanding March 31, 2020		4,200,000		$	1.20		2.9
Granted		-			-		-
Exercised		(2,603,333	)	$	1.20		-
Cancelled		-			-		-
Outstanding September 30, 2020		1,596,667		$	1.20		1.4

Exercisable March 31, 2020		4,200,000		$	1.20		2.9
Exercisable September 30, 2020		1,596,667		$	1.20		1.4

	Number of warrants		Weighted average exercise price		Weighted average remaining life in years
Outstanding March 31, 2021		1,596,667	$	1.20		1.4
Granted		-				-
Exercised		-				-
Cancelled		-				-
Outstanding September 30, 2021		1,596,667	$	1.20		1.1

Exercisable March 31, 2021		1,596,667	$	1.20		1.4
Exercisable September 30, 2021		1,596,667	$	1.20		1.1

The Company values the warrants using the Black Scholes model, with appropriate assumptions for warrant life, stock value, risk free interest rate, and volatility. The assumptions used for warrant valuation were as follows:

Stock Price at grant date	$	0.006
Exercise Price	$	1.200
Term in Years		3.00
Volatility assumed		73	%
Annual dividend rate		0.0	%
Risk free discount rate		1.79	%

NOTE 7 – FINANCIAL HIGHLIGHTS

Per share data ( a)
	June 30, 2021			March 31, 2021
Net asset value	$	0.64		$	1.03
Net increase (decrease) in net assets	$	(0.03	)	$	0.06
Net unrealized gain (loss) on investments	$	0.00		$	0.18
Ratios and Supplemental Data
Net assets, end of period	$	8,537,246		$	6,993,163
Weighted average common shares outstanding, end of period		13,268,871			5,836,832
Total operating expenses/net assets		4.5	%		11.0	%
Net increase (decrease) in net assets		-3.9	%		6.1	%
Total return		-0.9	%		1.2	%

SCHEDULE OF FINANCIAL HIGHLIGHTS

Per share data ( a)	Three months ended			Three months ended			Six months ended			Six months ended
	September 30, 2021			September 30, 2020			September 30, 2021			September 30, 2020
Net asset value	$	0.82		$	0.72		$	0.82		$	0.72
Net investment loss	$	(0.03	)	$	(0.03	)	$	(0.06	)	$	(0.03	)
Net unrealized gain on investments	$	0.10		$	0.05		$	0.11		$	0.08
Net increase in net assets	$	0.08		$	0.05		$	0.05		$	0.05

Ratios and Supplemental Data
Net assets, end of period	$	10,817,894		$	4,230,731		$	10,817,894		$	4,230,731

Weighted average common shares outstanding, end of period		13,271,996			5,836,832			13,269,764			5,836,832

Total operating expenses/net assets		3.3	%		3.8	%		6.8	%		4.7	%

Net investment loss/net assets		3.3	%		3.8	%		6.8	%		4.7	%

Total return		9.2	%		7.5	%		6.1	%		6.6	%

(a)

Per share data is based on the weighted average number of common shares outstanding at the end of the period.

NOTE 8 - SUBSEQUENT EVENTS

~~Subsequent~~On toOctober ~~June 30~~5, 2021, the Company ~~has~~filed ~~sold~~a $1Form 8-K announcing the Designation of 3,~~274~~000,000 ofmillion shares of ~~Series~~ B-13 Preferred ~~stock~~Stock. ~~and~~As ~~issued~~of 18November 13,~~750~~ 2021, the Company has sold $546,000 of shares of ~~Common~~Series B-3 Preferred Stock, and invested $~~952~~300,000 in ~~additional~~three follow-on investments.

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONS AND RESULTS OF OPERATIONS

PLAN OF OPERATIONS

The Company was originally formed to acquire and develop proprietary drugs for the treatment of cancer, arthritis, and other autoimmune diseases and had been evaluating a number of strategies. As of March 31, 2018, the Company had accumulated a deficit of $32,380,746 from all prior operations. In April 2018, the Board adopted a new business plan focused on the development of early -stage technology and life science businesses through early stage investment funding. The Company has recruited a number of experienced investment consultants from a network that includes angel investors, corporate managers, sophisticated early stage investors and successful entrepreneurs with experience across a number of technology and life science products and markets, and relies on input from these advisors in conducting due diligence and making investment decisions. In order to offset the risk in early-stage investing, the Company works with angel investment groups and other sophisticated investors and participates only after these groups have completed due diligence and committed to invest, in effect becoming lead investors. The Company then completes its own due diligence and invests under identical terms as the lead investors. The Company will do follow-on investments in existing portfolio companies, assuming adequate progress, when portfolio companies initiate new financing rounds. The Company currently does not typically invest more than $250,000 in any single investment. Generally, the Company’s investments represent less than 5% ownership interests, and the Company therefore has no effective control or influence over the management or commercial decisions of the companies in which it invests. The Company plans to generate revenue from realized gains from the sale of the businesses in which it has invested, or some or all of its shareholdings in those cases where portfolio companies go public. Generally, it is expected that investments will be realized from an exit within a period of four to five years following initial investment. Such exits or liquidity events are outside the Company’s control and depend on merger and acquisition (“M&A”) transactions or an initial public offering (“IPO”) which may result in cash or equity proceeds. Accordingly, it is difficult to forecast revenue, net income, and cash flow. Other than making its initial and, potentially, follow-on investments in its portfolio companies, the Company does not provide any financial support to any of its investees.

The Company has one regular employee – the CEO, Mr, Paul Russo. Prior to December 31, 2020, was acting as a consultant to the Company and did not receive contractual compensation for his services in the form of cash. As of January 1, 2021, Mr. Russo was engaged as an employee of the Company at a salary of $400,000 per annum of which 60% is paid monthly, and the balance deferred to be paid once the Company lists and starts trading on the Nasdaq exchange. The full terms of Mr. Russo’s employment are described in an engagement letter filed on Form 8-K on February 1, 2021, which was approved by the Compensation committee of the Board of Directors on that date. During the three months ended June 30, 2021, Mr. Russo received $80,000 gross payroll, no consulting fees and no options were granted. During the three months ended June 30, 2020, Mr. Russo received no payroll or consulting fees, and no options were granted to him.28

The Company has ~~created~~one aregular ~~portfolio~~employee of– ~~minority~~the ~~investments~~CEO, inMr, ~~early-stage~~Paul ~~start-up~~Russo. ~~companies~~Prior ~~and~~to ~~derives~~December ~~its~~31, ~~revenue~~2020, ~~opportunity~~was ~~from~~acting ~~the sale~~as ofa ~~those~~consultant ~~investments.~~to ~~Such sales are outside~~ the Company~~’s control~~ and ~~depend~~did onnot ~~M&A~~receive ~~transactions~~contractual orcompensation ~~IPOs~~for ~~which~~his ~~may~~services ~~result~~ in ~~cash~~the orform ~~equity~~of ~~proceeds~~cash. ~~Accordingly,~~As itof isJanuary ~~difficult to forecast revenue~~1, ~~net income~~2021, ~~and cash flow~~Mr. AsRusso ofwas ~~the~~engaged ~~date~~as an employee of ~~this filing,~~ the Company ~~had~~at ~~approximately~~a salary of $~~600~~400,000 per annum of ~~cash~~which to60% ~~cover~~was ~~its~~paid ~~operating~~monthly ~~expenses,~~from ~~and~~January ~~new~~through ~~investment~~April ~~requirements~~2021, and is75% ~~continuing to~~was ~~raise~~paid ~~additional~~in ~~funding~~subsequent onmonths, awith ~~recurring~~the ~~monthly~~balance ~~basis.~~deferred Ifto ~~successful,~~be itpaid ~~will~~once ~~have~~the ~~sufficient~~Company ~~funding~~lists ~~for further investments~~ and ~~ongoing operations.~~starts ~~However,~~trading ~~there~~on isthe noNasdaq ~~assurance~~exchange. ~~that~~The full ~~the~~terms ~~Company~~of ~~will~~Mr. beRusso’s ~~able~~employment toare ~~raise~~described ~~sufficient~~in ~~cash~~a toForm ~~cover~~8-K ~~its~~on ~~requirements~~February on1, ~~attractive terms~~2021, ifincorporated atby ~~all~~reference herein, ~~and~~which ~~whether~~was approved itby ~~will~~the beCompensation ~~able~~committee toof ~~continue~~the asBoard aof ~~going~~Directors ~~concern.~~on ~~These~~that ~~conditions~~date. ~~raise~~During ~~substantial~~the ~~doubt~~three ~~about~~months ~~the~~ended ~~Company’s ability~~September to30, ~~continue~~2021, asMr. Russo areceived ~~going~~$80,000 ~~concern.~~gross ~~Stay~~pay, atno ~~home~~consulting ~~orders~~fees and ~~general~~no ~~economic~~options ~~uncertainties~~were ~~arising~~granted. ~~out~~During of the ~~current~~three ~~Covid-19~~months ~~epidemic have~~ended ~~created~~September ~~additional~~30, ~~delays~~2020, ~~and uncertainty~~Mr. Russo Toreceived ~~date there has been~~ no ~~disruption~~payroll toor ~~the~~consulting ~~Company’s business operations~~fees, ~~although some~~and ofno ~~its~~options ~~portfolio~~were ~~investment~~granted ~~companies~~to ~~report delays in their programs~~him.

25The Company has created a portfolio of minority investments in early-stage start-up companies and derives its revenue opportunity from the sale of those investments. Such sales are outside the Company’s control and depend on M&A transactions or IPOs which may result in cash or equity proceeds. Accordingly, it is difficult to forecast revenue, net income, and cash flow. As of the date of this filing, the Company had approximately $485,000 of cash to cover its operating expenses, and new investment requirements, and is continuing to raise additional funding on a recurring monthly basis. If successful, it will have sufficient funding for further investments and ongoing operations. However, there is no assurance that the Company will be able to raise sufficient cash to cover its requirements on attractive terms, if at all, and whether it will be able to continue as a going concern. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. Stay at home orders and general economic uncertainties arising out of the current Covid-19 epidemic have created additional delays and uncertainty. To date there has been no disruption to the Company’s business operations, although some of its portfolio investment companies report delays in their programs.

At March 31, 2020, management determined that the Company was an investment company for purposes of ASC 946 disclosure, and committed to follow the specialized accounting and reporting guidance contained therein. Accordingly, a new company, Kyto Investments, Inc. (“KI”) was incorporated in Delaware in December 2020 in preparation for a restructuring and an N-2 Registration Statement filed in March 2021 for review by the SEC. KI is an internally managed, closed-end investment company that has elected to be regulated as a business development company (“BDC”) under the Investment Company Act of 1940, as amended (the “1940 Act”). Immediately upon effectiveness of this N-2 Registration Statement, the Company will merge with KI and the Company will be the surviving entity. As of the completion of the merger, the Company will constitute a “successor issuer” for the purposes of Rule 414 under the Securities Act and may continue the current offering by filing post-effective amendments to the Registration Statements. Prior to the merger, the Company had fewer than 100 non -affiliated investors and filed under the 1934 Act relying on exemption Rule 3( c )(1).

Results of Operations

Revenue: In the three months ~~ended~~and ~~June~~six ~~30,~~months ~~2021~~ended ~~and~~September ~~June~~ 30, ~~2020,~~2021 the Company reported no realized investment income as there were no liquidity events related to its investment portfolio. The Company reported $531,~~000~~350,449 and $01,403,415 of unrealized gains from investments respectively, ~~for~~ in these periods. In the three months and six months ended ~~June~~September 30, ~~2021~~2020 ~~and~~the ~~2020~~Company reported no realized investment income as there were no liquidity events related to its investment portfolio. The Company reported $478,248 of unrealized gains from investments respectively, in these same periods.

~~Professional fees: In the three months ended June 30, 2021 and June 30, 2020, the Company reported $166,954 and $12,938, respectively, of professional fees, mainly for legal and accounting services~~.

~~Other~~Professional ~~Operating expenses~~fees: ~~Other~~In ~~operating~~the ~~expenses~~three ~~include~~months ~~payroll~~and six months ended September 30, ~~consulting~~2021, ~~and~~the ~~travel~~Company ~~and~~reported ~~conference~~$107,201 ~~fees~~and ~~associated~~$273,359, ~~with~~respectively, ~~fund~~of ~~raising~~professional ~~and~~fees, ~~review~~mainly offor ~~investment~~legal ~~deal-flow~~and accounting services. In the corresponding three months ~~ended~~and ~~June~~six ~~30,~~months ~~2021~~ended ~~and~~September ~~June~~ 30, 2020, the Company ~~incurred other operating expenses~~ ofreported $~~219~~63,~~838~~605 and $2576,~~930~~543, respectively.

~~For the three months ended June 30, 2021 and 2020, the Company’s net decrease in net assets resulting from operations was $333,792 and $38,868, respectively.~~29

~~During~~Other ~~the~~Operating ~~three~~expenses: ~~months~~Other ~~ended~~operating ~~June~~expenses 30include payroll, ~~2021~~consulting, ~~the~~and ~~Company~~travel ~~was~~and ~~subject~~conference tofees ~~shelter~~associated inwith ~~place~~raising ~~regulations imposed by the State of California in mitigation~~capital ofand ~~the~~review ~~spread~~ of ~~the~~investment ~~Corona 19 virus~~deal-flow. ~~Since~~In the ~~Company~~three ~~does~~months ~~not have any dedicated office space~~ and ~~works~~six ~~virtually~~months ~~from~~ended ~~the~~September ~~homes~~30, ~~of its officers~~2021, ~~there was no major disruption in working routines which continued by video and teleconference. Uncertainty arising from Covid 19 created a slow down in~~ the ~~rate at which the~~ Company ~~was~~incurred ~~able~~other tooperating expenses ~~raise~~of ~~Series B funding~~$245,519 and ~~thereby~~$466,127, ~~continue~~respectively. toIn ~~make investments, however~~ the ~~Company~~corresponding ~~did~~three ~~see~~months aand ~~reduction~~six inmonths ~~travel~~ended ~~and~~September ~~investor~~30, ~~relations~~2020, ~~expenses during~~ the ~~period. The~~ Company ~~has more than 60 discrete~~ ~~investments~~incurred inother aoperating ~~range~~expenses of ~~different industry and geographic segments~~$96,506 ~~many of which are in the life science~~ and ~~medical space. While there is clearly a risk that our portfolio companies may be adversely affected in their ability to raise future funding or do business~~$122, ~~there~~936, ~~have been no management reports revealing major problems and some of our portfolio companies may actually benefit from new opportunities created~~respectively. We believe that our policy of spreading our investments in relatively small amounts over a large number of portfolio companies helps mitigate some of the risk that might be suffered by any of our investments.

For the three months and six months ended September 30, 2021, the Company’s net increase in net assets resulting from operations was $996,133 and $662,341, respectively. For the corresponding three months and six months ended September 30, 2020, the Company’s net increase in net assets resulting from operations was $318,137 and $279,269, respectively.

During the three months ended September 30, 2021, the Company was subject to shelter in place regulations imposed by the State of California in mitigation of the spread of the Corona 19 virus. Since the Company does not have any dedicated office space and works virtually from the homes of its officers, there was no major disruption in working routines which continued by video and teleconference. Uncertainty arising from Covid 19 created a slow-down in the rate at which the Company was able to raise Series B funding, and thereby continue to make investments, however the Company did see a reduction in travel and investor relations expenses during the period. The Company has more than 60 discrete investments in a range of different industry and geographic segments, many of which are in the life science and medical space. While there is clearly a risk that our portfolio companies may be adversely affected in their ability to raise future funding or do business, there have been no management reports revealing major problems and some of our portfolio companies may actually benefit from new opportunities created. We believe that our policy of spreading our investments in relatively small amounts over a large number of portfolio companies helps mitigate some of the risk that might be suffered by any of our investments.

Liquidity and Capital Resources

The Company had net assets of $810,~~537~~817,~~246~~894 and $6,993,163 at ~~June~~September 30, 2021 and March 31, 2021, respectively. Cash was $~~481~~316,~~506~~124 and $1,437,868 at ~~June~~September 30, 2021 and March 31, 2021, respectively.

Cash from operating activities

The Company used net cash of $13,~~632~~071,238 in operating activities during the ~~three~~six months ended ~~June~~September 30, 2021 compared to $~~282~~909,~~427~~564 used ~~for~~ for the ~~three~~six months ended ~~June~~September 30, 2020. Main reasons for the higher level in 2021 were an increase in investments in portfolio companies and increased professional fees and operating expenses.

Cash from investing activities

No cash was used in investing activities.

Cash from financing activities

The Company had a net cash inflow from financing activities of $~~675~~1,~~876~~949,494 in the ~~three~~six months ended ~~June~~September 30, 2021 compared to $~~375~~1,~~000~~ 273,250 in the three months ended ~~June~~September 30, 2020. This inflow included $~~553~~1,~~002~~826,001 proceeds from the sale of Series B preferred stock, and $122,~~874~~875 proceeds from the sale of common stock, respectively, in the ~~three~~six months ended ~~June~~September 30, 2021, compared to $~~375~~1,270,000 from the sale of Series B preferred stock in the corresponding six month prior period ended September 30, 2020.

The Company’s plan of operations for the next twelve months is to continue to focus its efforts on finding new sources of capital by means of private placements, and to use this capital to fund additional investments as they become available, and to cover operating expenses. The Company is planning to uplift from OTC to the NASDAQ market, and raise additional funding from an initial public offering (“IPO)” for which as an initial step it has submitted an N-2 filing to the SEC for review.

CRITICAL ACCOUNTING POLICIES

USE OF ESTIMATES

Significant estimates at ~~June~~September 30, 2021 and March 31, 2021 include the valuation of investments, deferred tax assets, tax allowance, stock options and warrants.

INVESTMENT AND VALUATION OF INVESTMENT AT FAIR VALUE

The Company reviews the performance of ~~the~~its ~~underlying~~ investments based on available information, including management reports, press releases, ~~web~~ web site announcements and progress reports, third party equity updates, ~~subsequent financing transactions,~~ management interviews and, where accessible, financial reports, to determine their ~~current~~fair ~~and future potential value and liquidity~~values. In the event that Management considers the fair value of an investment to be ~~impaired,~~greater or less than the current ~~carrying~~book value, of the ~~investment~~difference will be ~~written~~reflected ~~down~~as byunrealized angains ~~impairment~~or ~~charge to~~losses ~~reflect~~in ~~Management’s estimated valuation. The Company recognized impairment of one of its~~ investments ~~which was written down by $61,046~~ in ~~September,~~the ~~2019.~~statements ~~The~~of ~~Company has not experienced any other impairment write-downs in any prior or subsequent periods~~operations.

The Company adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820, “Fair Value Measurements and Disclosures”, for assets and liabilities measured at fair value on a recurring basis. ASC ~~820~~ 820 establishes a common definition for fair value to be applied to existing US GAAP that require the use of fair value measurements which establishes a framework for measuring fair value and expands disclosure about such fair value measurements.

27The Company has established procedures to estimate the fair value of its investments which the Company’s board of directors has reviewed and approved. The Company uses observable market data to estimate the fair value of investments to the extent that market data is available. In the absence of quoted market prices in active markets, or quoted market prices for similar assets or in markets that are not active, the Company uses the valuation methodologies described below with unobservable data based on the best available information in the circumstances, which incorporates the Company’s assumptions about the factors that a market participant would use to value the asset.

~~The~~For ~~Company~~investments ~~has~~for ~~established~~which ~~procedures~~quoted tomarket ~~estimate~~prices ~~the~~are ~~fair~~not ~~value~~available, ofwhich ~~its~~comprise ~~investments~~most ~~which~~of ~~the~~our ~~Company’s~~investment ~~board~~portfolio, offair ~~directors~~value ~~has~~is ~~reviewed~~estimated ~~and~~by ~~approved.~~using ~~The~~the ~~Company~~income, ~~will~~market, ~~use~~or ~~observable~~back-solve ~~market~~approach. ~~data~~The toincome ~~estimate~~approach is based on the ~~fair~~assumption that value ofis ~~investments~~created toby the ~~extent~~expectation of ~~that~~future ~~market~~benefits ~~data~~discounted ~~is available.~~to Ina current value and the ~~absence~~fair ofvalue ~~quoted~~estimate ~~market~~is ~~prices~~the inamount ~~active~~an ~~markets,~~investor orwould ~~quoted~~be ~~market~~willing ~~prices~~to ~~for~~pay ~~similar~~to ~~assets~~receive those orfuture inbenefits. ~~markets~~The ~~that~~market ~~are not~~approach ~~active,~~compares ~~the~~recent ~~Company~~comparable ~~will~~transactions ~~use~~to the ~~valuation~~investment. ~~methodologies~~The ~~described~~back ~~below~~solve ~~with~~method ~~unobservable~~involves comparing available data over a period of time and inferring a new valuation based on ~~the~~changes ~~best~~from ~~available~~a ~~information in~~known ~~the~~starting ~~circumstances~~point, ~~which~~for ~~incorporates~~example the cost of an investment. Adjustments are made for any dissimilarity between the ~~company’s~~comparable ~~assumptions~~transactions ~~about~~and the ~~factors~~investments. ~~that~~These valuation methodologies involve a ~~market~~significant ~~participant~~degree ~~would~~of ~~use~~judgment toon ~~value~~ the ~~asset~~part of our management and board.

~~For~~In ~~investments~~determining ~~for~~the ~~which~~appropriate ~~quoted~~fair ~~market~~value ~~prices~~of ~~are~~an ~~not~~investment ~~available,~~using ~~which~~these ~~will~~approaches, ~~comprise~~the most ofsignificant ~~our~~information ~~investment~~and ~~portfolio,~~assumptions ~~fair value will be~~may ~~estimated~~include, byas ~~using~~applicable: ~~the~~available ~~income~~current or market ~~approach.~~data, ~~The~~including ~~income~~relevant ~~approach~~and isapplicable ~~based~~comparable onmarket ~~the~~transactions, ~~assumption~~applicable ~~that~~market yields ~~value~~and ismultiples, ~~created~~security bycovenants, ~~the~~call ~~expectation of~~protection ~~future~~provisions, ~~benefits~~information ~~discounted~~rights, tothe anature ~~current value~~ and ~~the~~realizable ~~fair~~ value ~~estimate~~of isany collateral, the ~~amount~~investment’s anability ~~investor~~to ~~would~~make bepayments, ~~willing~~its toearnings ~~pay~~and todiscounted ~~receive those~~cash ~~future~~flows, ~~benefits.~~the ~~The~~markets ~~market~~in ~~approach~~which ~~compares~~the ~~recent~~company ~~comparable~~does ~~transactions~~business, comparisons toof ~~the~~financial ~~investment.~~ratios ~~Adjustments~~of ~~are~~peer ~~made~~companies ~~for~~that ~~any~~are ~~dissimilarity between~~public, ~~the~~merger ~~comparable~~and ~~transactions~~acquisition ~~and~~comparables, the ~~investments.~~principal ~~These~~market ~~valuation~~and ~~methodologies~~enterprise values, ~~involve~~environmental afactors, ~~significant~~subsequent ~~degree~~financings ofby ~~judgment on~~ the ~~part~~ ofportfolio ~~our~~investment, ~~management~~among ~~and~~other ~~board~~factors.

InThe ~~determining~~estimated ~~the appropriate~~ fair ~~value~~values ofdo annot ~~investment~~necessarily ~~using~~represent ~~these approaches,~~ the ~~most~~amounts ~~significant~~that ~~information and assumption~~ may ~~include, as~~be ~~applicable:~~ultimately ~~available~~realized ~~current~~due ~~market~~to ~~data,~~the ~~including~~occurrence ~~relevant~~or ~~and~~nonoccurrence of ~~applicable~~future ~~comparable~~circumstances ~~market~~that ~~transactions,~~cannot ~~applicable~~be ~~market~~reasonably ~~yields and~~determined. ~~multiples,~~Because ~~security~~of ~~covenants,~~the ~~call~~inherent ~~protection~~uncertainty ~~provisions,~~of ~~information rights,~~ the ~~nature~~valuation ~~and realizable value~~ of ~~any~~the ~~collateral~~investments, the ~~portfolio~~estimate ~~company’s~~of ~~ability~~fair tovalues ~~make~~may ~~payments,~~differ ~~its~~significantly ~~earnings~~from ~~and discounted cash flows,~~ the ~~markets~~value ~~in which the portfolio company does business, comparisons of financial ratios of peer companies~~ that ~~are~~would ~~public,~~have ~~merger~~been ~~and~~used ~~acquisition~~had ~~comparable,~~a ~~the~~broader ~~principal~~ market ~~and~~ ~~enterprise~~for ~~values, environmental factors, financing transactions by~~ the ~~portfolio company, among other factors~~investments existed.

The estimated fair values will not necessarily represent the amounts that may be ultimately realized due to the occurrence or nonoccurrence of future circumstances that cannot be reasonably determined. Because of the inherent uncertainty of the valuation of the investments, the estimate of fair values may differ significantly from the value that would have been used had a broader market for the investments existed.31

Level 1: Observable inputs such as quoted market prices in active markets for identical assets or liabilities

Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data

Level 3: Unobservable inputs for which there is little or no market data, which require the use of the reporting entity’s own assumptions. Most of our investments fall into this category.

RECENT ACCOUNTING PRONOUNCEMENTS

Management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying financial statements.

OFF-BALANCE SHEET ARRANGEMENTS

As of the date of this Quarterly Report on Form 10-Q, we do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.

IMPACT OF INFLATION

The Company does not foresee any implications being created by the current rate of inflation.

CONTRACTUAL OBLIGATION

The Company has no contractual obligations outside the normal course of business with its vendors, advisors, and consultants.

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not required for smaller reporting company.

ITEM 4.

CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that material information required to be disclosed in our periodic reports filed under the Securities Exchange Act of 1934, as amended, or 1934 Act, is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms and to ensure that such information is accumulated and communicated to our management, including our chief executive officer/chief financial officer (principal financial officer) as appropriate, to allow timely decisions regarding required disclosure. During the three months ended ~~June~~September 30, 2021 we carried out an evaluation, under the supervision and with the participation of our management, including the principal executive officer and the principal financial officer (principal financial officer), of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rule 13(a)-15(e) under the 1934 Act. Based on this evaluation, because of the Company’s limited resources and limited number of employees, management concluded that our disclosure controls and procedures were ineffective as of ~~June~~September 30, 2021. Notwithstanding this conclusion, we believe that our unaudited condensed financial statements contained in this Quarterly Report fairly present our financial position, results of operations and cash flows for the periods covered thereby in all material respects.

Management’s Report on Internal Control over Financial Reporting

With the participation of our Chief Executive Officer and Chief Financial Officer (principal financial officer), our management conducted an evaluation of the effectiveness of our internal control over financial reporting as of ~~June~~September 30, 2021 based on the framework in ~~Internal~~ Internal Controls—Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”). Based on our evaluation and the material weaknesses described below, management concluded that the Company did not maintain effective internal control over financial reporting as of ~~June~~September 30, 2021 based on the COSO framework criteria. Management has identified control deficiencies regarding the lack of segregation of duties and the need for a stronger internal control environment. Management of the Company believes that these material weaknesses are due to the small size of the Company’s accounting staff. The small size of the Company’s accounting staff may prevent adequate controls in the future, such as segregation of duties, due to the cost/benefit of such remediation. To mitigate the current limited resources and limited employees, we rely heavily on direct management oversight of transactions, along with the use of external legal and accounting professionals. As we grow, we expect to increase our number of employees, which will enable us to implement adequate segregation of duties within the internal control framework. In addition, we have identified the following material weaknesses: (i) the Company utilizes accounting software that does not prevent erroneous or unauthorized changes to previous reporting periods and/or can be adjusted so as not to provide an adequate audit trail of entries made in the accounting software, and (ii) we have identified a material weakness in our internal controls relating to the accounting of transactions that are either highly complex and/or unusual in nature. In such instances, we seek to augment our internal accounting capabilities by obtaining assistance from third-parties who have greater expertise in such areas.

29These control deficiencies could result in a misstatement of account balances that would result in a reasonable possibility that a material misstatement to our financial statements may not be prevented or detected on a timely basis. Accordingly, we have determined that these control deficiencies as described above together constitute a material weakness. However, management believes that despite our material weaknesses, our financial statements for the three and six month periods ended September 30, 2021 are fairly stated, in all material respects, in accordance with US GAAP.

These control deficiencies could result in a misstatement of account balances that would result in a reasonable possibility that a material misstatement to our financial statements may not be prevented or detected on a timely basis. Accordingly, we have determined that these control deficiencies as described above together constitute a material weakness. However, management believes that despite our material weaknesses, our financial statements for the year ended June 30, 2021 are fairly stated, in all material respects, in accordance with US GAAP.

Limitations on Effectiveness of Controls and Procedures

Our management, including our Chief Executive Officer and Chief Financial Officer (principal financial officer), does not expect that our disclosure controls and procedures or our internal controls will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include, but are not limited to, the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

PART II. OTHER INFORMATION

ITEM 1.

LEGAL PROCEEDINGS

None

ITEM 1A.

RISK FACTORS.

Not required for smaller reporting company.

ITEM 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

The Corporation filed a certificate of Designation in April 2021 for the issue of up to 3,200,000 shares of Series B-1 Preferred stock to accredited investors under Section 4(2) or Rule 506 of Regulation D of the Securities Act 1933. As of the filing date, the Corporation had sold a total of 35,~~200~~911,~~000~~416 shares of Series B-1 Preferred stock to accredited investors. The Company will use the net proceeds ~~for~~ for investment purposes and operating expenses.

ITEM 3.

DEFAULTS UPON SENIOR SECURITIES

None

ITEM 4.

MINE SAFETY DISCLOSURES

Not applicable

ITEM 5.

OTHER INFORMATION

None

ITEM 6.

EXHIBITS

Index to Exhibits on page 13

3033

INDEX TO EXHIBITS

EXHIBIT NUMBER		DESCRIPTION

3 (i) (a)		Articles of Incorporation of Kyto BioPharma Inc.

3(i) (b)		Articles of Amendment changing name to Kyto Technology and Life Science Inc *

3(ii)		Bylaws of Kyto Technology and Life Science Inc. **

3.4		Delaware incorporation and revised articles of incorporation **

18.1		Auditors preferability letter re adoption of ASC 946***

31.1		Section 302 certification of principal executive officer and principal financial & accounting officer

32.1		Certification pursuant to 18 USC Section 1350 adopted pursuant to section 906 of the Sarbanes Oxley Act of 2002 of the principal executive officer and principal financial accounting officer

*	Filed as Exhibit to Company’s Form 10-SB on September 12, 2003 with the Securities and Exchange Commission.
**	Previously filed with Form 8-K on July 17, 2019.
***	Filed as Exhibit with Form 10-K on July 2, 2020.

3134

SIGNATURES

In accordance with the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Kyto Technology and Life Science, Inc.

	By:	/s/ Paul Russo
		Paul Russo Chief Executive Officer, principal executive officer,

Date: ~~September~~November 3018, 2021

SIGNATURES

In accordance with the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Kyto Technology and Life Science, Inc.

	By:	/s/ Simon Westbrook
		Simon Westbrook Principal financial and accounting officer

Date: ~~September~~November 3018, 2021

3235

Filing Compare · Kyto Technology & Life Science, Inc.